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1 INTRODUCTION 
1.1 Autoimmune diseases 
Autoimmune diseases affect at least 5% of the whole population and have a high social impact, 
because patients have a long expectation of life during which they are subordinated to the follow 
up of the disease by means of very invasive techniques, e.g. Magnetic Resonance Imaging (MRI) 
in Multiple Sclerosis diagnosis, that are not suitable for a routine use. Autoimmune diseases are 
characterized by the erroneous activation of the immune system that, because of the loss of the 
physiological tolerance, is no more able to distinguish foreign molecules from self ones; 
consequently self molecules are targeted and endogenous tissues expressing those molecules are 
damaged. Physiologically, after the induction of an unknown agent that is potentially pathogenic 
and antigenic, the organism can reply by two different reaction of the immune system: the cell 
mediated immune response that involves the production of specialized antigen presenting cells 
that react with foreign antigens and activate cytotoxic and helper T lymphocytes, and the humoral 
response that involves B lymphocytes producing antibodies able to specifically bind the antigen. 
Autoimmune disorders are up to now considered as triggered by T cells further inducing a B cell 
response; this last response is characterized by the production of serum antibodies which bind 
endogenous antigens and that are defined autoantibodies. Autoimmune diseases can be classified 
in local pathologies, if the antigen is confined to a particular organ system (e.g. type I diabetes), 
and systemic pathologies, which are characterized by a response to ubiquitous antigens present in 
more than one tissue (e.g. Systemic Lupus Erythematosus).  
The etiology of these diseases is not yet fully understood and it is accepted that they have a 
multifactorial origin including genetic predisposition, female hormones, environmental factors 
and exogenous agents such as virus or bacteria. A pathogenic mechanism for autoimmune 
diseases has been proposed to be the so called molecular mimicry, a process by which exogenous 
agents can activate an immune response that cross-reacts with similar structures present in self 
molecules.  
Autoimmune diseases are chronic conditions with no cure; treatment involves attempts to limit 
the progression of the disease and to decrease the symptoms and the inflammation processes. 
Actual therapies for autoimmune diseases include the administration of immunomodulators, 
glucocorticoids and non-steroidal anti-inflammatory drugs; however some patients may benefit 
from treatment with biotechnological drugs such as very specific and effective, but expensive 
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monoclonal antibodies that are approved for example in the treatment of psoriasis, Crohn's 
disease and Rheumatoid Arthritis. 
1.2 Biomarkers of autoimmune diseases 
The main problem in autoimmune diseases diagnosis is due to their long period of latency and 
their initial sub-clinical manifestations; they are usually diagnosed when relevant clinical 
symptoms are present. Considering this in the last years several studies have been done with the 
aim of finding biomarkers for autoimmune diseases that could be used to set up diagnostic tests 
or to monitor the efficacy of therapeutic treatments. A biomarker can be defined as a 
physiological, anatomical or biochemical parameter which should be easily determined and used 
as indicator of normal physiological or pathogenic processes. Sera from patients suffering from 
autoimmune disorders often contain multiple types of autoantibodies; if these autoantibodies are 
present in high concentration in patients’ sera and they are exclusive of a certain disease they can 
be used as biomarkers.1 Evaluation of autoantibodies as disease biomarker is very important for 
an early diagnosis and in particular if autoantibodies concentration fluctuate with disease 
exacerbations or remissions, their quantitative and qualitative measurements can be very valuable 
in the follow-up of patients and in the evaluation of the efficacy of a certain therapeutic 
treatment2. 
1.3 Synthetic probes to detect autoantibodies as biomarkers 
Protein antigens are fundamental in the pathological mechanism triggering autoimmune diseases, 
particularly if they contain aberrant post-translational modifications (e.g. acetylation, 
citrullination, glycosylation, etc.)3. The detection of autoantibodies by protein antigen isolated 
from biological material or obtained by recombinant technologies, presents several difficulties 
including mutations, lack of post-translational modifications, uncorrected folding and potential 
cross-reactivity between structurally homologous protein epitopes. To avoid these problems the 
“Chemical Reverse Approach” has been developed as a novel concept to design antigenic peptide 
probes for the detection of serum autoantibodies as biomarkers. This strategy is termed reverse 
since the research of antigenic peptides is based on antibodies circulating in patients’ sera. The 
selection and the design of the chemical structure of the antigenic peptides is guided and 
optimized according to the specificity for autoantibodies. In this context it has been demonstrated 
that synthetic peptides, possibly but not necessarily deriving from the native proteins and 
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containing post-translationally modified amino acids, can be successfully used to set up 
diagnostic in vitro assays for the detection of biomarkers of diseases, such as Rheumatoid 
Arthritis 4 and Multiple Sclerosis 5. 
1.4 Immunological assays: classical Enzyme-Linked Immunosorbent Assay and advanced 
Biosensors 
Up to now there are few technologies in clinical development capable of detecting these 
biomarkers in the blood, the most commonly used in clinic to screen a large number of sera is the 
Enzyme-Linked Immunosorbent Assay (ELISA). For the screening of big numbers of sera and 
the detection of antibodies, a Solid Phase ELISA (SP-ELISA) is often performed. In this case the 
antigenic probe is coated on the solid phase surface of a multi-well suitable plastic plate and 
allows to interact with the autoantibodies present in sera that will be quantify thanks to the 
colorimetric reaction generated after the incubation with a specific secondary antibody, 
conjugated to an enzyme able to produce a colored molecule, when treated with a suitable 
substrate in the final step of the assay.  
A competitive ELISA assay protocol has been developed and optimized to measure the average 
affinity of polyclonal antibodies in serum, a parameter of great interest in exploring B cell 
population dynamics in vivo6. This assay is based on a classical SP-ELISA, but in this case serum 
is applied with increasing concentration of an inhibitor molecule in solution; then thanks to the 
application of the appropriate secondary antibody, only antibodies that didn’t bind to the inhibitor 
in solution will be detected through the colorimetric reaction. 
A more detailed characterization of the antibody-antigen interaction, giving important 
information for the prognostic values of disease biomarkers, can be achieved thanks to the use of 
biosensors. A biosensor is a technological devise composed of two elements: a biological 
recognition unit, able to specifically interact with a target or to form a complex with it, and a 
transducer system that converts into a recordable signal the change in property of the solution or 
surface due to the biological interaction. In contrast with conventional bioassays, biosensors 
allow the detection of molecular interactions as they take place, without requiring auxiliary 
procedures. In this project we have used an optical biosensor system (Biacore) to perform 
Biomolecular Interaction Analysis for different purposes, within the framework of the 
characterization of autoantibodies as biomarkers of autoimmune diseases.  
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1.4.1 SPR-based biosensor Biacore 
Biacore is a label free system exploiting the phenomenon of the Surface Plasmon Resonance 
(SPR) to monitor the interaction between molecules in real time. The approach involves attaching 
one interacting partner called ligand to the surface of a sensor chip, and then flowing the samples 
containing the other interaction partner, defined analyte, over the surface. Binding of molecules 
to the sensor surface generates a response, which is directly proportional to the bound mass; this 
response is measured in Resonance Units (RU) and is graphically expressed by a sensorgram, 
showing the progress of the interaction during time. SPR is a phenomenon that occurs in thin 
conducting films at an interface between media of different Refractive Index (RI). In Biacore 
system, the two media are the glass of the sensor chip and the sample solution, and the 
conducting film is a thin layer of gold on the sensor chip surface; the wave length of the incident 
light and the reflective index of the inner surface are constant, so the SPR phenomenon is used to 
monitor the change of reflective index in the flowing solution close to the sensor chip surface. 
Under conditions of total internal reflection, light incident on the reflecting interface leaks an 
electric field intensity called evanescent wave field across the interface into the medium of lower 
refractive index, without losing net energy. The amplitude of the evanescent field wave decreases 
exponentially with distance from the surface, and the effective penetration depth in terms of 
sensitivity to refractive index is about 150 nm. At a certain combination of angle of incidence and 
wavelength, the incident light excites plasmons in the gold film. As a result, a characteristic 
absorption of energy via the evanescent wave field occurs and SPR is seen as a drop in the 
intensity of the reflected light (Figure 1). Changes in solute concentration at the surface of the 
sensor chip cause changes in the RI of the solution, which can be measured as an SPR response 
and expressed in RU, in particular a difference of 0.1° in the angle of reflection generates a 
response of 1000 RU that correspond to a variation in mass over the chip surface of about 1 
ng/mm2 .  
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Figure 1: Schematic representation of the Surface Plasmon Resonance occurring in the inner core of a Biacore 
instrument. 
SPR arises in any thin conducting film under the conditions above described, although the 
wavelength at which resonance occurs and the shape of the energy absorption profile differ with 
different conducting materials. Gold is used in Biacore sensor chips because it combines 
favorable SPR characteristics with stability and a high level of inertness in biomolecular 
interaction contexts.  
This advanced technology can be used to investigate the specificity of an interaction, by testing 
the extent of binding between different pairs of molecules, or to describe the kinetics and affinity 
of an interaction, by analyzing the binding behavior in terms of mathematical interaction models, 
or to quantify the concentration of specific molecules present in the sample by measuring the 
response obtained from the sample itself.  
Biacore studies can be applied to a wide range of biomolecules including proteins, lipids, nucleic 
acids, carbohydrates and small molecules such as synthetic drugs. Analytes to be detected should 
have a molecular weight above 100 Da in order to produce a sufficient change in the reflective 
index; considering that the evanescent wave penetration depth is 300-400 nm, molecules longer 
than 400 nm can be detected but not accurately characterized because they produce a non-linear 
signal. 
The heart of Biacore systems is the sensor chip, which provides the physical conditions necessary 
to generate the SPR signal and to monitor the interactions occurring on its surface. A sensor chip 
is composed by two fundamental parts; the first is a glass surface covered by a thin gold layer (50 
nm) that is required to generate the SPR signal and the second is an inert matrix covering the gold 
layer containing the reactive groups necessary to anchor the ligand.  
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Different biological compatible matrices are commercially available offering the opportunity to 
immobilize the ligand through several approaches such as a covalent immobilization, where it is 
linked to the surface through a covalent chemical link or a high affinity capture, where it is 
attached by noncovalent but high specific interaction with another molecule and a hydrophobic 
adsorption, which exploits more or less specific hydrophobic interactions to attach either the 
molecule of interest or a hydrophobic carrier, such as a lipid monolayer or bilayer, to the sensor 
chip surface (Figure 2). 
 
Figure 2: Three most commonly used approaches for attaching biomolecules to the sensor chip surface. 
The most commonly used sensor chip is the CM5 type, carrying a matrix of carboxymethylated 
dextran covalently attached to the gold surface (Figure 3), the dextran matrix is flexible, allowing 
relatively free movement of attached ligands within the surface layer and it provides a high 
surface capacity for immobilizing a wide range of ligands with every chemical strategies.  
  
Figure 3: Schematic illustration of the structure of a CM5 sensor chip. 
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Other sensor chips frequently used include the CM4, with a lower degree of carboxymethylation 
resulting in reduced immobilization capacity; the CM3, containing a carboxymethylation 
consisting of shorter dextran chains helpful to reduce steric effects when working with large 
molecules; the sensor chips SA, on the dextran matrix of which, streptavidin has been covalently 
pre-attached to allow the high affinity capture of biotinylated ligands; sensor chip NTA with 
immobilized nitrilotriacetic acid, providing a means for capturing polyhistidine-tagged ligands 
through metal chelation. 
Sample containing analyte can be injected over the immobilized ligands thanks to a sophisticated 
microfluidic system. The sensor surface itself forms one wall of a flow cell, which is an integral 
part of the microfluidic system that consists of a series of channels and valves in a plastic block, 
the Integrated Microfluidic Cartridge (IFC). The flow cells are formed by pressing the sensor 
chip against a set of open channels on the surface of the IFC, so that the chip can easily be 
exchanged. Delivery of sample and buffer to the flow cells is precisely controlled by the pump 
system and by the valves in the IFC, in this way a continuous flow of liquid is maintained over 
the sensor surface throughout the analysis. 
Thanks to the valves, the operator can regulate the flow and chose in how many channels the 
sample has to be injected (Figure 4). For each cycle of analysis a maximum of 4 channels (flow 
cells) can be simultaneously used, the flow cells are optimized to be used in pairs (2-1 and 4-3) 
and the flow cell 1 could also be used as reference for all the other three channels (2-1, 3-1, 4-1). 
 
Figure 4: Schematic representation of the 4 flow cells and of the valves involved in the control of the flow; in this 
case sample flows in channel 1 and channel 2. 
The signal registered in the reference channel will be subtracted from the one obtained in the 
active channels. This subtraction has the advantage of removing the aspecific interactions that 
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can be registered on a gold surface when injecting a complex matrix. The other advantage is the 
removal of the so call bulk effect that can mask interactions involving low molecular weight 
analytes and that is due to a high difference in the reflective indices of the sample solution and of 
the running buffer.  
Covalent immobilization to the dextran matrix is the most commonly used approach for attaching 
the ligand to the surface, and it is also the method of choice for immobilizing capturing 
molecules. Covalent immobilization generally results in stable attachment of the ligand to the 
surface under the buffer conditions normally used for surface regeneration that removes bound 
analyte at the end of each analysis cycle but leaves the ligand attached to the surface. 
To obtain a good immobilization level, the electrostatic pre-concentration of ligands in the 
dextran matrix must be achieved. It’s important to consider that at pH values above 3.5 the 
carboxymethylated dextran on the sensor chip surface is negatively charged, so the primary 
requirement for the electrostatic pre-concentration on the surface is that the pH of the ligand 
solution should lie between 3.5 and the isoelectric point of the ligand, so that the surface and the 
ligand carry opposite net charges (Figure 5).  
 
Figure 5: Schematic representation of ligand pre-concentration on chip surface; ligand is concentrated electrostatic 
attraction between ligand and chip is possible only when the pH lies between the isoelectric point of the ligand and 
the pKa of the surface. 
In addition, the electrostatic interactions involved in pre-concentration are favored by low ionic 
strength in the coupling buffer. The optimum values of pH and ionic strength can be determined 
experimentally for every ligand with the pH scouting procedure; this procedure consists in 
injecting the ligand in different buffers over the non-activated surface of the chip and evaluating 
the instrumental response at the end of the injection which depends only on the electrostatic 
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interactions between the chip surface and the ligand and that consequently will give an indication 
of whether the conditions are suitable. 
The general pattern for essentially all covalent immobilization methods consists in the following 
steps: 
- chip surface activation by the injection of appropriate reagents; 
- ligand injections in the previously identified best immobilization buffer up to reaching a 
satisfactory immobilization level; 
- injection of a reagent to deactivate remaining active groups on the surface and to remove non-
covalently bound ligand. 
The most common immobilization chemistries (Figure 6) are: 
- amine coupling, exploiting primary amine groups of the ligand after activation of the surface; 
- thiol coupling, exploiting thiol-disulfide exchange between thiol groups and active disulfides 
introduced on either the ligand (surface thiol coupling) or the surface matrix (ligand thiol 
coupling); 
- aldehyde coupling, using the reaction between hydrazine or carbohydrazide groups introduced 
on the surface and aldehyde groups obtained by oxidation of carbohydrates in the ligand. 
 
Figure 6: Covalent immobilization approaches for attaching the ligand to the surface.  
Amine          Ligand thiol            Surface thiol            Aldehyde 
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1.4.1.1 Binding studies 
Once the ligand has been immobilized on the surface of the chip, binding measurement can be 
done to quantify the interaction between the ligand and the samples containing the analyte we 
want to reveal.  
A binding experiment is performed for each sample to be tested, by repeating the same cycle of 
analyses consisting in the following steps: sample injection under a continuous flow of running 
buffer to allow the formation of the complex, running buffer flow to obtain a partial dissociation, 
chip surface regeneration to completely remove the analyte that interacted with the ligand without 
altering the ligand itself. During the injection time the interaction between ligand and analyte 
generates a change in the reflective index and is converted into an instrumental signal that is 
directly related to the change in mass concentration on the surface, so that molar responses are 
proportional to the size of the molecule involved. A given response will represent a higher molar 
concentration of a small molecule than a large one: conversely, a given number of molecules 
binding to the surface will give a lower response if the molecule is small. This response is 
graphically expressed by a sensorgam (Figure 7) showing the progress of the interaction during 
time. 
 
Figure 7: Typical sensorgram resulting from a binding experiment; the signal in Resonance Units is direclty related 
to the quantity of the analyte that binds to the ligand. 
To compare the results obtained injecting different samples, two kinds of reference points 
illustrated in Figure 7 can be considered: the binding values that indicate the maximum 
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interaction signal that is revealed at the end of the injection or the stability values that indicate the 
signal registered 20 seconds after the end of the injection and that only depends on very high 
specific interactions. 
1.4.1.2 Kinetic and affinity studies 
The biosensor Biacore T100 allows the characterization of the kinetic and the affinity of the 
interaction between the biomolecules of interest. Kinetic and affinity are normally determined 
from the binding characteristics of a series of analyte concentrations. These concentrations may 
be injected in separate cycles with surface regeneration between the cycles (multi-cycle analysis) 
or sequentially in a single cycle with no regeneration between injections (single-cycle analysis).  
The minimal requirements to perform a kinetic and affinity evaluation are the knowledge of the 
molecular weight of the analyte, the application of a concentration series of analyte with at least 
four non-zero concentrations and one blank cycle consisting of zero concentration sample.  
Results from these two approaches are evaluated in the same way, experimental data obtained 
with every sample are fitted to a series of mathematical models describing the interaction. The 
association phase during sample injection contains information on both association and 
dissociation processes and allows the calculation of the association rate ka (M-1s-1), from the 
dissociation phase when buffer flow removes dissociated analyte molecules, the dissociation rate 
kd (s-1) can be obtained. For the simple 1:1 binding model, the affinity constant KD (M) is equal 
to the ratio of the rate constants (kd/ka) and can therefore be derived from kinetic measurements.  
The fitting procedure used to determine rate constants from experimental data uses numerical 
integration methods with an iterative approximation algorithm to find the best mathematical 
model describing the interaction. The standard kinetic interaction models provided with Biacore 
systems are: a) the 1:1 binding that describes one molecule of analyte binding to one molecule of 
ligand; b) the bivalent analyte that indicates the interaction of a monovalent ligand with analyte 
molecules that carry two identical and independent binding sites; c) the heterogeneous ligand 
describing the interaction of one analyte with two independent ligands on the surface; in this 
case, the observed binding is the sum of the interaction with the two ligands.  
The closeness of the fit is judged in terms of the chi-square value, which describes the deviation 
between the experimental and the fitted curves. The fitting algorithm seeks to minimize chi-
square, and is judged to be complete when the difference in chi-square values between successive 
iterations is sufficiently small. The significance of the parameter values returned by the fitting 
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procedure is indicated by the standard error, which represents the degree to which the value can 
be varied without significantly affecting the closeness of fit; one parameter is considered 
significant if its standard error is no more than 1/10 of the parameter value. Other indicators of 
the closeness of the fitted model are the residuals, which indicate the difference between 
experimental and fitted value for each data point in the sensorgrams. The residuals should lie 
within reasonable limits and for a perfect fit they scatter around zero (typically ±1-2 RU). 
In order to obtain a high quality of kinetic and affinity data, it is necessary that the sensorgrams 
have a sufficient curvature during the association and the dissociation phase; consequently 
interactions characterized by a very slow kinetic have to be monitored for a longer time and for 
interactions characterized by a fast kinetic, the flow should be decreased. The optimal 
concentration range of the analyte has to be chosen in order to achieve the saturation of the signal 
at the highest concentration used.  
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2 AIM OF THE PROJECT 
This PhD work deals with different projects grouped together at first by the aim of selecting the 
best synthetic peptide bearing aberrant post-translational modifications that could be used as 
probe in non invasive in vitro assays (SP-ELISA or biosensor analysis), to allow a rapid and 
relatively low expensive detection of specific autoantibodies as diagnostic or prognostic 
biomarkers of autoimmune diseases.  
The second aim is to deeply characterize the kinetic and the affinity of the interactions between 
antibodies from patients’ sera and previously selected antigens thanks to an advanced Surface 
Plasmon Resonance based biosensor Biacore, in order to obtain information that could have a 
prognostic value for the follow-up of the disease or that could clarify which is the minimal 
epitope of a high molecular weight antigen, required for antibody recognition. 
In particular, the following four projects have been pursued in the framework of this PhD thesis: 
• The first topic deals with specific autoantibodies recognizing citrullinated antigens and 
currently used as diagnostic biomarkers of rheumatoid arthritis. We used SPR to 
thoroughly characterize the kinetic and the binding affinity of immunoglobulins from RA 
patients or normal health subjects to different synthetic citrullinated peptides of 
previously proved diagnostic power, using both patients’ sera and affinity purified 
antibody fractions.  
• The other three projects are based on the knowledge of the ability of the N-glucosyl 
moiety chemically introduced on CSF114(Glc) peptide to detect  specific autoantibodies 
in MS patients’ sera, when the peptide is employed in in vitro assays. Considering the 
recent discovery that the same N-glucosylation present in CSF114(Glc) can be introduced 
by a bacterial enzyme on the adhesin protein of Haemophilus influenzae, the second topic 
investigates the ability of recombinant glucosylated protein to interact with antibodies in 
MS patient’s sera. The final aim is to investigate if the MS immune deregulation can be 
triggered by a bacterial infection through a mechanism of molecular mimicry. 
• The third topic deals with the SPR characterization of the interaction of CSF114(Glc) 
with some phage clones and with one selected soluble human antibody domain, in order 
to understand if this kind of engineered antibodies can be relevant for the development of 
antigen detection strategies to be used in MS diagnosis.  
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• A recent study suggested a clinical correlation between Rett syndrome and MS, so the last 
part of this thesis we studied the ability of both CSF114(Glc) and the recombinant 
glucosylated adhesin protein mentioned above, to reveal antibodies in Rett patients’, using 
immunoenzymatic assays on a large number of patients and control sera.    
All together these studies could help to solve a very common problem in the field of autoimmune 
diseases, regarding the knowledge of the real in vivo antigen that triggers the pathological 
autoimmune response and contribute to develop better diagnostic and prognostic assay. 
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3: Biosensor characterization of Anti-Citrullinated Protein/Peptide Antibodies 
(ACPA) from Rheumatoid Arthritis patients’ sera. 
3.1 Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) is a systemic autoimmune disease occurring in 1% of the adult 
population worldwide, it is characterized by chronic synovial inflammation that may led to the 
destruction of joints, of tissue around joints and of other organs in the whole body. 
As shown in Figure 8, three different phases can be identified in RA1: the initiation of the disease 
that takes place in peripheral lymphoid organs and whose symptoms are similar to common 
arthritis, is characterized by synovitis causing swelling of small joints and pain upon motion. 
Disease is probably initiated by dendritic cells that present self-antigens to autoreactive T cells, 
which in turn activate autoreactive B cells through cytokines and co-stimulatory molecules, 
resulting in the production of autoantibody and the deposition of immune complexes in the joint. 
After the migration of immune cells into the joint, antigen presentation can also occur at the 
synovium, but direct T-cell contact can also activate other cells in an antigen-independent 
manner. The propagation stage is mediated by immune complexes binding to Fc receptors on 
macrophages, neutrophils and mast cells; this leads to the release of pro-inflammatory cytokines 
such as the Tumor Necrosis Factor-α (TNF-α) and chemokines by these activated cells, as well as 
to marked leukocyte infiltration and consequent synovial pannus formation. The terminal phase is 
characterized by joint and bone damage and by the possible involvement of other organs such as 
kidney, blood vessels and lungs; during this last step high levels of cytokines and chemokines 
activate and recruit synovial fibroblasts, macrophages, osteoclasts and neutrophils, which release 
proteases, Reactive Oxygen Species (ROS), nitric oxide and prostaglandin E2.  
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Figure 8: Stepwise progression of the immune response involved in the development of RA; three different phases 
can be identified and all steps collectively contribute to irreversible bone and cartilage destruction. 
Although the etiology of RA is poorly understood, genetic factors, humoral and cellular 
autoimmune mechanisms and environmental factors are all involved in the pathogenesis of the 
disease2. It has been demonstrated that some common factors of risk for the development of the 
disease include oral contraceptives, female hormones, smoke and infectious agents such as the 
Epstein-Barr Virus (EBV). 
In patients with early disease, the joint manifestations are often difficult to distinguish from other 
forms of inflammatory polyarthritis and the sub-clinical manifestation of the disease could be 
very long, so the diagnosis of RA is extremely complicated.  
Up to now there is no cure for RA, the therapy is based on the administration of classical drugs 
(nonsteroidal anti-inflammatory drugs, corticosteroids and immunosuppressants) used to reduce 
inflammation in order to relieve pain and prevent or slow joint damages; some patients can also 
benefit of the treatment with innovative biological drugs such as very expensive monoclonal 
antibodies targeting TNF-α.  
In this background the detection of specific biomarkers that allow an early diagnosis and 
treatment of the pathology is fundamental in order to control inflammation and to prevent the 
irreversible damages typical of the disease. 
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3.2 Anti-Citrullinated Peptides/Protein Antibodies: a diagnostic criteria for RA. 
The best known RA biomarker is the Rheumatoid Factor (RF), a class of IgM antibodies directed 
against the Fc-region of the IgG isotype of immunoglobulins. However, RF is not a specific RA 
marker as it can be found also in other pathological conditions and in healthy individuals. The 
discovery of the involvement of citrullinated epitopes in RA using anti-perinuclear factor and 
anti-keratin antibodies boosted the identification of novel highly specific biomarkers of RA3. 
A family of specific autoantibodies recognizing different citrullinated peptides and proteins and 
so named Anti-Citrullinated Peptide/Protein Antibodies (ACPA) has been extensively studied in 
the last decades. ACPA represent a family of heterogeneous antibodies with overlapping 
specificity, they have been detected in up to 80% RA patients4 and correlate with disease 
severity; moreover they are present in the early stage of RA when the differential diagnosis from 
other chronic arthritis may not be easy and they can also be found in healthy subjects who later 
developed RA. In 2010 new diagnostic criteria for RA have been defined5, attributing a score to 
the different clinical evidences observed in the patient (Table 1), such as the presence of synovitis 
in at least one joint, the absence of an alternative diagnosis that better explains the synovitis and 
the presence of autoantibodies as serological markers; the diagnosis is confirmed if the patient 
reaches a total score of 6 or more. Because ACPA represent an important biomarker of the 
disease they have been included in the serological criteria for the classification of RA.  
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Clinical manifestations Score 
Joints involved: 
• 1 big joint 
• 2 – 10 big joints 
• 1 – 3 small joints (with or without big joint involvment) 
• 4 – 10 small joints (with or without big joint involvment) 
• > 10 joints (at least 1 small joint) 
 
0 
1 
2 
3 
5 
Serology (at least one positive parameter) 
• RF and ACPA negative 
• RF or ACPA slightly positive 
• RF or ACPA very positive 
 
0 
2 
3 
Acute-phase indicators: 
• Normal protein C and erythrocyte sedimentation coefficient 
levels 
• Abnormal protein C or erythrocyte sedimentation coefficient 
levels 
 
 
0 
 
1 
Clinical symptoms duration: 
• < 6 weeks 
• > 6 weeks 
 
0 
1 
Table 1: Rheumatoid Arthritis classification criteria.  
It has been demonstrated that ACPA recognize different self proteins6, such as filaggrin, 
fibrinogen, vimentin, collagen II, enolase and histone H47, but also viral citrullinated sequences 
derived from EBV-encoded proteins8, the arginyl residues of which have been post-
translationally transformed into citrullyl ones.  
Citrulline is a non standard amino acid deriving from a post translational modification catalyzed 
by the enzyme Peptidyl-Arginine Deiminase (PAD). This modification results in the deimination 
of arginine residues of proteins into citrulline via the hydrolysis of the guanido group of arginine 
giving an ureido group and free ammonia; consequently for each deiminated residue, the 
modified protein acquired one neutral charge instead of one net positive charge (Figure 9). 
Five PAD isotypes have been described, among them only PAD4 has a nucleic localization9 
compared with the cytosolic distribution of the other isotypes and together with PAD2 its 
presence has been demonstrated in synovial fluid cells and extracellular synovial fluid.  
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Figure 9: Deimination of arginine into citrulline catalyzed by the PAD. 
Deimination is a physiological process that regulates genes expression, the normal development 
of tissues and organs such as skin and brain, and also the response to infections because it is a 
fundamental step in the unfolding of the chromatin followed by Neutrophil Extracellular Traps 
(NET) formation10. 
PAD is a Ca2+ dependent enzyme that is inactive at normal intracellular calcium concentration, 
but events such as cell death or oxidative stress can increase the Ca2+ concentration up to the 
threshold level, activating the enzyme and inducing proteins deimination.  
Several in vitro assays have been developed to specifically reveal ACPAs from RA patients’ sera 
using synthetic citrullinated peptides as probes as, for example, the anti-Viral Citrullinated 
Peptides (VCP1 and VCP2)11 test or the anti-Modified Citrullinated Vimentin (MVC) one. Up to 
now the more frequently used assay for ACPA detection is based on a mixture of filaggrin 
derived Ciclic Citrullinated Peptides (CCPs)12. Interestingly, the comparison of the performance 
of the tests based on CCPs, and VCPs suggested that different citrullinated sequences can detect 
different subgroups of ACPA in the same set of patients. 
3.3 Objective 
The association of ACPAs, measured using any of the above-mentioned antigens, with erosive 
arthritis has suggested a role of the antibodies in inducing inflammation and joint damage. One of 
the possible pathogenic activities of ACPAs is the formation of immune complexes, with 
consequent release of pro-inflammatory cytokines such as TNF-α from monocytes and 
macrophages13.  
Considering that the affinity of autoantibodies for their target is considered a relevant parameter 
in determining their pathogenicity, the aim of the current project was to employ the SPR-
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biosensor Biacore to characterize the affinity and the kinetic of ACPAs, analyzing at first the 
binding of immunoglobulins from RA patients or normal health subjects and then of affinity 
purified antibodies from RA patients, to different synthetic citrullinated peptides of previously 
proved diagnostic power. 
3.4 Results and discussion 
In the first part of this project the affinity of ACPAs was measured by SPR, analyzing the 
interaction of IgG fractions from RA sera containing ACPA (9 patients, RA1-RA9) and normal 
health sera (2 donors, NHS1 and NHS2) with 4 different citrullinated Multiple Antigen Peptides 
(MAPs) and a tetanus toxoid peptide. Then three diagnostic citrullinated peptides and two non-
citrullinated arginine containing control peptides were selected and their interaction with anti-
peptide antibody fractions isolated from five RA patients’ sera were characterized.  
3.4.1 Sensor chips preparation for the characterization of IgG preparations 
Two viral citrullinated peptides (VCP1 and VCP2) and two histone citrullinated peptide (HCP1 
and HCP2)14 were synthesized as tetrameric MAPs by the company Toscana Biomarkers srl and 
P30 peptide of Tetan Toxoid (947–967)15 was received from the Institute of Biochemistry, 
University of Lausanne. For each peptide the best immobilization buffer maximizing the 
electrostatic interaction with chip surface was selected with the pH scouting procedure and 
peptides were covalently immobilized onto gold sensor chips to reach immobilization levels 
reported in Table 2.  
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Name Sequence Immobilization buffer 
Immobilized 
Peptide (RU) 
VCP1 (Gly Gly Asp Asn His Gly Cit Gly Cit Gly Cit Gly Cit Gly Cit Gly Gly Gly Cit Pro Gly Ala Pro Gly)4 Lys2 Lys βAla  
CH3COO-Na+ 
0.1 mM  
pH 4.5 
885 
VCP2 (Gly Gln Ser Cit Gly Gln Ser Cit Gly Cit Gly Cit Gly Cit Gly Cit Gly Cit Gly Lys Gly)4 Lys2 Lys βAla  
CH3COO-Na+ 
0.1 mM  
pH 4.5 
2080 
HCP1 (Ala Lys Cit His Cit Lys Val Leu Cit Asp Asn Ile Gln Gly Ile Thr Lys Pro Ala Ile)4 Lys2 Lys βAla  
CH3COO-Na+ 5 
mM 
 pH 6.0 
4100 
HCP2 (Lys Pro Ala Ile Cit Cit Leu Ala Cit Cit Gly G ly Val Lys Cit Ile Ser Gly Leu Ile)4 Lys2 Lys βAla 
CH3COO-Na+ 5 
mM 
 pH 5.0 
3300 
P30 (Phe Asn Asn Phe Tyr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ser Ala His Leu Glu)
 4 Lys2 Lys βAla 
CH3COO-Na+ 
10mM pH 5 6025 
Table 2: MAPs used for the SPR characterization of IgG fractions, optimal immobilization buffer and quantity of 
peptide immobilized on chip surface expressed in Resonance Unit (RU). 
Peptides were linked according to the amine coupling strategy: an amine bond was formed 
between a primary amine group of each peptide and the previously activated carboxylic group on 
chip surface, then free reactive sites on chip were blocked with the appropriate reagent. The 
instrumental signal generated with the immobilization of P30 peptide is given in Figure 10. 
 
Figure 10: Sensorgram for amine coupling immobilization of tetanus P30 peptide on channel 2 of a CM5 chip type. 
Since sensor chips contain four independent channels, two sensor chips were employed for the 
immobilization of five ligands. One channel of each sensor chip was used as reference to subtract 
unspecific interaction between samples and gold surface, this channel was activated and directly 
blocked.  
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3.4.2 Affinity evaluation of ACPA from IgG preparations 
IgG antibodies from patients or control sera, obtained by protein G-affinity chromatography were 
flowed over each immobilized peptides in individual cycle of analysis based on the following 
steps: sample injection (association), washing with running buffer (dissociation), and finally chip 
surface regeneration. Results were elaborated separately for each sample with Biacore Evaluation 
Software 2.0, fitting the experimental values to theoretical kinetic models and obtaining a high 
quality fitting with both the 1:1 binding model and the bivalent analyte one. According to this 
latter model, after analyte–ligand interaction at the first site, engagement of the second site does 
not contribute to SPR response because there is no change in RI or mass over the chip; there is 
only a sort of rearrangement of the bound analyte. However, a low amount of peptide was 
immobilized on the sensor chip, thereby limiting the rebinding effect, and in fact the ‘‘check data 
components’’ option of the software indicated that the interaction with the first binding site was 
greater than the interaction with the second one. Thus the 1:1 binding model, considering the 
interaction between a monovalent analyte molecule and a monovalent immobilized ligand was 
selected and validated by three statistical parameters: the residual values between the 
experimental points and the theoretical ones that were closely distributed along the zero, the 
minimal chi-square value, and the standard errors that were less than 10% of the referred 
parameter value.  
The 9 RA samples resulted to be ACPA positive according to the biosensor assay because 
antibodies interacting at least with two different citrullinated peptides were detected in each 
patient serum. As reported in Table 3, the vast majority of interactions between RA IgG and 
histone derived peptides were characterized by higher affinity (10-6 M > KD  > 10-8 M) compared to 
the interactions between RA IgG and peptides VCP1 and VCP2 that were characterized by lower 
affinity (10-5 M > KD  > 10-6M).  
IgG from healthy subject (NHS1 and NHS2) recognized HCP2 citrullinated peptide, and in 
particular NHS1 IgGs interacted with HCP2 with higher affinity (KD = 10-9 M) than NHS2 IgGs 
(KD = 10-7 M) (Figure 11 A). 
IgG from RA patients or controls interacted with peptide P 30 with high affinity (10-7 M > KD  > 
10-9M) as expected with antibodies induced by repeated cycles of immunization. The 
sensorgrams resulting from the kinetic study of NHS2 IgG and tetanus peptide is reported in 
Figure 11 B. Results obtained with P30 peptide were important because they could be considered 
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as an internal control, confirming the ability of the biosensor assay to reveal high affinity 
antibodies and consequently giving significant results. 
KD (M) 
 
RA1 RA2 RA3 RA4 RA5 RA6 RA7 RA8 RA9 NHS1 NHS2 
VCP1 1.1 × 
10-6 
3.8 × 
10-6 
No 
binding 
5.8 × 
10-6 
No 
binding 
1.2 × 
10-4 
2.0 × 
10-6 
1.0 × 
10-6 
No 
binding 
No 
binding 
No 
binding 
VCP2 1.4 × 
10-6 
1.5 × 
10-6 
1.5 × 
10-7 
4.8 × 
10-7 
No 
binding 
1.3 × 
10-6 
8.7 × 
10-7  
5.5 × 
10-7 
6.1 × 10-
5
 
No 
binding 
No 
binding 
HCP1 5.9 × 
10-8 
1.9 × 
10-7 
1.4 × 
10-7 
6.9 × 
10-8 
1.8 × 
10-6 
1.0 × 
10-4 
No 
binding 
7.0 × 
10-8 
No 
binding 
No 
binding 
No 
binding 
HCP2 3.2 ×  
 10-8 
2.6  ×  
10-8 
1.9 ×   
10-7 
1.8 ×  
10-7 
4.4 × 
10-8 
8.5 ×  
10-8 
5.7 ×  
10-8 
9.2 × 
10-8 
3.6 ×  
10-8 
3.0 ×  
10-9 
2.3 ×  
10-7 
P30 1.7 × 
10-8 
2.7 × 
10-8 
7.5 × 
10-8 
4.7 × 
10-8 
7.6 × 
10-8 
9.5 × 
10-8 
7.2 × 
10-8 
7.1 × 
10-8 
3.8 × 10-
8
 
2.5 × 
10-9 
7.7 × 
10-7 
Table 3: Affinity constants KD calculated with the 1:1 binding model for interactions between IgG samples (9 RA 
patients and 2 Normal Health Subjects) and four citrullinated peptides and tetanus peptide. 
 
  
Figure 11: Sensorgrams showing the kinetic of the interaction between peptide HCP2 and IgG fraction from NHS2 
(A) or between peptide P30 and NHS2 IgG. Experimental curves are reported in different colors according to the 
sample concentration, black lines represent the 1:1 binding mathematical model fitted to the experimental values.  
To confirm the presence of IgG antibodies in NHS samples as well as in RA sera, interacting 
with peptide HCP2, we performed binding studies with NHS1, NHS2 and RA1 IgG preparations. 
For each sample three cycles of analysis were performed, characterized by the following steps: 
sample injection, secondary anti-human antibody application, sensor surface regeneration. All the 
samples were tested at the same concentration and in each cycle a different secondary antibody 
was applied (anti-IgG, anti-IgA or anti-IgM). Figure 12 shows the result of the binding study 
performed with NHS2 sample: a similar binding level was registered at the end on sample 
injection indicating the reproducibility of the assay and the efficacy of surface regeneration; once 
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the secondary antibodies were injected, a significant enhancement in the response was registered 
only in the case of the anti-IgG.  
 
Figure 12: Result of the binding study performed with NHS2 sample applying three different secondary anti-human 
antibodies; an increase in the SPR signal was obtained with the anti-IgG antibody.  
The same results were obtained with the other two tested samples confirming the presence of IgG 
isotype antibodies not specific for RA disease that, in the experimental conditions of this SPR 
assay, interacted with immobilized HCP2. 
3.4.3 Sensor chips preparation for purified ACPA detection  
Considering the results obtained from the above reported biosensor analysis, we decided to 
deeply characterize the affinity and the kinetic of ACPA interaction with different antigens, by 
testing anti-peptide antibodies purified by affinity chromatography with three citrullinated 
peptides, from five ACPA positive RA patients.  
For this purpose a new sensor surface was prepared by immobilizing the two viral citrullinated 
peptides VCP1 and VCP2, the histone citrullinated peptide HCP1 and two control sequences 
(VArgP2 and HArgP1); because of its aspecificity problems HCP2 was not used. The five 
selected peptides listed in Table 4, were synthesized as tetrameric MAP by the company Toscana 
Biomarkers srl. For each peptide the best immobilization buffer maximizing the electrostatic 
interaction with chip surface was selected with the pH scouting procedure and they were 
covalently immobilized onto gold sensor chips to reach immobilization levels listed in Table 4.  
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Name Sequence Immobilization buffer 
Immobilized 
Peptide (RU) 
VCP1 
(Gly Gly Asp Asn His Gly Cit Gly Cit Gly Cit Gly Cit Gly 
Cit Gly Gly Gly Cit Pro Gly Ala Pro Gly)4 Lys2 Lys βAla 
Cys 
CH3COO-Na+ 
0.5 mM  
pH 4.5 
4080 
VCP2 (Gly Gln Ser Cit Gly Gln Ser Cit Gly Cit Gly Cit Gly Cit Gly Cit Gly Cit Gly Lys Gly)4 Lys2 Lys βAla Cys 
CH3COO-Na+ 
0.1 mM  
pH 4.5 
4234 
HCP1 (Ala Lys Cit His Cit Lys Val Leu Cit Asp Asn Ile Gln Gly Ile Thr Lys Pro Ala Ile)4 Lys2 Lys βAla Cys 
CH3COO-Na+ 
0.1 mM 
 pH 4.5 
4750 
VArgP2 (Gly Gln Ser Arg Gly Gln Ser Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Lys Gly)4 Lys2 Lys βAla Cys 
Running Buffer 
pH 7.4 3336 
HArgP1  (Ala Lys Arg His Arg Lys Val Leu Arg Asp Asn Ile Gln Gly Ile Thr Lys Pro Ala Ile)4 Lys2 Lys βAla Cys 
CH3COO-Na+ 
0.1 mM 
 pH 5.0 
4282 
Table 4: MAPs used for the SPR characterization of purified ACPAs, optimal immobilization buffer and quantity of 
peptide immobilized on chip surface expressed in Resonance Unit (RU). 
Thanks to the C-terminal cysteine residue that was introduced in each of the five peptides, the 
thiol coupling strategy was employed for their immobilization on Biacore sensor chips. By this 
approach, each peptide was covalently immobilized in a well defined orientation on the chip 
surface, obtaining a better exposition of its antigenic branches. This coupling approach consisted 
in the activation of carboxylic groups on chip surface, in the introduction of active disulfide 
groups and in the injection of the peptide containing the free thiol in order to allow the exchange 
reaction between thiols and active disulfide groups introduced in the dextran matrix. Free reactive 
sites on chip surface were blocked with appropriate reagents. Figure 13 shows the resonance 
signal generated by the immobilization of VCP1 peptide on channel 2. The channel 1 of each 
sensor chip was used as reference to subtract unspecific interaction between samples and gold 
surface, this channel was activated and directly blocked obtaining the sensorgram shown in 
Figure 13.  
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Figure 13: Sensorgrams registered from channel 1 during the blank immobilization and from channel 2 during the 
immobilization of VCP1 according to the ligand thiol coupling strategy. 
3.4.4 SPR characterization of purified ACPA 
Each anti-peptide antibody fraction was diluted up to a suitable final concentrations and flowed 
over each immobilized peptide in an individual cycle of analysis based on the same steps 
described for IgG fractions characterization. Results were elaborated separately for each sample 
fitting the experimental values to the theoretical 1:1 binding model that was validated by the 
statistical parameters of the residual values, the chi-square value, and the standard errors. The 
affinity constants KD, and the kinetic parameters of the association rate ka and dissociation rate 
kd, describing the interactions between each purified antibody fraction and the three citrullinated 
peptides were calculate and reported in Table 5.  
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 ka (L/mol·s) kd (1/s) KD (mol/L) ka (L/mol·s) kd (1/s) KD (mol/L) ka (L/mol·s) kd (1/s) KD (mol/L) 
 VCP1 VCP2 HCP1 
RA1 anti 
VCP1 
51.7 ± 10.8 × 
102 
64.0 ± 0.4 
× 10-4 
1.24 ± 0.03 
× 10-6 
67.9 ± 0.8 × 
102 
93.0 ± 1.0 × 
10-4 
1.37 ± 0.03 
× 10-6 
64.8 ± 2.6 × 
103 
33.1 ± 0.4 × 
10-4 
5.10 ± 0.27 
× 10-8 
RA2 anti 
VCP1 
87.3 ± 1.8 × 
102 
10.0 ± 0.2 
× 10-3 
1.15 ± 0.04 
× 10-6 
10.6 ± 0.2 × 
103 
96.1 ± 1.3 × 
10-4 
9.09 ± 0.29 
× 10-7 
14.9 ± 0.1 × 
103 
21.0 ± 0.7 × 
10-5 
1.41 ± 0.06 
× 10-8 
RA3 anti 
VCP1 
54.0 ± 0.7 × 
102 
63.7 ± 0.4 
× 10-4 
1.18 ± 0.02 
× 10-6 
68.1 ± 1.0 × 
102 
62.9 ± 0.8 × 
10-4 
9.24 ± 0.25 
× 10-7 
10.1 ± 1.2 × 
103 
19.5 ± 2.6 × 
10-4 
1.93 ± 0.49 
× 10-7 
RA4 anti 
VCP1 
11.4 ± 0.2 × 
103 
12.5 ± 0.2 
× 10-3 
1.10 ± 0.04 
× 10-6 
10.9 ± 0.2 × 
103 
48.3 ±0.6 × 
10-4 
4.44 ± 0.14 
× 10-7 
59.0 ± 0.2 × 
103 
28.1 ±0.2 × 
10-4 
4.76 ± 0.05 
× 10-8 
RA5 anti 
VCP1 
15.8 ± 0.5 × 
103 
34.4 ± 0.6 
× 10-4 
2.18 ± 0.11 
× 10-7 
11.8 ± 3.5 × 
103 
59.1 ± 3.4 × 
10-4 
4.99 ± 1.77 
× 10-7 
28.3 ± 1.0 × 
103 
22.2 ± 0.3 × 
10-4 
7.82 ± 0.38 
× 10-8 
RA1 anti 
VCP1 
33.9 ± 1.3 × 
103 
35.5 ± 1.3 
× 10-3 
1.05 ± 0.08 
× 10-6 
10.7 ± 0.1 × 
103 
71.3 ± 0.6 × 
10-4 
6.68 ± 0.12 
× 10-7 
66.0 ± 0.4 × 
103 
16.4 ± 1.0 × 
10-4 
2.48 ± 0.17 
× 10-8 
RA2 anti 
VCP1 
60.5 ± 1.1 × 
102 
10.9 ± 0.2 
× 10-3 
1.81 ± 0.07 
× 10-6 
85.0 ± 0.2 × 
102 
12.3 ± 0.3 × 
10-3 
1.45 ± 0.04 
× 10-6 
36.9 ± 0.3 × 
103 
15.1 ± 0.1 × 
10-4 
4.10 ± 0.06 
× 10-8 
RA3 anti 
VCP1 
63.1 ± 1.0 × 
102 
92.6 ± 0.7 
× 10-4 
1.47 ± 0.03 
× 10-6 
52.7 ± 0.9 × 
102 
50.5 ± 
0.6×10-4 
9.58 ± 0.28 
× 10-7 
14.0 ± 0.9 × 
103 
29.5 ± 0.6 × 
10-4 
2.11 ± 0.18 
× 10-7 
RA4 anti 
VCP1 
51.3 ± 0.4 × 
103 
49.4 ± 3.4 
× 10-3 
9.62 ± 0.74 
× 10-7 
17.8 ± 0.5 × 
103 
91.7 ± 2.1 × 
10-4 
5.15 ± 0.26 
× 10-7 
27.2 ± 1.6 × 
103 
34.4 ± 0.4 × 
10-4 
1.27 ± 0.09 
× 10-7 
RA5 anti 
VCP1 
83.8 ± 1.6 × 
102 
61.6 ± 0.6 
× 10-4 
7.36 ± 0.21 
× 10-7 
46.9 ± 0.8 × 
102 
46.5 ± 0.4 × 
10-4 
9.92 ± 0.25 
× 10-7 
34.3 ± 0.8 × 
104 
14.9 ± 0.3 × 
10-3 
4.33 ± 0.19 
× 10-8 
RA1 anti 
VCP1 
17.7 ± 0.2 × 
103 
20.3 ± 0.1 
× 10-3 
1.15 ± 0.02 
× 10-6 
38.6 ± 0.7 × 
103 
97.1 ± 1.2 × 
10-4 
2.52 ± 0.08 
× 10-7 
56.1 ± 
0.2×103 
14.1 ± 
0.1×10-4 
2.51± 0.03 
× 10-8 
RA2 anti 
VCP1 
86.5 ± 0.7 × 
102 
53.2 ± 0.2 
× 10-4 
6.15 ± 0.07 
× 10-7 
12.0 ± 0.1 × 
103 
21.8 ± 0.1 × 
10-4 
1.82 ± 0.02 
× 10-7 
40.8 ± 
0.1×103 
65.8 ± 
1.5×10-5 
1.61 ± 0.04 
× 10-8 
RA3 anti 
VCP1 
12.1 ±0.1 × 
103 
55.1 ± 0.2 
× 10-4 
4.54 ± 0.05 
× 10-7 
96.9 ± 1.7 × 
102 
41.5 ± 0.4 × 
10-4 
4.29 ± 0.12 
× 10-7 
52.2 
±1.0×103 
223.4 ± 
2.2×10-5 
4.28 ± 0.12 
× 10-8 
RA4 anti 
VCP1 
22.9 ± 0.2 × 
103 
56.4 ± 0.3 
× 10-4 
2.46 ± 0.03 
× 10-7 
21.0 ± 0.3 × 
103 
59.6 ± 0.7 × 
10-4 
2.84 ± 0.07 
× 10-7 
43.8 ± 
1.1×103 
21.6 ± 
0.2×10-4 
4.94 ± 0.17 
× 10-8 
RA5 anti 
VCP1 
26.6 ± 0.6 × 
103 
38.7 ± 0.8 
× 10-4 
1.45 ± 0.04 
× 10-7 
84.5 ± 1.1 × 
103 
14.0 ± 0.2 × 
10-4 
1.66 ± 0.05 
× 10-8 
90.9 ± 0.4 × 
103 
13.6 ± 0.1 × 
10-4 
1.49 ± 0.02 
× 10-8 
Table 5: Kinetic parameters ka and kd and affinity constant KD calculated with the 1:1 binding model for interactions 
between purified antibodies fractions and citrullinated peptides. 
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As a negative control demonstrating the requirement of citrulline residues for antibodies 
recognition, we then tested the binding of anti-VCP2 antibodies to non-citrullinated arginine-
containing peptide VArgP2, and the binding of anti-HCP1 antibodies to non-citrullinated 
arginine-containing peptide HArgP1. In four cases out of five, no binding signals were detected 
to VArgP2, while RA3 and RA5 showed respectively no and low binding to HArgP1. In the case 
in which the interaction signal was proportional to the injected concentration, the experimental 
data were fitted to the 1:1 binding model and the affinity constants KD were calculated (Table 6).  
 KD (mol/L) 
 RA1 anti VCP2 RA2 anti VCP2 RA3 anti VCP2 RA4 anti VCP2 RA5 anti VCP2 
VArgP2 No binding No binding No binding 3.39 ± 0.02 × 10-7 No binding 
      
 RA1 anti HCP1 RA2 anti HCP1 RA3 anti HCP1 RA4 anti HCP1 RA5 anti HCP1 
HArgP1 1.80 ± 0.04 × 10-7 6.95 ± 0.21 × 10-9 Low binding 1.76 ± 0.12 × 10-5 No binding 
Table 6: Affinity constant KD calculated with the 1:1 binding model for interactions between the  non citrullinated 
sequences and antibodies purified with the corresponding citrullinated peptide. 
In order to summarize all the kinetic and affinity results, we used the Biacore T100 Kinetic 
Summary application and we obtained the ka/kd plot. This graph provides an overview of kinetic 
and affinity properties for the different interactions studied, by plotting the association rate 
parameter (ka) against the dissociation rate parameter (kd), both on logarithmic scale. Affinity 
constants KD (calculated as kd/ka ratio) are displayed on diagonal lines. Thus, interactions having 
the same affinity but different kinetic are indicated by points lying on the same diagonal line. In 
Figure 14 we reported the ka/kd plot for the 15 interactions between each purified antibody 
fraction and the peptide used for its purification and for the 4 characterized interactions with the 
two arginine containing control peptides. 
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Figure 14: ka/kd plot for the 1:1 binding model summarizing interactions between 15 anti-peptide purified antibody 
fractions and the citrullinated peptide used for their purification and 4 purified antibodies interactions with non-
citrullinated control peptides. Different symbols on the plot correspond to different immobilized peptides. 
The results indicated that binding to citrullinated peptides was characterized by wide differences 
in affinity: ACPAs interacted with VCP1 and VCP2 with slower association and faster 
dissociation rate and consequently lower affinity (10-6 M > KD > 10-7M), as compared to 
antibodies that specifically bound to the histone peptide HCP1 with higher affinity (KD= 10-8 M). 
The kinetic of interaction between purified anti-VCP2 antibodies from RA3 patient and VCP2, 
characterized by a faster antibody/antigen dissociation, is reported in Figure 15 A as a 
representative example of high kd (50.5×10-4 s-1). The lack of binding between RA3 anti-VCP2 
antibodies and the arginine-containing control peptide (VArgP2) did not allow calculation of 
kinetic parameters (Figure 15 B). A representative example of low kd sensorgrams is given in 
Figure 15 C that shows the interaction between anti-HCP1 antibodies from RA1 patient and 
immobilized peptide HCP1, characterized by a slower antigen/antibody dissociation. The 
interaction between RA1 anti-HCP1 antibodies and the arginine-containing peptide HArgP1 is 
given in Figure 15 D. 
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Figure 15: Sensorgrams showing: A) a low affinity interaction between RA3 anti-VCP2 antibodies and VCP2; B) 
the lack of an interaction signal with control peptide VArgP2; C) a high affinity interaction between RA1 anti-HCP1 
antibodies and HCP1; D) the interaction between RA1 anti-HCP1 antibodies and the control peptide HArgP1. 
Experimental curves are reported in different colors according to the sample concentration, black lines represent the 
1:1 binding mathematical model fitted to the experimental values. 
On the whole, the data reported in Table 5 indicated a high cross-reactivity of anti-peptide 
antibodies. In fact, each antibody fraction, obtained by affinity chromatography on a given 
peptide, reacted also with the other two citrullinated peptides. Under this aspect, it is of interest 
that purified anti-VCP1 and anti-VCP2 antibodies had a higher affinity for HCP1 than for VCP1 
and VCP2. 
These results confirmed and extended previous data on the binding specificity, the cross-
reactivity and the affinity of ACPA. It has been demonstrated that ACPA represent a family of 
antibodies with overlapping specificities and variable cross-reactivity. The analysis of RA sera on 
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panels of citrullinated peptides from filaggrin or fibrin has demonstrated that, despite the 
existence of major epitopes, recognized by many sera, RA patients displayed many different 
reactivity profiles16. Comparing the results obtained testing a panel of sera on VCP2, VCP1 and 
CCP, a general overall correlation was found, but some sera reacted with only one or two 
antigens, thus suggesting that different non overlapping epitopes may be targeted by ACPA17.  
Analyzing the binding to non citrullinated sequences, we found that in most cases the antibodies 
were specific for citrullinated peptides because no interaction signal was registered with the non 
citrullinated sequences. When a specific signal was detected, the calculated affinity constants 
indicated that RA1 and RA4 bound with a much lower affinity the arginine containing peptides 
with respect to HCP1, while RA2 bound the arginine-containing peptide with a higher affinity 
than HCP1. RA4 displayed the same affinity for both VCP2 and VArgP2 peptides. This result 
represented an additional evidence for the exquisite specificity of antibodies from RA patients for 
citrullinated sequences. The only exception was represented by the antibodies specific for the 
citrullinated histone peptide obtained from RA2 patient that bound with a higher affinity the 
arginine containing sequence. It was likely that these antibodies were specific for the C-terminal 
portion of the peptide that did not contain citrullines, and thus represent an example of anti-
histone antibodies detectable in RA sera18. 
According to the results of the present study, ACPA resulted to be heterogeneous not only in 
terms of specificity, but also of affinity. ACPA specific for the EBNA-derived peptides VCP1 
and VCP2 were in fact characterized by a lower affinity than those binding the histone peptide. 
VCP1 and VCP2 contain a glycine-citrulline stretch, that represents an epitope shared by the two 
sequences and targeted by antibodies present in RA sera; a second non overlapping epitope is 
located in the N-terminal portion of VCP217. Thus, the structural similarity of VCP1 and VCP2 
may explain a similar affinity of antibodies that bind the two peptides. HCP1, on the contrary, is 
structurally different: it does not contain stretches of citrullines flanked by small/neutral 
aminoacids and, despite the substitution of arginine with citrulline, it has a strong positive charge 
due to several lysine residues.  
Citrullinated proteins as well as CCP, which is a mixture of synthetic peptides, bear multiple 
epitopes recognized by RA sera and thus allow an average evaluation of affinity without 
detecting a difference in affinity among antibodies binding to the different antigens. On the 
contrary, using synthetic peptides that bear a limited number of epitopes and allow analyzing an 
oligoclonal population of antibodies, a spectrum of affinity was detected. Thanks to the present 
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biosensor assay we characterized the interaction of ACPA with citrullinated peptides derived 
from exogenous antigens (VCP1, VCP2) or autoantigens (HCP1) and we found that the affinity 
for HCP1 was higher, also when antibodies affinity purified on VCP1 and VCP2 were tested. 
These results may suggest that antibodies initially elicited by an infectious antigen (such as EBV) 
could be then selected and expanded by autoantigens (such as histones). 
3.5 Conclusions 
The Surface Plasmon Resonance biosensor Biacore was employed to evaluated the affinity of the 
total IgG fraction of nine RA patients’ sera and two NHS sera for four citrullinated peptides and 
for one tetanus toxoid peptide. The presence of ACPA was confirmed in every RA sera, because 
they recognized at least two citrullinated peptides. Histone peptide HCP2 was recognized by both 
NHS samples highlighting some specificity problems. Tetanus peptide interacted with high 
affinity antibodies in every tested sample, confirming the ability of the chosen approach to detect 
high affinity antibodies. The kinetic and the affinity of the interaction between purified antibodies 
from RA patients’ sera, and citrullinated peptides VCP1, VCP2, and HCP1 were performed 
observing high cross-reactivity and heterogeneity. Calculated affinity constants for ACPA-
peptide interactions presented sensible differences (1-fold in KD values) between viral peptides 
VCP1-VCP2 and histone peptide HCP1 and as we recently reported in our publication, this result 
suggested that two different ACPA subfamilies were identified19. These findings have a potential 
clinical relevance since the peptides here analyzed are employed in solid phase assays for the 
diagnosis of RA and from this point of view it will be very interesting to test ACPAs purified 
from patients in different phase of the disease in order to understand if there is a change in the 
affinity of ACPAs interaction with a certain peptide during the progression of the disease or if a 
subfamily of autoantibodies is exclusive and so detectable in one phase of the disease and not in 
the others.  
3.6 Matherials and methods 
All experiments were conducted using a Biacore T100 instrument from GE Healthcare. All 
solutions and buffers were prepared with milliQ water obtained by the Sartorius system (arium 
611 VF). Sensor chips CM5, amine coupling kit, thiol coupling kit and Running Buffer HBS-EP+ 
10x (0.1 mol/L HEPES, 1.5 mol/L NaCl, 30 mmol/L EDTA, 0.5% v/v p20) were purchased by 
GE Healthcare. Running Buffer was diluted ten times with milliQ water at pH 7.4 and filtered 
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daily with a Millipore Express™ PLUS 0.22µm system. Sodium acetate and Sodium hydroxide 
were purchased by Carlo Erba (Milano). The four citrullinated peptides VCP1, VCP2, HCP1 and 
HCP2 and the two non-citrullinated control sequences VArgP2 and HArgP1 were synthesized as 
tetrameric Multiple Antigen Peptides, by the Company Toscana Biomarkers srl; peptide P30 was 
a gift of Prof. Corradin from the Institute of Biochemistry, University of Lausanne. 
3.6.1 ACPA purification from patients’ sera 
Five ACPA positive RA patients (RA1-RA5) were enrolled in this project. IgG fractions 
containing ACPAs were obtained, from the laboratory of Clinical and Experimental Medicine of 
the University of Pisa (Prof. Migliorini), by precipitation with 50% saturated ammonium sulfate 
and purified by Protein-G affinity chromatography. In order to isolate anti-peptide antibodies, 
citrullinated MAPs were conjugated to CNBr activated Sepharose (Sigma-Aldrich) according to 
the standard manufacturer instructions. Antibodies bound to the column were eluted by 100 mM 
glycine buffer (pH 2.8), and dialyzed overnight against PBS. The anti-peptide antibody 
concentration was determined by UV absorbance at 280nm. A total of fifteen purified anti-peptide 
antibody fractions were obtained by affinity chromatography from five different RA sera using 
each of the three citrullinated MAP. 
3.6.2 PH scouting procedure 
Immobilization buffers were selected separately for each peptide using the pH scouting 
procedure, using the following buffers: PBSbuffer pH 7.2, sodium acetate buffer 0.1 mM pH 4.5 
and 6.0, sodium acetate buffer 0.5 mM pH 4.5 and 5.0, sodium acetate buffer 5 mM pH 4.5, 5.0 
and 6.0, sodium acetate buffer 10 mM pH 6.0. Peptides were solubilized in each buffer at a final 
concentration of 10 µg/mL and injected over the non-activated sensor chip surface for 120s at a 
flow rate of 10µL/min; after each injection chip surface was regenerated with a pulse of 0,1M 
NaOH for 30s at a flow rate of 10µL/min. The selected buffer and the immobilized peptide 
quantities are reported in Table 4. 
3.6.3 Citrullinated MAPs and tetanus peptide immobilization: amine coupling 
The five peptides listed in Table 2 were individually immobilized on a different channel of sensor 
chips CM5-type according to the amine coupling strategy. For immobilization, sensor chip 
surface was activated with two injections of N-hydroxysuccinimide (NHS 0.1 M) and 1-ethyl-3-
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(3-dimethylaminopropyl)-carbodiimide (EDC 0.4 M) 50:50 for 420 and 240 seconds respectively 
at a flow rate of 10 µL/min. After surface activation each peptide, solubilized in the previously 
selected immobilization buffer (10 µg/mL), was injected for 420 seconds at a flow rate of 10 
µl/min. Immobilization was continued in manual mode by injecting peptide solution up to 
reaching a satisfactory immobilization level. Non-reacted sites on sensor chip surface were 
blocked injecting ethanolamine-HCl 1 M pH 8.5 for 420 and 60 seconds at a flow rate of 30 
µL/min.  Reference channels were activated injecting NHS/EDC 50:50 and directly blocked with 
ethanolamine-HCl. 
3.6.4 Affinity studies with total IgG fractions 
RA and NHS IgG samples (at different initial concentrations tested by UV absorbance at 280nm) 
were diluted in running buffer to final concentration of 3732.8, 1866.4, 933.2, 466.6, 233.3, 116.6 
and 58.3 nM. Each diluted sample was injected over each immobilized peptide for 120 seconds at 
a flow rate of 30 µL/min.  Running buffer was then flushed for 200 seconds at a flow rate of 30 
µL/min and finally the chip surface was regenerated by injecting a glycine solution 10 mM pH 
2.5 for 30 seconds and a sodium hydroxide solution 0.1 M for 60 seconds both at a flow rate of 
30 µL/min. 
Binding studies on HCP2 were performed injecting selected samples [466.6 nM] for 120 seconds 
at a flow rate of 30 µL/min, followed by the injection of anti-human IgG or IgA or IgM –alkaline 
Phosphatase antibody (Sigma) 1:4000 for 240 seconds at a flow rate of 5 µL/min, running buffer 
was then flushed for 200 seconds and chip surface was regenerated as above described for 
affinity studies.  
3.6.5 Citrullinated MAPs and control sequences immobilization: thiol coupling 
The five MAP reported in Table 4 were individually immobilized on a different channel of sensor 
chips CM5-type according to the ligand thiol coupling strategy consisting in the following steps: 
- chip surface activation with two injections of N-hydroxysuccinimide (NHS 0.1 M) and 1-ethyl-
3-(3-dimethylaminopropyl)-carbodiimide (EDC 0.4 M) 50:50 for 420 s at a flow rate of 10 
µL/min; 
- active disulfide groups introduction by injecting twice a solution of 67% 120mM 2-(2-
pyridinyldithio)ethaneamine (PDEA) and 33% sodium borate 0.1 M pH 8.5 for 420 s at a flow 
rate of 10 µL/min; 
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- peptide injection in the selected immobilization buffer [10µg/mL] for 420 s and 60 s at a flow 
rate of 10 µL/min; 
- non-reacted disulfide groups on sensor chip surface blocking by injecting 50mM cysteine and 
1M NaCl in 0.1M sodium acetate pH 4.3 for 240 s at a flow rate of 10 µL/min; 
- free reactive sites formed by NHS/EDC activation blocking with 1M ethanolamine-HCl pH 8.5 
for 420 s at a flow rate of 10 µL/min. 
Reference channel was activated injecting NHS/EDC 50:50 and PDEA and directly blocked with 
cysteine buffer and ethanolamine-HCl. 
3.6.6 SPR kinetic and affinity studies with anti-peptide antibodies 
Anti-citrullinated peptide antibody fractions (at different initial concentrations tested by UV 
absorbance at 280nm) were diluted in running buffer to final concentration of 2000, 1000, 500, 
250, 125, 62.5, and 31.25 nM. Diluted samples were injected over each ligand for 120 s at a flow 
rate of 30 µL/min. Running buffer was then flushed for 200 s at a flow rate of 30 µL/min and 
finally the chip surface was regenerated by injecting a 10mM glycine solution pH 2.5 for 30 s and 
a 0.1M NaOH solution for 60 s both at a flow rate of 30 µL/min. 
Each sample was applied in a different cycle of analysis and instrumental results were elaborated 
with the Biacore Evaluation Software 2.0 and summarized with the Biacore T100 Kinetic 
Summary application. 
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4: Autoantibodies from Multiple Sclerosis patients’ sera: isolation, detection 
and characterization of their interaction with a Haemophilus influenzae N-
glucosylated adhesion protein. 
 
4.1 N-glycosylation, a widespread post-translational modification 
In the field of the research of the native antigen triggering the autoimmune response 
characterizing multiple sclerosis (MS) disease, different hypothesis have been done, but at now a 
proved and overall accepted explanation is not present. Nevertheless, in the pathogenesis of MS 
the production of autoantibodies targeting myelin proteins is believed to be a key point. Growing 
evidences indicated that antibodies can bind aberrant glucosylated self-proteins, or that they can 
recognize non modified self-antigens that, because of molecular mimicry reasons, are 
homologous to glucosylated infectious agents proteins. In this background, the present research 
will be conducted with the aim of understanding the importance, for MS antibodies interaction, of 
the N-glucosylation enzymatically introduced on a bacterial protein, in comparison to the results 
obtained with a synthetic peptide bearing the same N-glucosylation and currently used as probe 
to detect autoantibodies biomarker of MS. This work will be helpful in the complex context of 
the study of the initial event involved in MS pathogenesis.      
Protein synthesis is a well-known process whose last steps include post-translational 
modifications (PTM) such as glycosylation, acetylation, phosphorylation, etc., leading to changes 
in the protein structure and affecting its biological function. In particular protein glycosylation 
plays important roles in major biological events such as cell-cell and cell-matrix interactions, 
intracellular localization, stabilization of the three-dimensional structure, thermal and chemical 
stability, receptor binding, cellular signaling or protein clearance.  
Glycosylation is the most abundant protein PTM occurring in eukaryotic and prokaryotic cells1. 
In the past decade, the first evidence of a system of N-glycosylation in bacteria was discovered 
by studying the human mucosal pathogen C. jejuni2. Glycoproteins are now being recognized 
increasingly in prokaryotes; some examples of bacterial glycoproteins include the flagellins of 
Pseudomonas aeruginosa3 and the non-pilus adhesins of Chlamydia trachomatis4. 
In eukaryotes cell membranes proteins and secreted proteins are highly glycosylated and nearly 
50% of the plasma protein are so modified. There are three major types of protein glycosylation: 
N-linked is the most common, it involves the transfer of an oligosaccharide onto the side chain 
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amide nitrogen of asparagine residues of acceptor proteins; O-linked, in which monosaccharides 
are sequentially added onto the side chain hydroxyl oxygen atom of serine or threonine residues; 
GPI-anchored, requiring a complex glycosylphosphatidylinositol moiety that is transferred to the 
C-terminus of a target protein with the function of anchoring it to the cell membrane. 
Although a number of variations occur, studies in model organisms revealed that two 
homologous processes represent the core of N-glycosylation both in eukaryotes and prokaryotes. 
In eukaryotes the biosynthesis of N-glycans begins on the cytosolic face of the Endoplasmic 
Reticulum (ER) where the conserved tetradecasaccharide (Glc3Man9GlcNAc2) is assembled onto 
a dolichyl pyrophosphate carrier and then en-bloc transferred, by the multimeric Oligosaccharyl 
Transferase (OT) complex, to the asparagine side chain of the acceptor polypeptides; 
phosphorylated lipids function as good leaving groups in the OT reaction and remain bound to 
the membrane, where they can be recycled for further rounds of biosynthesis. In prokaryotes the 
assembly process begins at the plasma membrane where unique monosaccharide building blocks 
are assembled together and transferred by a simple monomeric OT enzyme to the acceptor 
proteins; in addition the first sugar Asn-linked in prokaryote glycoproteins is an N,N’-
diacetylbacillosamine (Bac) instead of the initial N-acetylglucosamine (GlcNAc) present on 
eukaryote glycoproteins. A schematic illustration of the lipid-linked glycans that is conserved in 
eukaryotes and variable in bacteria is shown in Figure 16. 
 
Figure 16: Representative glycan structures, in eukaryotes and bacteria, indicated with colored geometric symbols 
CHAPTER 4 
39 
The final heterogeneity of N-glycans found among eukaryotes is a consequence of a successive 
elaboration, taking place in the Golgi apparatus that is introduced thanks to a series of 
glycosidases and glycosyltransferases that trim and add carbohydrates such as sialic acid, fucose 
or galactose; this step is absent in prokaryotes. The acceptor substrate of N-glycosylation is the 
side chain amide of asparagine residue in receptive Asn-X-Ser/Thr consensus sequences; OT 
does not glycosylate proteins that contain a proline in position X5 and prefers Ans-X-Thr sites 
compared with Asn-X-Ser ones6. A specific conformation of the acceptor peptide is required to 
increase the nucleophilicity of the amide group of asparagine7, and from recent experimental data 
appeared that the sequence requirements of the acceptor substrate are less strict than previously 
reported.8  
Mutations in almost every step of glycan biosynthesis and processing lead to a group of 
debilitating and often fatal diseases termed Congenital Disorders of Glycosylation, underscoring 
the importance of this PTM for human health9. Some glycomic analyses have noticed an altered 
protein glycosylation during HIV infection10 or allergy11 and abnormal glycosylation of target 
antigen has also been involved in the pathophysiology of autoimmune diseases. Hence high 
levels of antibodies directed to glycated antigen were found in antiphospholipid syndrome 
patients’ sera12; in systemic sclerosis antibodies directed to 4-sulfated N-acetyl-lactosamine were 
associated with higher prevalence of pulmonary hypertension13; in multiple sclerosis  
polymorphism in the gene coding for  the glycosylation enzyme MGAT5 correlated to disease 
severity14.  
4.2 N-glucosylated HMW1 adhesin from Haemophilus influenzae 
The nontypeable Gram-negative bacterium Haemophilus influenzae is a common cause of human 
respiratory tract disease including otitis media, sinusitis, conjunctivitis, bronchitis and pneumonia 
and it initiates infection by colonizing the upper respiratory tract15. H. influenzae expresses a 
related High Molecular Weight protein called HMW1, that promotes efficient adherence to 
respiratory epithelial cells and facilitate the process of colonization16. It was demonstrated that 
HMW1 adhesin interacts with a glycoprotein receptor expressed by epithelial cells and 
containing N-linked oligosaccharide chains with a sialic acid in an α2-3 configuration17. 
HMW1 is synthesized as preproprotein and is secreted by the Two Partner Secretion (TPS) 
system18. TPS pathway consists of a large extracellular protein, TpsA, and a cognate outer 
membrane pore-forming translocator protein called HMW1B (Figure 17). 
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Amino acids 1–68 of HMW1 direct the preproprotein to the Sec apparatus, where they are 
cleaved by signal peptidase I. Subsequently, amino acids 69–441 target the proprotein to the 
outer membrane and interact with the outer membrane translocator protein, undergoing removal 
by an unknown process. Following translocation across the outer membrane, the mature 160 kDa 
HMW1 protein remains associated with the bacterial surface via a non-covalent interaction that 
requires the C-terminal 20 amino acids of the protein and that is dependent upon disulfide bond 
formation between two conserved cysteine residues in this region19.  
 
Figure 17: Schematic representation of proteolytic cleavage of HMW1 and two partner secretion system, resulting in 
mature HMW1exposition on the outer membrane of the cell. 
Recent studies demonstrated that HMW1 is a glycoprotein and its glycosylation appears to 
increase its stability, to protect against premature degradation and to be fundamental for protein 
adherence to target structures. In addition, glycosylation appears to influence HMW1 tethering to 
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the bacterial surface, as indicated by the fact that the little amount of HMW1 that is secreted is 
not glycosylated20. 
Analysis of mature HMW1 proteolytic fragments by mass spectrometry identified 31 sites of 
modification carrying 47 hexose units, corresponding to a molecular mass of about 7.6 kDa. All 
of the modified sites were asparagine residues, in all except one case within the conventional 
sequence motif for eukaryotic N-linked glycosylation, Ans-X-Ser/Thr21. Interestingly, the 
modifying carbohydrates at these sites are hexose (glucose or galactose) or dihexose sugars 
(glucose-glucose or glucose-galactose) rather than N-acetylated sugars, revealing an unusual 
carbohydrate modification and suggesting a glycosyltransferase with a novel enzymatic activity 
capable of both transferring nucleotide activated monosaccharides to asparagine side chains 
without the requirement for a lipid donor, and to generate O-glycosydic bonds between hexose 
sugar21 (Figure 18). The enzyme responsible for the glycosylation of HMW1 is the cytoplasmic 
N-glycosyltransferase (GTase) HMW1C. 
 
Figure 18: Overview of the sequential transfer of hexoses from UDP-activated donors to the eukaryotic-like Asn-
X-Ser/Thr sequons of HMW1 by the glycosyltransferase HMW1C in the cytoplasm. 
HMW1C has the potential to contribute to several different processes that occur during HMW1 
synthesis: glycosylation may increase the stability of HMW1 in the cytoplasm and in the 
periplasm, alternatively the HMW1C protein may improve the stability of HMW1 by acting as a 
chaperone. It is still unclear whether glycosylation influences interaction of HMW1 with the 
periplasmic domain of the translocator protein HMW1B prior to transit, or with its pore during 
transit or with the docking region of HMW1B upon surface tethering. At now it is not understood 
how HMW1C recognizes its target and chooses specific glycosylation sites, as only a subset of 
Ans-X-Ser/Thr motifs in HMW1 are modified, based on mass spectrometry analysis; it is clear 
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that HMW1C interacts directly with HMW1, but the number of enzyme molecules that bind to 
HMW1 and the duration of this interaction in the cytoplasm is still unknown20. 
The HMW1C protein is encoded by the hmw1 gene cluster and shares homology with a group of 
bacterial proteins that are generally associated with the TPS systems and that are expressed in a 
number of other Gram-negative bacterial pathogens (e.g. the enterotoxigenic Escherichia coli, 
Yersinia pseudotuberculosis, Yersinia pestis and Actinobacillus pleuropneumoniae).  
The Actinobacillus pleuropneumoniae HMW1C (ApHMW1C) is 65% identical to Haemophilus 
inlfuenzae HMW1C and it has been demonstrated that ApHMW1C is able to transfer glucose and 
galactose to known asparagine glycosylation sites on HMW1, analogous to HMW1C. In addition 
it has been proved that ApHMW1C can complement a deficiency of HMW1C and mediate 
HMW1 glycosylation and adhesive activity in whole bacteria22. 
Currently HMW1C is classified into the GT41 family which includes both eukaryotic and 
bacterial O-linked GlcNAc (OGT) transferases23; the OGT enzymes contain a long N-terminal 
domain responsible for the recognition of a broad range of target proteins and a C-terminal 
glycosyltransferase domain responsible for transferring GlcNAc to target proteins. Given that 
HMW1C and ApHMW1C lack the N-terminal domain and that they catalyze N-glycosylation 
and in particular that they transfer simply hexose sugars to asparagine sites on HMW1 adhesin, 
HMW1C-like proteins clearly differ from enzymes of the GT41 family suggesting the existence 
of a new family of bacterial HMW1C-like proteins with similar glycosyltransferase activity24.  
4.3 Multiple Sclerosis: the state of the art. 
Multiple Sclerosis is the most frequent chronic inflammatory demyelinating disease involving 
different areas of the Central Nervous System (CNS). MS affects 0.05% to 0.15% of white 
populations, leading over time to severe disability in half of them. MS occurs twice as often in 
women as in men and usually starts between the ages of 20 and 40 years. Multiple sclerosis is a 
disease that predominantly affects CNS white matter and leads to demyelinating lesions that are 
mainly characterized by disturbance of the blood brain barrier, local edema and global atrophy. 
Demyelination of axons, activation of microglia, and infiltration of immune cells, such as T cells, 
macrophages and B cells, are key features of these lesions25. Two lesion patterns have been noted 
most frequently, one characterized by significant antibody deposits and remyelination, the other 
by oligodendrocyte loss without remyelination. Although in particular the extent of the humoral 
immune response appears to be stable over time in MS patients, it varies significantly inter-
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individually26. Together with the high variability of the clinical phenotype and in disease 
progression, it is possible to speculate whether different pathogenetic pathways and even 
etiologies underlie those histologically defined subtypes.  
In the absence of specific biomarkers, the diagnosis and the prognosis of the disease continues to 
rely on clinical history, neurological examination and clinical evidences of temporal and spatial 
dissemination of CNS lesions. MRI is up to now the most reliable and sensitive technique in 
detecting MS lesions for the diagnosis of the disease27, but it cannot be considered a routine 
technique when the clinical symptoms are not still visible to guide a targeted MRI check-up. 
Because plaques may form in any part of the CNS, the symptoms of MS vary widely from person 
to person and from stage to stage of the disease. The most common symptoms include muscle 
weakness, loss of balance, visual disturbances, tremors, vertigo, muscle spasticity and cognitive 
disturbances. The symptoms of MS may occur in one of three patterns: the most common is the 
relapsing remitting one, in which there are clearly defined symptomatic attacks lasting one day or 
more, followed by complete or almost complete improvement and the period between attacks 
may be a year or more at the beginning of the disease, but may shrink to several months later on. 
In the primary progressive pattern, the disease progresses without remission or with slight 
improvements. The secondary progressive is the pattern in which people with MS begin with 
relapses and remissions followed by more steady progression of symptoms.  
To date there are three major drugs approved for the treatment of MS, but none of them are cure, 
they can only slow disease progression in many patients. Novantrone is a cytotoxic drug with 
immunosuppressive properties that seems to reduce relapse rates and progression; Glatiramer 
acetate, a randomly synthesized polypeptide mixture based on four amino acids that are contained 
at high levels in myelin proteins, seems to decrease relapse rates too and to have neuroprotective 
properties; Interferon beta (IFN-β), is the most active molecule in decreasing relapse rates, it also 
seems to affect disease progression, it is known that IFN-β has both antiviral and 
immunomodulatory effects, although the mechanism of action in MS is still not entirely 
understood.  
Both genetic and environmental factors influence the susceptibility and the course of MS. 
Prevalence is high in white people, but MS is rare in Asians and Africans; family members of MS 
patients are at greater risk. Multiple genome screens and family studies recently completed, 
indicate that MS follows a polygenetic trait which involves a large number of genes with each 
contributing little to the overall risk, but between them only the human leukocyte antigen (HLA) 
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class II alleles DRB1*1501 and HLA-DQB1*0601 have consistently been associated with MS in 
white people28. Evidence from clinical and epidemiological studies suggests that environmental 
factors, such as viral infections, may play an important role in the etiology of MS29,30.  
A role of the immune system in the pathogenesis of MS was first suggested by observations of 
acute demyelinating episodes induced by an anti-myelin immune response in animal models of 
Experimental Autoimmune Encephalomyelitis (EAE). In conclusion from all the studies it was 
established that a Th-1 CD4+ T cell response to myelin antigens was destructive, whereas a Th-2 
CD4+ T cell response was protective31, but this hypothesis has not been confirmed in humans. 
Recent studies demonstrated that CD4+ T cells can recognize a large number of different 
antigens, among them a variety of self and foreign antigens including peptides derived from 
microbes32. Nevertheless, the high degeneracy in T cell recognition observed provides a possible 
explanation of how autoreactive T cells may be activated by epitopes from exogenous infectious 
agents that for molecular mimicry reasons share structural or sequence homology to self-
antigens33 and consequently can initiate the first demyelinating episode. This hypothesis is 
supported by a recent study that demonstrated molecular mimicry between a portion of myelin 
basic protein, a candidate autoantigen for MS, and the protein U24 of human herpesvirus-6, a 
viral agent that could be associated with MS34. Another study performed in mice using a 
proteolipid protein mimic peptide from protease IV of Haemophilus influenzae demonstrated that 
the infection of the target organ with a mimic-expressing pathogen during childhood may activate 
a population of autoreactive T cells that cross-reacted with myelin epitopes and that could be later 
reactivated and expanded by different stimuli (e.g. stress, trauma, vaccination or reinfection with 
the same mimic expressing virus) and that consequently could be involved in inducing the 
autoimmune disease35. Many microbes have been associated with the disease because many 
features of MS are compatible with a chronic CNS infection, but up to now evidence is lacking 
that any of them play a definitive role in the pathogenesis of MS. 
In this background the primary event that drives the immune response in CNS is still unknown, 
but it is accepted that antigens released from the CNS compartment are processed and presented 
by antigen-presenting cells to T cells in the lymphoid tissue. Similarly B cell response initiates 
when soluble antigens enter lymph nodes. After that, the polyreactive autoimmune process 
defined as epitope spreading36 takes place and clonal expanded B and T cell enter the CNS where 
they encountered their target antigens. CD8+ T plays a central role in the inflammation process, 
they can lyse neurons and oligodendrocytes37; CD4+ T cells synthesize proinflammatory 
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cytokines and chemokines recruiting other inflammatory cells but they have also the capacity of 
releasing neurotropic factors as Brain-Derived Neurotrophic Factor, suggesting that some of them 
are important for neuroregeneration and protection38.  
Concerning the humoral response, antibodies binding to CNS cells may have a detrimental effect 
by activating the complement cascade or directly damaging the myelin sheaths of axons39; 
however antibodies may also promote regeneration depending on the microenvironment40. The 
oligoclonal immune response observed in patients with MS thus represents an ambivalent role 
(Figure 19).  
Figure 19: The possible role of B cells in MS pathogenesis; unknown antigens are presented by the antigen 
presenting cells to T and B cells; activated B cells undergo clonal expansion and secrete antigen-specific antibodies 
that may have a destructive or a protective role. 
Consequently it is of priority to determine clinical assays, supporting the concept of the 
individualized medicine, to delineate patients who would respond to B cell depletion therapies, 
where deleterious antibodies would be removed from circulation, or to promote antibody therapy 
in the case in which remyelination is stimulated by circulating antibodies.  
The autoimmune hypothesis generated in the EAE model involving both molecular mimicry and 
epitope spreading can explain many aspects of MS but experimental support for this hypothesis is 
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still limited. The first problem is that CD4+ T cells specific for myelin antigens were also found 
in healthy donors, indicating that autoreactive T cells are part of the normal T-cell repertoire and 
not necessarily harmful41. Similarly, myelin-specific antibodies are not confined to MS, but can 
be detected in different neurologic diseases and even in healthy control subjects42 and moreover 
the exact target antigens of myelin proteins remain elusive.  
4.4 N-glucosylated peptide CSF114(Glc) for MS autoantibodies detection 
Although the immune system play a fundamental role in the pathogenesis of MS, target antigens 
are still uncertain and pathways leading to tissue destruction have not been fully elucidated. The 
most studied putative self-antigens of CNS myelin are the myelin basic protein, the proteolipid 
lipoprotein and the myelin oligodendrocyte glycoprotein, and they are mostly post-translationally 
modified43. 
Growing evidences indicate that post-translational modifications, in particular aberrant 
glycosylation44, can mask self-antigens, creating new ones no longer recognized by the immune 
system, and so can play a fundamental role for specific autoantibodies recognition in MS. 
It was demonstrated that the synthetic N-glucosylated peptide CSF114(Glc), selected from a 
library of peptides through the chemical reverse approach, was able to detect autoantibodies in a 
subpopulation of MS patients’ sera by Enzyme-Linked Immunosorbent Assay (ELISA)45 and 
using a surface plasmon resonance biosensor approach46; in addition this glucopeptide mimetic 
was successfully used to identify novel autoantigens in MS47. The ability of the glucosylated 
sequence to detect autoantibodies in MS patients' sera was correlated to the N-linked β-D-
glucopyranosyl moiety48 characterized by a type I’ β-turn structure that optimally exposes the 
minimal epitope Asn(Glc) to autoantibodies as shown in Figure 20 and that possibly reproduces 
an aberrant N-glucosylation of myelin proteins49.  
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Figure 20: Ribbon diagram of the calculated lower energy conformer of CSF114(Glc) derived from NMR data. 
4.5 Objective 
The initial mechanism responsible for the triggering of the autoimmune response in MS is still 
unknown, but two main accepted theories are present. It could be possible that aberrant N-
glucosylation of myelin proteins, by a still unknown mechanism, could transform self-antigens in 
non-self ones and trigger an autoimmune response; conversely the molecular mimicry between 
exogenous structures (e.g. glucosylated bacterial proteins) and self-proteins could be responsible 
for the induction of the autoreactive immune response.  
In the last years, CSF114(Glc) peptide was successfully employed to detect autoantibodies in MS 
patients’ sera and this ability was related to the presence of one N-glucosylation chemically 
introduced on the side chain amide of an asparagine residue. Following the hypothesis that MS 
immune deregulation could be triggered by a viral or a bacterial infection that because of 
molecular mimicry reasons stimulates autoreactive immune cells and considering that recent 
studies demonstrated that the same N-glucosylation introduced in CSF114(Glc) is generated in 
vivo by the HMW1C glycosyltransferase on HMW1 adhesin from Haemophilus inlfuenzae, we 
investigated if a portion of this N-glucosylated bacterial protein was able to interact with 
autoantibodies in MS patients’ sera and if there was a correlation between antibodies detected by 
both N-glucosylated molecules.  
To answer those questions the following experiments have been performed: 
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• SP-ELISA assay to investigate the ability of glucosylated and non glucosylated proteins 
to detect antibodies in MS sera as compared to control sera; 
• competitive ELISA assay to calculate the relative mean affinity and to understand the 
cross-reactivity of anti-CSF114(Glc) antibodies, present in MS sera, for protein and 
peptide inhibitors applied in solution; 
• SPR binding study on one selected glucosylated adhesin derived peptide, to investigate its 
ability to interact with specific antibodies when MS sera are injected under a continuous 
flow;  
• antibody purification from one MS serum by two sequential affinity chromatographies to 
elute antibodies highly specific for the glucosyl moieties of glucosylated adhesin or of 
CSF114(Glc);  
• SP-ELISA titration assay with purified antibody fractions, to confirm the ability of the 
sequential affinity chromatography process to deplete serum from antibodies recognizing 
the non glucosylated antigens;  
• SPR kinetic and affinity studies to characterize the kinetic and the affinity of the 
interaction between each purified antibody fraction and each glucosylated and non 
glucosylated antigen and to understand the cross-reactivity of purified antibodies for the 
different antigens;  
• SPR binding study with MS and control sera on immobilized adhesin proteins with and 
without glucosylation, to realize at first if they are able to interact with antibodies flowing 
in solution and then to compare results obtained when the same molecules are employed 
in SP-ELISA assay;  
• immunohistochemistry assay to investigate if one selected MS serum and if purified 
antibody fractions can bind to some mimetic structures present on rat nervous tissues. 
4.6 Results and discussion 
This study was conducted using the protein HMW1ct, corresponding to the C-terminal fragment 
of HMW1 adhesin of H. influenzae. We received HMW1ct in the framework of a collaboration 
with Prof. Barbara Imperiali of the Department of Biology of the Massachusetts Institute of 
Technology (MIT, Cambridge, USA); this protein fragment was produced by recombinant 
technologies and in vitro N-glucosylated by the HMW1C glycosyltransferase using as substrate 
UDP activated glucose. HMW1ct structure is represented in Figure 21: it corresponds to the 
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residues 1205 – 1536 listed in Table 7 and contains 12 potential Asn-X-Ser/Thr N-glucosylation 
sites; 8 of them were in fact in vitro glucosylated using the HMW1C enzyme. We received both 
the N-glucosylated (HMW1ct-Glc) and the unmodified protein (HMW1ct). 
HMW1ct sequence 
ANSGALTTLAGSTIKGTESVTTSSQSGDIGGTISGGTVEVKATESLTTQSNSKIKATTGEA
N(1)VTSATGTIGGTISGNTVN(2)VTANAGDLTVGNGAEIN(3)ATEGAATLTTSSGKLTTE
ASSHITSAKGQVN(4)LSAQDGSVAGSINAAN(5)VTLN(6)TTGTLTTVKGSNIN(7)ATSGT
LVINAKDAELNGAALGN(8)HTVVN(9)ATNAN(10)GSGSVIATTSSRVN(11)ITGDLITING
LNIISKNGINTVLLKGVKIDVKYIQPGIASVDEVIEAKRILEKVKDLSDEEREALAKLGVS
AVRFIEPN(12)NTITVDTQNEFATRPLSRIVISEGRACFSNSDGATVCVNIADNGR 
Table 7: HMW1ct sequence in one letter aa code; the 8 N-glucosylated sites are reported in red. 
 
Figure 21: Ribbon diagram of HMW1ct fragment calculated structure, potential Asn-X-Ser/Thr glucosilation sites 
are shown in yellow and red. 
4.6.1 SP-ELISA optimization for protein antigens 
The first part of this project was devoted to the optimization of an ELISA procedure using 
HMW1ct and HMW1ct-Glc proteins as antigens. In order to study the coating efficiency of these 
antigens to maxisorp plates, proteins were diluted in different buffers to find the best conditions 
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of pH and ionic strength maximizing their adsorption on the solid support. Three coating buffers 
were used: carbonate buffer at pH 9.6, PBS at pH 7.2 and PBS at pH 5.0. Three sera were applied 
at 1:100 dilution: one IgG positive, one IgM positive and one IgG and IgM negative to 
CSF114(Glc). After the addition of the appropriate enzyme labeled secondary antibody and the 
application of its substrate, the resulting colorimetric reaction was read at 405nm; registered 
absorbance directly quantify serum antibodies bound to the coated antigens. No significant 
difference in absorbance values was registered when using in the coating step the three buffers 
mentioned above. However, the best buffer for the following SP-ELISA assays was identified as 
PBS at pH 7.2, being the one minimizing unspecific interactions with the plate surface, as 
indicated by the lower blank value, and maximizing the difference between positive and negative 
IgG sera. 
Protein stability and the importance of protein folding for antibody recognition were then 
investigated to understand if conformational epitopes were present on HMW1ct-Glc and on 
HMW1ct. To do this an SP-ELISA assay in denaturant condition was set up. Adhesin proteins 
were coated in PBS buffer at pH 7.2 and after overnight incubation at +4 °C, the denaturant 
solution was applied. This solution contained urea to reversibly denaturate proteins and β-
mercaptoethanol to reduce the disulfide bridge involving the two cysteine residues that were 
present in the C-teminal part of the proteins. A iodoacetamide solution was then applied in order 
to covalently modify the SH group of cysteine residues, making impossible the disulfide bridge 
regeneration. The assay was then performed applying the same sera used in the coating 
optimization step. Absorbance values obtained for IgG and for IgM in the previous ELISA assay 
in native condition and in the ELISA assay in denaturant one are shown in Figure 22. 
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Figure 22: Comparison between results obtained from the classical SP-ELISA in native conditions and the SP-
ELISA in denaturant conditions 
Very similar results were obtained and they could indicate that the denaturing process was not 
adequate for HMW1ct proteins or that the disulfide in the C-terminal part was not important for 
protein conformation or that antibodies didn’t recognize conformational epitopes, maybe because 
they were not present when the proteins were adsorbed on the solid support. 
4.6.2 Sera screening in SP-ELISA 
A total of 26 MS sera and 22 Normal Blood Donor (NBD) sera were screened in SP-ELISA assay 
coating glucosylated HMW1ct and non glucosylated HMW1ct proteins. Results were compared 
with previously obtained data coating CSF114(Glc) peptide.  
The graphs summarizing the distribution of antibody levels detected in MS and in NBD sera are 
reported in Figure 23 for each of the 3 antigens for both IgG and IgM. The mean of the 
absorbance values and the relative Standard Deviation (SD) for IgG and IgM reveled in MS and 
in NBD sera with the present SP-ELISA are listed in Table 8. 
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Figure 23: Distribution graphs indicating serum IgG and IgM in MS patients and in healthy subjects; coated antigens 
are HMW1ct-Glc, HMW1ct and CSF114(Glc). Mean and SD are shown inside the graphs. 
 IgM IgG 
Coated 
antigen 
MS NBD MS NBD 
Mean SD Mean SD Mean SD Mean SD 
HMW1ct-Glc 0.82 0.43 0.60 0.40 1.07 0.52 0.84 0.45 
HMW1ct 0.62 0.28 0.49 0.34 0.68 0.31 0.65 0.31 
CSF114(Glc) 0.52 0.35 0.32 0.25 0.55 0.41 0.25 0.22 
Table 8: Mean and SD calculated for the screening of 26 MS and 22 NBD sera, in SP-ELISA. 
HMW1ct coated on plates was able to detect the same level of serum IgG and a similar level of 
IgM in both NBD and MS groups; HMW1ct was not able to detect specific antibodies in MS sera 
as compared to healthy subjects, anti-HMW1ct antibodies seemed to be physiologically present 
in human serum. The glucosylated protein was able to discriminate between MS and NBD in the 
case of IgM, but the difference was lower in the case of IgG. A significant difference between the 
two groups emerged in the case of both IgG and IgM when coating peptide CSF114(Glc), 
confirming its ability to be used as probe to detect specific autoantibodies in MS patients’ sera. 
To quantify the ability of N-glucosylated protein and N-glucosylated peptide to detect specific 
antibodies in MS sera in comparison to NBD control sera, the Receiver Operating Characteristic 
(ROC)-based analysis was employed comparing different combinations of cut-off values, 
specificities and sensitivities. Three ROC curves shown in Figure 24 for anti-HMW1ct-Glc IgM 
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and for anti-CSF114(Glc) IgM and IgG activities were constructed based on 26 cases of MS 
versus 22 controls. 
  
 
Figure 24: ROC curves analysis of IgMs interacting with HMW1ct-Glc and CSF114(Glc), and of IgG interacting 
with CSF114(Glc) in MS versus NBD sera. 
A discriminative power for anti-HMW1ct-Glc IgM was found with an area under the curve of 
0.65 and a p-value of 0.07; the optimal diagnostic cut-off value for the method was 1.18 with a 
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sensitivity of 19.2% and a specificity of 90.9%. According to this cut-off value, an increased 
antibody level was detected in 5/26 MS sera and in 2/22 NBD sera. 
Analyzing the data obtained with immobilized CSF114(Glc), we obtained a discriminative power 
indicated by an area under the curve of 0.72 and a p-value of 0.009; the diagnostic cut-off for the 
method was set at 0.73 with a sensitivity of 19.2% and a specificity of 90.9%. We registered an 
increased antibody level in 5/26 MS sera and in 2/22 NBD sera. 
From this ROC based analysis the same sensitivity and specificity was found for the two assays 
with a different cut-off value, but the higher area under the curve and the lower p-value indicated 
that the CSF114(Glc) based SP-ELISA assay had a higher statistical significance in detecting 
specific antibodies in MS patients’ sera. 
In the case of IgG a discriminative power was found only for anti-CSF114(Glc) antibodies with 
an area under the curve of 0.72 and a p-value of 0.009; from the ROC analysis the optimal 
diagnostic cut-off for the method was 1.1 with a sensitivity of 19.2% and a specificity of 100%, 
meaning that an increased antibody level was revealed in 5/26 MS sera and that no false positive 
serum was detected among the applied NBD samples. 
Figure 25 reports a graphical comparison of the antibody levels detected in MS and in NDB 
group with the three coated antigens. A complete different trend in registered absorbances can be 
seen among the different sera for IgGs revealed by the three molecules and an overall different 
trend was observed also in the case of IgMs, suggesting that different antibody families were 
revealed through the SP-ELISA assay when HMW1ct, HMW1ct-Glc or CSF114(Glc) were used 
as probes on the solid support.  
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Figure 25: Comparison between absorbance values obtained with each MS serum and each NBD serum on the three 
coated molecules. 
Concerning MS sera and according to the above established cut-off values, 3/5 patients were IgM 
positive to both HMW1ct-Glc and CSF114(Glc) and 2 of them exhibited the highest absorbance 
levels on HMW1ct too.  
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In the case of IgG in MS group and according to the cut-off value of 1.1, 5 sera were positive to 
CSF114(Glc) and 4 of them displayed a high absorbance level on coated HMW1ct-Glc and  
among this 4 MS patients, 2 had a low IgG titer against the coated HMW1ct. 
In conclusion in the experimental conditions of this SP-ELISA we were able to identify one MS 
serum containing high levels of IgM and 2 MS sera containing high levels of IgG antibodies that 
specifically recognized the two N-glucosylated molecules CSF114(Glc) and HMW1ct-Glc, 
without interacting with the non glucosyalted HMW1ct. 
4.6.3 Competitive ELISA assay 
Considering the previously described results of the screening of the small cohort of sera, we 
decided to continue the project by coating on the solid support the peptide CSF114(Glc) and by 
testing the two proteins as inhibitors in solution. For this purpose we selected 5 MS sera and 2 
NBD sera IgG positive to HMW1ct-Glc and/or to CSF114(Glc) to be used in competitive ELISA 
assays according to the method of Wrath, Stanley and Steward50.  
Sera were at first titrated by testing them at 5 different dilutions in the same experimental 
conditions of the competitive assay; from the titration curve (one example is given in Figure 26) 
the semi-saturating dilution giving an absorbance of around 0.5, to be used in competitive 
ELISA, was found for each MS serum. No positive NBD serum was found in the experimental 
conditions of the competitive ELISA. 
 
Figure 26: IgG titration curve obtained with 3 MS and 2 NBD sera coating CSF114(Glc). The optimal dilution 
resulted to be 1:100 for MS 3 and 1:250 for MS 4 and MS 5.  
The competitive ELISA was performed coating CSF114(Glc) and incubating each MS serum in 
triplicate at the previously selected dilution with increasing concentration of inhibitors in 
solution. HMW1ct-Glc, HMW1ct and CSF114(Glc) were used as inhibitors in the concentration 
0,00
0,20
0,40
0,60
0,80
1,00
1,20
1:100 1:200 1:300 1:400 1:800
A
40
5n
m
dilution
NBD 1 NBD 2 MS 3 MS 4 MS 5
CHAPTER 4 
58 
range from 10-5 to 10-10 M. Then the anti-human IgG secondary antibody was added and 
absorbance was read at 405 nm. From registered absorbance we calculated the inhibition curve 
reporting the absorbance values (%) for each inhibitor concentrations used; as a representative 
example the inhibition curves obtained for MS 1 serum are shown in Figure 27.  
 
Figure 27:Inhibition curves obtained from the competitive ELISA performed with MS 1 serum. 
Experiments were repeated twice and the average relative mean affinity of serum anti 
CSF114(Glc) antibodies for the three inhibitors was calculated in terms of IC50 and is reported in 
Table 9. This value indicates the molar concentration of each inhibitor that is necessary to inhibit 
half of the maximum binding (corresponding to the absorbance of serum without inhibitors). 
Consequently IC50 is inversely related to antibodies affinity for the inhibitor: lower IC50 value 
indicates stronger inhibitors. 
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CSF114(Glc) coated_IC50 value (M) 
Serum HMW1ct-Glc HMW1ct CSF114(Glc) 
MS 1 10
-8.5
 10
-5
 10
-7
 
MS 2 10
-9
 10
-5.5
 10
-7.5
 
MS 3 10
-9
 
no inhibition 10
-7.5
 
MS 4 10
-9
 
no inhibition 10
-7
 
MS 5 10
-9
 
no inhibition 10
-8
 
Table 9: IC50 quantifying the relative mean affinity of anti CSF114(Glc) antibodies in MS sera for 3 inhibitors 
applied in solution. 
The data reported in table 9 indicated that the N-glucosylated protein was able to inhibit 
antibodies binding in MS sera with a higher affinity than peptide CSF114(Glc), the difference 
was between 1.5 and 2 log unit. The other observation was that the N-glucosylated moieties on 
HMW1ct-Glc seemed to be fundamental for antibody recognition because non glucosylated 
HMW1ct inhibited antibodies binding in MS 1 and MS 2 sera only, with 3.5 log lower affinity. 
For a statistical validation of the results, we repeated six times MS 1 inhibition experiment 
coating CSF114(Glc) and using as inhibitors in solution CSF114(Glc) and HMW1ct-Glc. We 
obtained an average IC50 of 10-7.5 M with a standard deviation of 0.35 for the peptide, and an 
average IC50 of 10-9.0 M with a standard deviation of 0.38 for the protein. We also repeated three 
times MS 2 inhibition experiments coating CSF114(Glc) and using the same two inhibitors in 
solution; the average IC50 of CSF114(Glc) was 10-7.3  M with a standard deviation 0.25, 
concerning HMW1ct-Glc the average IC50 was 10-9.3 M with a standard deviation 0.34. 
Considering that the IC50 standard deviation was always below 1.0, we could asses that 
competitive assay results were significant. 
Because no positive NBD serum to CSF114(Glc) was found in the experimental conditions of the 
competitive ELISA, we decided to titrate NBD sera coating HMW1ct-Glc. By doing this, two 
NBD sera, whose titration is shown in Figure 28, were selected for the next assays. 
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Figure 28: IgG titration curve obtained with 2 NBD sera coating HMW1ct-Glc. The optimal dilution resulted to be 
1:400 for NBD 1 and 1:200 for NBD 2. 
The competitive ELISA was performed coating HMW1ct-Glc and the binding of NBD sera was 
inhibited adding increasing concentrations of HMW1ct-Glc, HMW1ct and CSF114(Glc). 
Inhibition curves and IC50 values are reported in Figure 29 and in Table 10 respectively. 
  
Figure 29: Inhibition curves resulting from the competitive ELISA performed with 2 NBD sera. 
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HMW1ct-Glc coated_IC50 value [M] 
Serum HMW1ct-Glc HMW1ct CSF114(Glc) 
NBD 1 10
-7.5
 10
-6.5
 
no inhibition 
NBD 2 10
-7.5
 10
-7
 
no inhibition 
Table 10: IC50 quantifyng the relative mean affinity of anti HMW1ct-Glc antibodies in NBD sera for 3 inhibitors 
applied in solution. 
Obtained results indicated that anti HMW1ct-Glc antibodies present in NDB sera had a similar 
relative mean affinity for both proteins (with no more than 1 log difference), suggesting that these 
antibodies recognize an epitope shared by the two proteins and probably not related to the 
presence of the N-glucosylations. Peptide CSF114(Glc) could not inhibit NBD antibodies binding 
to HMW1ct-Glc at the concentrations used in the assay, confirming the hypothesis that N-
glucosilation is not a key point for NBD antibodies binding. 
Summarizing results obtained in the case of NBD sera, the same antibody levels against 
HMW1ct-Glc and HMW1ct were revealed by the SP-ELISA and a similar relative mean affinity 
of anti HMW1ct-Glc antibodies for HMW1ct-Glc and HMW1ct was calculated through the 
competitive assay. Taken together these results are in agreement with the idea that antibodies 
recognizing the protein HMW1 were physiologically present in serum of people who contracted 
H. influenzae during their life and that these antibodies were not specific for the N-glucosylated 
moieties of the bacterial protein.  
Bacterial outer membrane proteins were shown to be targets of bactericidal antibodies or to be 
capable of stimulating the production of protective antibodies in animal models of infection51. 
Being HMW1 adhesin one of the major surface membrane proteins of H. influenzae, antibodies 
specific for this family of high molecular weight proteins are believed to have an important 
protective role in human host immunity. This idea was supported by different works that 
demonstrated that HMW1-like adhesion proteins of nontypable H. influenzae were the major 
target of antibodies in serum from children who had recovered from Haemophilus otitis52, or that 
anti-HMW1 antibodies had the ability to mediate opsonophagocytic killing of the bacterium53 
and also that they could interrupt the attachment of the bacterium to the epithelial surface of the 
upper respiratory tract, the first critical step in the colonization of the human host54. A deep 
characterization of surface accessible B-epitopes on HMW1 whole protein was done by using 
monoclonal antibodies generated by immunizing mice with HMW1 purified from H. influenzae 
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prototype strains. This study demonstrated that the most recognized surface epitope of HMW1 
corresponds to a 155 aminoacid segment near the C-terminal region of the protein55. 
To completely understand the question if antibodies from MS serum recognized conformational 
epitopes on HMW1ct-Glc, we also performed some competitive ELISA assays using as inhibitor 
in solution a sample of reduced proteins and another of peptide fragments obtained after tryptic 
digest of the two proteins. Both sample were produced by the Department of Biology of the 
Massachusetts Institute of Technology. The binding of two MS sera to peptide CSF114(Glc) was 
inhibited with the new samples; as expected non glucosylated samples did not inhibit antibodies 
binding, and reduced or digested HMW1ct-Glc affinity was the same than native HMW1ct-Glc.  
The initial hypothesis that in our in vitro system antibodies did not recognize conformational 
epitopes when proteins were coated on ELISA plates (as explained in 4.5.2) was confirmed by 
the present competitive experiment because native HMW1ct-Glc, applied as inhibitor in solution 
and so without any restrictions to its conformation, showed the same inhibition power in terms of 
IC50 of the reduced and of the digested protein. Results obtained with the digested sample 
suggested that glucosylated adhesin derived peptides could have the same activity of the whole 
protein when used as inhibitor in solution and consequently they could be employed to discover 
the main epitope of the protein HMW1ct-Glc. 
4.6.4 HMW1ct mutants for competitive ELISA 
The HMW1ct-Glc protein is characterized by the presence of 8 N-glucosylations on the 
asparagine side chain of classical Asn-X-Ser/Thr N-glucosylation consensus sequences. The high 
molecular weight of the protein and the presence of the 8 glucosyl moieties, suggested that it is a 
multivalent antigen, so with the aim of simplify the potential native epitope represented by 
HMW1ct-Glc, it was decided to eliminate some N-glucosylation sites sequentially, to understand 
which particular sugar or which group of them were the most important for antibodies 
recognition. Accordingly, a series of adhesin mutants containing a different number of N-
glucosylation sites, listed in Table 11, were produced in the laboratory of Prof. Barbara Imperiali 
at the Department of Biology of the Massachusetts Institute of Technology (MIT, Cambridge, 
USA). We subsequently performed competitive ELISA using these mutants as inhibitors in 
solution and the corresponding non glucosylated mutants as control.  
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Mutant name Structure 
Removed 
glucosylation 
sites 
Remaining 
glucosylation 
sites 
Number of 
glucosylations 
HMW1ct(1,2,3,5,6,9)
Glc 
 
NLS(4) 
NAT(7) 
NHT(8) 
NGA(10) 
NIT(11) 
NNT(12) 
NVT(1) 
NVT(2) 
NAT(3) 
NVT(5) 
NTT(6) 
NAT(9) 
Mix of 5 and 6 
HMW1ct(1,2,5,6)Glc 
 
NAT(3) 
NLS(4) 
NAT(7) 
NHT(8) 
NAT(9) 
NGA(10) 
NIT(11) 
NNT(12) 
 
NVT(1) 
NVT(2) 
NVT(5) 
NTT(6) 
4 
HMW1ct(5,6)Glc 
 
NVT(1) 
NVT(2) 
NAT(3) 
NLS(4) 
NAT(7) 
NHT(8) 
NAT(9) 
NGA(10) 
NIT(11) 
NNT(12) 
NVT(5) 
NTT(6) 2 
Table 11: HMW1ct-Glc mutants tested in competitive ELISA; the ribbon diagram showing their structure, the 
removed glucosylation sites (red) and the resulting in vitro glucosylated ones (purple =100% glucosylation, light 
blue =50% glucosylation) are listed in this table. 
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The competitive ELISA were performed coating CSF114(Glc) and incubating the same 5 MS 
sera, tested in the previously described competitive assays, with 6 different concentrations (from 
10-6 to 10-11 M) of the mutants, with and without glucosylations. From the resulting inhibition 
curves, the IC50 of each inhibitor for each serum was calculated. 
As a representative example, the inhibition curves indicating the relative mean affinity of anti 
CSF114(Glc) antibodies in MS 4 serum for the 6 adhesin mutants, are shown in Figure 30. 
 
Figure 30: Inhibition curves obtained from the competitive ELISA incubating MS 4 serum with increasing 
concentrations of native HMW1ct and of the 3 mutants with and without glucosylations. 
As listed in Table 12 the same order of potency of the different inhibitors was conserved among 
the 5 sera and was the following: HMW1ct-Glc was comparable to HMW1ct(1,2,3,5,6,9)Glc and 
to HMW1ct(1,2,5,6)Glc and they were stronger inhibitor than HMW1ct(5,6)Glc. The proteins 
without glucosylation did not inhibit antibodies binding to coated CSF114(Glc) at the tested 
concentrations, except for HMW1c(1,2,5,6) that had a significantly lower affinity, in the range of 
10-6.5 M. 
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HMW1ct-
Glc HMW1ct 
HMW1ct 
(1,2,3,5,6,9)
Glc 
HMW1ct 
(1,2,3,5,6,9) 
HMW1ct 
(1,2,5,6) 
Glc 
HMW1ct 
(1,2,5,6) 
HMW1ct 
(5,6)Glc 
HMW1ct 
(5,6) 
MS 1 10
-9.5
 
no 
inhibition 10
-10
 
no 
inhibition 10
-9
 10
-6.5
 
10-8 no inhibition 
MS 2 10
-9.5
 
no 
inhibition 10
-10
 
no 
inhibition 10
-9.5
 10
-6.5
 
10-7 no inhibition 
MS 3 10
-10
 
no 
inhibition 10
-10
 
no 
inhibition 10
-9
 10
-6.5
 
10-7.5 no inhibition 
MS 4 10
-9
 
no 
inhibition 10
-9
 
no 
inhibition 10
-10
 10
-6.5
 
10-7.5 no inhibition 
MS 5 10
-9
 
no 
inhibition 10
-10
 
no 
inhibition 10
-10
 
no 
inhibition 10
-6.5
 10-6 
Table 12: IC50 (M) quantifying the relative mean affinity of anti CSF114(Glc) antibodies from 5 MS sera for protein 
inhibitors applied in solution 
The data we obtained comparing all the performed competitive assays, confirmed the relevance 
of the glucosyl moiety and indicated that the minimum number of glucosylations required to 
inhibit MS sera binding to CSF114(Glc), with the same high potency of the 8 times glucosylated 
HMW1ct, was 4. However, we cannot exclude that a protein with only two glucosyl units, 
different from 5,6 or a protein with four glucosyl residues, different from 1,2,5,6 could have a 
higher potency than the native HMW1ct-Glc.  
4.6.5 Competitive ELISA with adhesin derived peptides. 
Taking into account the results obtained with HMW1ct(1,2,5,6)Glc, we tried to better understand 
the role of its glucosylations and we realized that two sub clusters, consisting of two sequons 
each, could be identified in this mutant: the first formed by sequons 1 and 2, resulting in spatial 
proximity but connected by a long loop; the second formed by sequons 5 and 6, located at only 
one amino acid distance along the protein sequence. Considering that peptides fragments deriving 
from HMW1ct-Glc tryptic digest were able to inhibit MS anti-CSF114(Glc) antibodies binding 
with the same affinity of the whole glucosylaed protein and that the HMW1ct(1,2)Glc mutant 
was hard to produce because of technical reasons, in order to compare the role of the two sub 
clusters of sequons and to better understand which of them was the more relevant for antibody 
recognition, two di-N-glucosylated peptides were synthesized in our laboratory (Table 13). 
Accordingly, pept(5,6)Glc, derived from sub cluster 5-6, and pept(1,2)Glc, derived from sub 
cluster 1-2, were prepared by Solid Phase Peptide Synthesis (SPPS) technique. The 
corresponding non glucosylated sequences were also synthesized as negative controls. 
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Peptide name Sequence 
Pept(1,2)Glc Ac-YAN(Glc)VTSATGTIGGTISGNTVN(Glc)VTANKKK-NH2 
Pept(5,6)Glc Ac-AN(Glc)VTLN(Glc)TT-NH2 
Pept(1,2) Ac-YANVTSATGTIGGTISGNTVNVTANKKK-NH2 
Pept(5,6) Ac-ANVTLNTT-NH2 
Table 13:Sequence of synthetic di-N-glucosylated peptides derived from HMW1ct(1,2,5,6)Glc mutant. 
A poli-lysine tag was inserted in pept(1,2) and pept(1,2)Glc to increase their hydrophilicity, but 
nevertheless their solubility resulted to be poor in the aqueous buffer needed for the competitive 
assay, consequently we dissolved all the four lyophilized peptides in a stock solution of water and 
Dimethyl Sulfoxide (DMSO) 1:1 and then we diluted them in the appropriate buffer to perform 
the test. 
The binding of the five MS sera to CSF114(Glc) was inhibited applying six different 
concentrations of the synthesized peptides, with and without glucosylations, and CSF114(Glc) 
was used as inhibitor in each plate as an internal control of the performance of the assay. 
Inhibitor peptides were test at the same concentrations of adhesin proteins (from 10-6 to 10-11 M). 
From the resulting inhibition curves, the IC50 quantifying the affinity of each peptide for the five 
sera was calculated and reported in Table 14. The graph illustrating the result of the competitive 
ELISA with MS 1 and MS 3 sera are shown in Figure 31. 
  
Figure 31: Inhibition curves describing the affinity of adhesin derived peptides for anti CSF114(Glc) antibodies in 
MS1 and MS3 sera. 
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 Pept(1,2)Glc Pept(1,2) Pept(5,6)Glc Pept(5,6) CSF114(Glc) 
MS 1 10-8 no inhibition 10-9 no inhibition 10-7 
MS 2 10-7 no inhibition 10-8 no inhibition 10-7 
MS 3 10-7.5 no inhibition 10-9 no inhibition 10-8 
MS 4 10-7.5 no inhibition 10-8 no inhibition 10-7 
MS 5 10-6 no inhibition 10-7.5 no inhibition 10-7.5 
Table 14: IC50 values (M) calculated for the 4 adhesin derived peptides and for CSF114(Glc). 
The results of the competitive assay performed with adhesin derived peptides confirmed the 
importance of the N-glucosylation for the interaction with specific MS antibodies; in fact both 
peptides containing two Glc residues could inhibit anti CSF114(Glc) antibodies binding to 
CSF114(Glc) in all the five patients sera, while the non glucosylated control sequences never 
reach the IC50 value at the concentrations used in the assay. The second observation is that the 
same order of potency of the different inhibitors was conserved among the five sera and in 
particular pept(5,6)Glc was a more potent inhibitor than pept(1,2)Glc, with both peptides 
showing an affinity 1 or 2 orders of magnitude greater than that of CSF114(Glc); the higher 
affinity of adhesin derived peptides could be linked to the presence of two Glc units instead of the 
only one present in CSF114(Glc) sequence. 
To understand if one glucosylation site on pept(5,6)Glc was more important than the other for 
antibody recognition and if both were necessary to inhibit MS sera binding to CSF114(Glc), two 
peptides bearing a single Glc unit in position 5 or 6, reported in Table 15, were synthesized by 
PeptLab. 
Peptide name Sequence 
Pept(5)Glc Ac-AN(Glc)VTLNTT-NH2 
Pept(6)Glc Ac-ANVTLN(Glc)TT-NH2 
Table 15: Mono N-glucosylated peptide sequences derived from pept(5,6)Glc. 
Both peptides were applied in competitive ELISA with five MS sera and their ability to inhibit 
the binding of anti CSF114(Glc) antibodies was evaluated. The result of the competitive ELISA 
performed with MS 3 serum is shown in Figure 32 as a representative example.  
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Figure 32: Inhibition curves obtained incubating MS 3 serum with the 5 peptides listed in the legend. 
In the following Table 16 the IC50 values, calculated for the two peptides with the five MS sera, 
are listed.  
 MS 1 MS 2 MS 3 MS 4 MS 5 
Pept(5)Glc 10-8 10-6.5 10-8 10-7 10-6.5 
Pept(6)Glc 10-6.5 10-6 10-7 10-7 no inhibition 
Table 16: IC50 values (M) calculated for the two mono-glucosylated adhesin derived peptides. 
The affinity of anti CSF114(Glc) antibodies present in MS sera for the two peptides was 
generally lower or comparable to the affinity for CSF114(Glc) itself, but always lower than the 
affinity for pept(5,6)Glc, indicating that both sites were involved in the interaction with 
antibodies and so pept(5,6)Glc higher affinity was linked to the presence of two glucose moieties. 
Comparing the affinity of the two mono-glucosylated peptides, we realized that pept(5)Glc was a 
stronger inhibitor than pept(6)Glc, consequently the glucosylation in position 5 seems to be more 
relevant than the other for antibody interaction in our in vitro system. 
4.6.6 Adhesin peptides immobilization on Biacore sensor chip 
We subsequently decided to characterize the kinetic and the affinity of antibody binding to the 
immobilized peptide pept(5,6)Glc, since it exhibited the highest affinity for anti CSF114(Glc) 
antibodies in competitive assays and consequently we thought that it could be used as probe to 
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detect antibodies in MS sera. With this aim, we planned to synthesize a new version of this 
peptide with a free N-terminal alanine residue, in order to use its amine group to covalently 
immobilize the peptide on the carboxylic groups present on Biacore sensor chip surface by the 
amine coupling strategy. Pept(5,6) with a free N-terminal alanine was also synthesized as 
negative control. 
The pH scouting procedure was separately performed with the two peptides to find the best 
immobilization buffer maximizing their electrostatic pre-concentration on chip surface. Peptides 
were diluted in buffers of different pH and molarity but abnormal resonance signals were 
registered indicating problems of precipitation or peptides aggregation in solution. By adding 5% 
dimethyl sulfoxide (DMSO) to each solution, we avoided peptides aggregation and we selected 
0.1 mM CH3COONa at pH 4.0 with 5% DMSO as the best immobilization buffer, although 
giving a pre-concentration signal of no more than 20 RU (Figure 33). The same problem of 
aggregation and very low electrostatic interaction with chip surface was observed in the case of 
the unglucosylated pept(5,6) and therefore we added 5% DMSO to the solutions and we 
identified 5 mM CH3COONa at pH 4.5 as the best immobilization buffer. 
 
Figure 33: Results of the pH scouting performed with pep(5,6)Glc, 5% DMSO was added to each solution and very 
low electrostatic interaction signals were registered. 
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We tried to immobilize pept(5,6)Glc on channel 2 and pept(5,6) on channel 3 of the same sensor 
chip through the amine coupling strategy. Chip surface was activated and peptides were 
individually injected several times increasing their concentration in the immobilization buffer and 
decreasing the flow rate to facilitate the formation of the covalent bond; finally free reactive sites 
on the surface were blocked. 
The same baseline level was registered at the beginning of the immobilization procedure and at 
the end of the method with pept(5,6)Glc (Figure 34) and with pept(5,6), indicating that no 
covalent immobilization was achieved.  
 
Figure 34: Sensorgram showing the same baseline signal immediately after surface activation (A) and after ten 
consecutive injection of pept(5,6)Glc (B). 
The immobilization of low molecular weight ligands is often hard to achieve in SPR-based 
system and in this case we thought that the immobilization was not possible also because 
pept(5,6), solubilized at a pH below its isoelectric point of 9.8, had only one net positive charge 
due to the presence of a free N-terminal group, so the electrostatic interaction with the chip 
surface could be too feeble. Another problem could be the presence of DMSO, necessary to 
solubilize the peptide in the immobilization buffer, but interfering somehow with the coupling 
reaction. 
We decided to overcome this problem by synthesizing a new longer adhesin derived peptide, 
whose sequence is reported in Table 17, and containing the glucosylation sequons 5, 6 and 7 of 
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HMW1ct-Glc, because those sequons were reported to be the first in vivo glucosylated by the 
bacterial enzyme22. The non glucosylated peptide was also synthesized as negative control. 
Peptide name Sequence 
pept(5,6,7)Glc YAN(Glc)VTLN(Glc)TTGTLTTVKGSNIN(Glc)ATS-NH2 
pept(5,6,7) YANVTLNTTGTLTTVKGSNINATS-NH2 
Table 17: Sequence of peptides synthesized for Biacore studies; they contain glucosylation sequons 5, 6 and 7 of 
HMW1ct protein. 
Pept(5,6,7) was employed for the optimization of the immobilization protocol. It has an 
isoelectric point of 10.4 and 2 net positive charges at pH below 8.0 and it was soluble in aqueous 
buffers. Through the pH scouting procedure,100 mM sodium acetate at pH 6.2 was selected as 
the best immobilization buffer giving a satisfactory pre-concentration of the peptide on chip 
surface (Figure 35). 
 
Figure 35: Sensorgrams showing the electrostatic interaction between pept(5,6,7) diluted in different buffers, and 
Biacore chip surface. 
The amine coupling protocol was then applied to covalently immobilize the peptide and at the 
end of the procedure an immobilization level of 2124 RU was obtained as shown in Figure 36. 
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Figure 36: Resonance signal obtained from the immobilization of pept(5,6,7) on channel 1. 
The same immobilization strategy is going to be followed to immobilize the corresponding 
glucosylated peptide with the idea of performing binding studies with MS sera and affinity and 
kinetic studies with purified antibodies. For these assays pept(5,6,7) will be used as reference to 
subtract the signal due to aspecific interactions and pept(5,6,7)Glc will be used as active ligand.  
4.6.7 Antibody purification from one MS serum 
With the aim of obtaining a very specific fraction of antibodies present in one MS serum and 
recognizing the N-glucosylated epitopes present on CSF114(Glc) and on HMW1ct-Glc, we set up 
a purification method consisting of two sequential affinity chromatographies: the first using a 
column with the non glucosylated antigen to deplete serum from antibodies specific for the 
unglucosylated portion of the molecule, and the second using a column containing the 
glucosylated antigen to elute antibodies highly specific for the glucosyl moieties.   
Peptide CSF114(Glc) and non glucosylated peptide CSF114 were used in the past to purify 
antibodies and their immobilization to sepharose resin, according to the amine coupling strategy, 
was already optimized . 
On the contrary adhesin proteins were never used to purify antibodies, so we investigated two 
different immobilization strategies: the thiol coupling, because in HMW1ct sequence two 
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cysteine residues were present and their free thiol groups could be used for the linkage to the 
sepharose resin; the amine coupling that could involve one of the numerous free primary amine 
groups present on lysine residues side chains or on the N-terminal alanine residue.  
4.6.7.1 Adhesin proteins conjugation to sepharose by thiol coupling 
Commercial CNBr-activated sepharose resin was washed and coupled to N-(2-
aminoethyl)maleimide previously dissolved in carbonate buffer at pH 8.3, free reactive groups on 
resin were blocked with a glycine solution at pH 6.0 and the resin was exhaustively washed with 
two buffers at different pH in order to remove all the not covalently bound reagents. In the 
meanwhile HMW1ct and HMW1ct-Glc disulfides were reduced by the addiction of dithiothreitol 
(DTT) as reducing agent and each solution was then add to two sepharose resins. The free 
reactive sites functionalized with maleimide groups were blocked with a cysteine solution at 
neutral pH. The expected reaction scheme is shown in Figure 37. 
 
Figure 37: Stepwise immobilization of adhesin proteins to CNBr-sepharose resin by the thiol coupling strategy . 
After an overnight incubation each protein solution was recovered and its absorbance at 280nm 
was read and compared to the one registered before the incubation with the resin in order to 
quantify the protein remained in solution and so to calculate the yield of the coupling step (Table 
18).  
CHAPTER 4 
74 
4.6.7.2 Adhesin proteins conjugation to sepharose by amine coupling 
Commercial CNBr-activated sepharose resin was washed and adhesin proteins were diluted in 
carbonate buffer at pH 8.3 and applied to the resins. After an overnight incubation free reactive 
sites on resin were blocked with a glycine solution at pH 8.0 and the resin was exhaustively 
washed with two buffers at different pH in order to remove all the not covalently bound proteins. 
In Figure 38 the expected reaction scheme is given. 
 
Figure 38: Stepwise immobilization of adhesin proteins to CNBr-sepharose resin by the amine coupling strategy. 
Absorbance at 280 nm of every samples in coupling buffer before the coupling and after the 
reaction with the resin was checked and proteins conjugated to the resin were quantified. 
A comparison of adhesin proteins covalently linked to sepharose by the thiol coupling approach 
and by the amine coupling one is reported in the following Table 18. 
Thiol coupling Amine coupling 
HMW1ct HMW1ct-Glc HMW1ct HMW1ct-Glc 
57,0% 37,5% 37,3% 43,8% 
Table 18: Comparison between the percentage of HMW1ct and HMW1ct-Glc proteins coupled to sepharose 
according to two different immobilization strategies. 
The two immobilization strategies showed similar performances, but we decided to follow the 
amine coupling strategy for two reasons: at first it is the “cleanest” approach because there was 
no need to use a reducing reagent such as DTT that could alter the secondary structure of the 
proteins or that could remain attached to the column and interfere with antibodies binding and 
consequently with their purification; the second reason is the relative higher quantity of the 
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glucosylated protein (5%) that we were able to link by the amine coupling approach as compared 
to the thiol coupling. 
4.6.7.3 Sequential affinity chromatography 
MS 1 serum was selected for antibody purification because of its high IgG titer in SP-ELISA 
against CSF114(Glc) and HMW1ct-Glc. Two affinity columns were prepared to be sequentially 
used following the selected amine coupling strategy: in the first HMW1ct was linked to the 
sepharose resin and in the second HMW1ct-Glc was immobilized. The same procedure was used 
to obtain a CSF114 and a CSF114(Glc) containing column. 
MS 1 serum was diluted, filtered and loaded onto the column functionalized with the protein 
HMW1ct; after being recirculated three times, the unretained fraction was recovered from the 
column and directly applied to the second column functionalized with HMW1ct-Glc and 
recirculated three times. Both columns were extensively washed and antibodies specifically 
bound to each column were eluted using an acid buffer. Eluted antibodies were neutralized, 
centrifuged with the appropriate centrifugal filter to remove the elution buffer and immediately 
recovered with PBS buffer at neutral pH. Purified antibodies concentration was calculated by 
measuring the absorbance at 280 nm and resulted to be 38.5 µg/mL for 1,5 mL of antibodies 
eluted from the first column (anti-HMW1ct Abs) and 35.0 µg/mL for 1,7 mL of antibodies eluted 
from the second column (anti-HMW1ct-Glc Abs). 
The same purification procedure was followed using two chromatography columns 
functionalized with CSF114 and CSF114(Glc), respectively. After serum loading and columns 
washing, specific antibodies were eluted from the two columns and their concentrations were 
calculated according to their absorbance at 280 nm. We obtained 1.8 mL of antibodies eluted 
from the first column (anti-CSF114 Abs) at a concentration of 38.3 µg/mL, and 1.5 mL of 
antibodies eluted from the second column (anti-CSF114(Glc) Abs) at a concentration of 27.7 
µg/mL. 
4.6.8 Purified antibodies titration 
The specificity of the four purified antibody fractions for the different antigens was investigated 
by performing an SP-ELISA titration assay.  
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Plates were coated with HMW1ct and HMW1ct-Glc and anti-HMW1ct or anti-HMW1ct-Glc Abs 
were applied at six different dilutions on both coated proteins. The registered absorbance values 
are shown in Figure 39. 
 
Figure 39: SP-ELISA titration of purified anti-HMW1ct and anti-HMW1ct-Glc antibodies. 
The result of the titration assay clearly demonstrated the success of the purification procedure 
based on two sequential affinity chromatographies. Antibodies eluted from the first column 
showed a very similar titer against HMW1ct as well as against HMW1ct-Glc, suggesting that 
they recognized some epitopes shared by both proteins and consequently dependent upon their 
amino acidic sequence. On the contrary antibodies eluted from the second column had a high titer 
against HMW1ct-Glc only. Considering that HMW1ct-Glc differs from HMW1ct for the 
presence of 8 glucosyl moieties, antibodies eluted from the second column should bind very 
specifically those glucosyl units. 
An SP-ELISA titration assay was then performed coating CSF114 and CSF114(Glc) and 
applying five different concentrations of anti-CSF114 and anti-CSF114(Glc) Abs. As reported in 
Figure 40, the sequential affinity chromatography on peptides was successful in obtaining one 
antibody fraction specifically recognizing the glucosylated epitope of CSF114(Glc); in fact anti-
CSF114(Glc) Abs titer was high on CSF114(Glc) but no absorbance was registered on coated 
CSF114. Antibodies eluted from the column functionalized with CSF114 displayed a low titer on 
coated CSF114(Glc) and no titer on CSF114, indicating that the experimental conditions of the 
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titration assay, probably in terms of incubation time and temperature, were inadequate to detect 
purified anti-CSF114 Abs. 
 
Figure 40: SP-ELISA titration of purified anti-CSF114 and anti-CSF114(Glc) antibodies. 
In both sequential affinity chromatographies the initial loading of serum on the column 
functionalized with the non glucosylated antigen allowed a complete depletion of antibodies 
recognizing non glucosylated epitopes and consequently to collect antibodies very specific for the 
glucosyl moieties present on the antigen immobilized on the second column. 
4.6.8.1 HMW1ct not retained fraction characterization 
During the previously described sequential affinity chromatography process a little amount of the 
Flow Through (FT) fraction that was not retained from the HMW1ct containing column was 
preserved for the following analysis.  
To confirm the performance of the sequential affinity chromatography process in depleting serum 
of anti HMW1ct antibodies and to evaluate the relative mean affinity of polyclonal antibodies 
remained in the FT fraction of MS 1 serum after the depletion step, we decided to perform a 
titration assay and a competitive ELISA.  
For the titration experiment plates were coated with HMW1ct, HMW1ct-Glc and CSF114(Glc) 
and the FT fraction was applied at seven different final dilutions; absorbance levels registered at 
the end of the assay are shown in Figure 41. 
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Figure 41: SP-ELISA titration of the FT fraction obtained from the HMW1ct-column. 
In agreement with results obtained titrating purified anti-HMW1ct-Glc Abs, this FT fraction too 
had a high concentration dependent antibody titer against the glucosylated protein as compared to 
the low titer detected against the unglucosylated protein, confirming the performance of the 
depletion step; as expected antibodies binding to CSF114(Glc) were also present in this sample. 
The residual absorbance registered on coated HMW1ct could depend on the saturation of the 
HMW1ct column that did not allow to achieve a complete depletion of anti-HMW1ct antibodies 
from MS serum or could be due to the presence of antibodies in the FT fraction that recognized 
some epitopes of HMW1ct that were not accessible when the protein was covalently bound to the 
sepharose resin but that are better exposed when the same protein was absorbed on the ELISA 
plate. 
A competitive ELISA was then performed coating HMW1ct-Glc and the binding of anti-
HMW1ct-Glc antibodies, contained in the FT fraction, was inhibited applying six different 
concentrations of HMW1ct, HMW1ct-Glc, CSF114 and CSF114(Glc). The inhibition curves 
indicating the inhibition values (%) for every inhibitor concentrations used are reported in Figure 
42. The only molecule that inhibited the binding of anti-HMW1ct-Glc antibodies, at the tested 
concentrations, was HMW1ct-Glc with an IC50 value of 10-8 M. This experiments represented the 
first attempt to calculate the relative mean affinity of anti-HMW1ct-Glc antibodies from MS 
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serum in competitive ELISA and interestingly the peptide CSF114(Glc) did not inhibit their 
binding at the concentration used in this assay. To better understand the reason for the lack of the 
inhibition ability of the peptide, another competitive assay was performed coating CSF114(Glc) 
and incubating the same FT fraction with increasing concentrations of HMW1ct-Glc, HMW1ct, 
CSF114(Glc) and CSF114. As shown in Figure 42, both the glucosylated peptide and the 
glucosylated protein resulted to be able to inhibit the binding of anti-CSF114(Glc) antibodies 
with an IC50 of 10-8 and 10-9.5 M, respectively, thus confirming the previously obtained results 
with the five MS patients’ sera. Non glucosylated molecules never inhibited antibodies binding. 
 
Figure 42: Inhibition curves obtained from the competitive ELISA assays and indicating the relative mean affinity of 
anti HMW1ct-Glc or of anti-CSF114(Glc) antibodies, present in MS 1 FT fraction, for the different inhibitors 
applied in solution. 
It should be taken into account that the antibody fraction obtained from MS serum is polyclonal 
and thus contains a family of different immunoglobulins, possibly interacting with different 
epitopes of the relatively large protein antigen HMW1ct-Glc and only a subgroup of this 
heterogeneous population of antibodies may cross-react with CSF114(Glc) peptide; this could be 
the reason why the peptide did not inhibit their binding when HMW1ct-Glc was absorbed on the 
plate. This hypothesis was in line with the results obtained with the other competitive assay; in 
fact when CSF114(Glc) was coated, antibodies in the FT fraction interacting with a small antigen 
like the peptide, were inhibited by both glucosylated molecules. 
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4.6.9 Surface Plasmon Resonance studies with purified antibodies  
We decided to exploit the technology of the Surface Plasmon Resonance biosensor Biacore T100 
to investigate the cross reactivity of each purified antibody fraction with each antigen and to 
deeply characterize the kinetic and the affinity of these interactions. 
4.6.9.1 Biosensor surface preparation  
HMW1ct, HMW1ct-Glc, CSF114 and CSF114(Glc) were individually immobilized onto a 
different channel of the sensor chip surface. For each ligand the best immobilization buffer, 
maximizing the electrostatic interaction with chip surface, was selected with the pH scouting 
procedure consisting in injecting each molecule in buffers of different pH and ionic strength. The 
pH scouting performed with HMW1ct-Glc is shown in Figure 43 as a representative example.  
 
Figure 43: Sensorgrams resulting from the pH scouting experiment performed dissolving HMW1ct-Glc in the 
buffers listed in the legend and injecting it over chip surface. 
The optimal selected buffers and the immobilization level of each molecule are reported in Table 
19. 
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 HMW1ct HMW1ct-Glc CSF114 CSF114(Glc) 
Immobilization 
buffer 
5mM 
CH3COONa  
pH 4.5 
10mM 
CH3COONa  pH 
4.5 
0.5mM 
CH3COONa 
pH 5 
0.1mM 
CH3COONa pH 
5.5 
Immobilized 
molecule 
(RU) 
8886  7360  2390  1483  
Table 19: Optimal immobilization buffer and quantity of proteins and peptides immobilized on chip surface 
expressed in Resonance Unit (RU). 
Ligands were immobilized through the amine coupling strategy, this coupling approach consisted 
in the activation of carboxylic groups on chip surface and in the injection of the ligand containing 
at least one free primary amine group in order to allow the amide bond formation between the 
free amine and an active carboxylic group introduced in the dextran matrix. Remaining free 
reactive sites on chip surface were then blocked with ethanolamine. Figure 44 shows the 
resonance signal generated by the immobilization of HMW1ct-Glc on channel 2. The channel 1 
of each sensor chip was used as reference to subtract unspecific interaction between samples and 
gold surface, this channel was activated and directly blocked obtaining the sensorgram showed in 
Figure 44. 
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Figure 44: Sensorgram illustrating the amine coupling immobilization of HMW1ct-Glc on channel 2 and the 
blocking of channel 1 used as reference for the studies. 
4.6.9.2 Kinetic and affinity studies  
The four purified antibody fractions were diluted in running buffer up to four different final 
concentrations and flowed over the four immobilized ligands in an individual cycle of analysis 
based on the following steps: sample injection to estimate the association phase, washing with 
running buffer to evaluate the dissociation phase, and chip surface regeneration to remove all the 
analyte molecules bound to the ligand. Results were elaborated separately for each sample fitting 
the experimental values to the 1:1 binding model. This model, describing the interaction between 
a monovalent analyte molecule and a monovalent immobilized ligand, was validated by three 
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statistical parameters: the residual values between the experimental points and the theoretical 
ones that were closely distributed around zero, the minimal chi-square value, and the standard 
errors that were less than 10% of the referred parameter value. The kinetic parameters of the 
association rate ka and dissociation rate kd and the affinity constants KD (kd/ka), describing each 
characterized interaction, were calculate and reported in Table 20.  
  HMW1ct-Glc HMW1ct CSF114(Glc) CSF114 
Anti-HMW1ct-Glc 
Abs 
ka (1/Ms) (91.8±0.5) × 10
3
 
no interaction 
(27.0±0.6) × 10
4
 
no interaction kd (1/s) (25.5±0.1) × 10
-4
 (69.2±0.9) × 10
-4
 
KD(M) 2.8 × 10
-8
 2.6 × 10
-8
 
Anti-HMW1ct 
Abs 
ka (1/Ms) (15.6±0.2) × 10
3
 (45.6±0.7) × 10
3
 (94.8±3.5) × 10
3
 
no interaction kd (1/s) (10.9±0.1) × 10
-4
 (19.4±0.1)× 10
-4
 (38.8±2.3) × 10
-5
 
KD(M) 7.0 × 10
-8
 4.2 × 10
-7
 4.1 × 10
-9
 
Anti-CSF114(Glc) 
Abs 
ka (1/Ms) (22.5±0.1) × 10
3
 
no interaction 
(10.6±0.3) × 10
4
 
no interaction kd (1/s) (120.5±0.9) × 10
-6
 (75.1±0.8) × 10
-5
 
KD(M) 5.3 × 10
-9
 7.1 × 10
-9
 
Anti-CSF114 Abs 
ka (1/Ms) 
no interaction no interaction 
(135.6±0.6) × 10
3
 (50.7±0.2) ×10
3
 
kd (1/s) (26.2±0.2) × 10
-4
 (79.0±0.4) × 10
-5
 
KD(M) 1.9 × 10-8 1.6 × 10-8 
Table 20: Affinity constants KD and kinetic parameters ka and kd, calculated according to the 1:1 binding model for 
each studied interaction. 
The kinetic and affinity results were summarized using the Biacore T100 Kinetic Summary 
application and the ka/kd plot was obtained. This graph showed the association rate parameter (ka) 
against the dissociation rate parameter (kd), both on logarithmic scale, affinity constants KD 
(calculated as kd/ka ratio) were displayed on diagonal lines. Thus, interactions having the same 
affinity but different kinetic properties were indicated by points lying in different positions on the 
same diagonal line. The ka/kd plot summarizing every characterized interactions is shown in 
Figure 45. 
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Figure 45: ka/kd plot for the 1:1 binding model summarizing interactions between 4 purified antibody fractions and 4 
immobilized ligands indicated by different colors in the plot.  
The results confirmed the total cross-reactivity of anti-CSF114(Glc) Abs and anti-HMW1ct-Glc 
Abs: both fractions interacted with CSF114(Glc) and HMW1ct-Glc but they did not bind to the 
corresponding non glucosylated antigen. The interactions between anti-HMW1ct-Glc Abs and 
HMW1ct-Glc or CSF114(Glc) (shown in Figure 46 A and B), were characterized by a faster 
dissociation rate and consequently lower affinity (KD= 2 × 10-8 M), as compared to anti-
CSF114(Glc) Abs that bound to the same two antigens, as shown in Figure 46 C and Figure 46 D, 
with higher affinity (7 × 10-9 M > KD > 5 × 10-9 M) because of the slower dissociation rate. The 
sensorgrams resulting from the kinetic study between anti-HMW1ct-Glc Abs and the non 
glucosylated HMW1ct and between anti-CSF114(Glc) Abs and CSF114 are showed in Figure 47 
A and Figure 47 B, as representative examples of lack of interaction that did not allow calculation 
of affinity and kinetic parameters. 
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Figure 46: Sensorgrams showing the progress of the interaction between: anti-HMW1ct-Glc Abs and HMW1ct-Glc 
(A) and with CSF114(Glc) (B); anti-CSF114(Glc) Abs with CSF114(Glc) (C); and with HMW1ct-Glc (D). 
Experimental curves are shown in different colors according to the injected concentrations, black curves indicates the 
fitted 1:1 binding model. Residuals are shown below each characterized interaction. 
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Figure 47: Sensorgrams showing the lack of binding between anti-CSF114(Glc) Abs and CSF114 (A), and anti-
HMW1ct-Glc Abs and HMW1ct (B)  
Concerning fractions eluted from the non glucosylated molecules, we observed that anti-CSF114 
Abs exhibited the same affinity for CSF114(Glc) and CSF114 (KD= 1 × 10-8 M) and that they did 
not bind to the adhesin proteins. Anti-HMW1ct Abs resulted to be the most heterogeneous 
fraction, characterized by the presence of antibodies with a different specificity of binding and 
consequently recognizing all the immobilized ligands, except for CSF114, with a wide difference 
in affinity (10-7 M > KD > 10-9 M). The kinetics of the interaction of anti-HMW1ct Abs with 
HMW1ct and of anti-CSF114 Abs with CSF114 are reported in Figure 48 A and B. 
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Figure 48:Sensorgrams showing the interaction between anti-HMW1ct Abs and HMW1ct (A) and between anti-
CSF114 Abs and CSF114 (B). Experimental curves are colored according to the injected concentrations, black 
curves indicates the fitted 1:1 binding model. Residuals are shown below each characterized interaction. 
4.6.9.3 Binding studies with sera 
18 MS sera and 20 NBD sera, previously tested in SP-ELISA coating HMW1ct-Glc, HMW1ct 
and CSF114(Glc), were used to perform binding studies on the same three antigens covalently 
immobilized onto Biacore sensor chips. Each serum was tested at 1:50 and 1:100 dilution in a 
different cycle of analysis consisting in sample injection, running buffer flow to monitor the 
dissociation and chip regeneration by washing the surface with two buffers at different pH. The 
maximum binding level registered at the end of the injection for the 1:100 dilution was 
determined for each sample with each ligand and is listed in Table 21 for MS sera and in Table 
22 for NBD ones. 
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BIACORE SP-ELISA 
  Binding (RU) IgG   IgM   
  
HMW1ct-
Glc HMWct1 
CSF114 
(Glc) 
HMW1ct-
Glc HMWct1 
CSF114 
(Glc) 
HMW1ct-
Glc HMWct1 
CSF114 
(Glc) 
MS1  76.3 12.8 71.2 1.70 0.30 1.50 0.62 0.50 0.43 
MS2 52.9 37.1 90.5 1.76 1.43 1.19 0.63 0.67 0.23 
MS3 73.1 14.9 117.9 1.48 0.68 1.19 1.58 1.00 0.97 
MS4 22.8 3.5 69.0 1.74 0.78 1.06 0.31 0.29 0.11 
MS5 47.6 10.2 68.6 1.46 0.90 1.11 0.79 0.60 0.63 
MS6 0.0 0.0 42.8 0.89 0.87 0.14 1.80 1.36 1.74 
MS7 32.4 23.4 76.0 0.66 0.79 0.21 1.01 0.76 0.67 
MS8 20.0 15.6 63.1 0.50 0.50 0.21 0.89 0.93 0.41 
MS9 48.6 37.2 101.5 0.54 0.53 0.06 0.52 0.60 0.20 
MS10 45.4 31.2 94.4 1.32 0.63 0.83 0.83 0.38 0.26 
MS11 47.2 20.3 71.1 2.04 0.53 0.35 1.26 0.74 0.47 
MS12 39.7 2.9 64.2 1.56 0.32 0.50 1.40 0.74 0.86 
MS13 34.9 20.7 80.9 1.18 0.60 0.59 1.04 0.69 0.45 
MS14 37.6 23.3 57.0 1.31 0.94 0.50 0.83 0.73 0.50 
MS15 26.5 15.0 54.3 1.26 1.16 0.48 0.29 0.30 0.20 
MS16 28.6 9.3 61.6 1.16 0.50 0.44 1.00 0.62 0.96 
MS17 30.8 15.3 60.3 1.49 0.89 0.59 0.83 0.71 0.41 
MS18 28.8 8.5 62.3 1.58 0.56 0.46 1.00 0.53 0.73 
Table 21: Comparison between binding levels of MS sera registered with SPR studies and IgG or IgM titer obtained 
in SP-ELISA. 
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BIACORE SP-ELISA 
  Binding (RU) IgG   IgM   
  
HMW1ct-
Glc HMWct1 
CSF114 
(Glc) 
HMW1ct-
Glc HMWct1 
CSF114 
(Glc) 
HMW1ct-
Glc HMWct1 
CSF114 
(Glc) 
NBD1 8.4 0.4 62.3 0.45 0.45 0.32 0.39 0.39 0.29 
NBD2 16.6 5.7 114.9 0.5 0.26 0.13 0.83 0.43 0.18 
NBD3 13.7 5.5 109.8 0.66 0.53 0.04 0.29 0.25 0.08 
NBD4 0.7 0.0 36.9 0.29 0.98 0.18 0.37 0.33 0.28 
NBD5 14.0 7.9 48.3 1.62 1.43 0.91 0.86 0.41 0.89 
NBD6 41.6 25.5 54.0 1.82 0.72 0.57 1.49 1.43 0.73 
NBD7 38.3 18.9 64.8 0.62 0.72 0.62 0.28 0.34 0.41 
NBD8 16.3 0.0 45.3 0.5 0.34 0.09 0.36 0.29 0.24 
NBD9 21.5 10.1 51.7 0.32 0.47 0.12 0.65 0.28 0.44 
NBD10 14.9 5.6 53.8 0.22 0.23 0.02 0.19 0.19 0.09 
NBD11 40.9 12.3 47.6 0.92 0.49 0.28 0.72 0.65 0.91 
NBD12 14.0 1.6 45.2 0.8 0.54 0.31 0.24 0.25 0.36 
NBD13 17.0 8.8 35.4 0.75 0.93 0.14 0.87 0.51 0.44 
NBD14 29.9 16.2 59.5 1.03 0.85 0.35 0.45 0.34 0.14 
NBD15 35.3 11.4 50.8 1.16 0.62 0.2 0.48 0.49 0.16 
NBD16 21.0 3.0 44.2 1.31 0.85 0.08 1.69 1.44 0.22 
NBD17 29.9 9.5 53.8 0.56 0.62 0.14 0.49 0.4 0.28 
NBD18 24.0 6.6 56.9 0.94 0.55 0.2 1.1 0.92 0.33 
NBD19 3.6 0.0 37.7 0.39 0.21 0.05 0.34 0.36 0.13 
NBD20 28.7 8.0 51.2 0.75 0.55 0.08 0.28 0.23 0.04 
Table 22: Comparison between binding levels of NBD sera registered with SPR studies and IgG or IgM titer 
obtained in SP-ELISA. 
In Table 23 we reported the mean and the relative Standard Deviation (SD) of the binding values 
registered with the two groups of sera on the three immobilized antigens with the present SPR 
assay. 
Binding level (RU) 
Immobilized 
antigen 
MS NBD 
Mean SD Mean SD 
HMW1ct-Glc 38.5 18.2 21.5 11.8 
HMW1ct 16.7 10.8 7.8 6.7 
CSF114(Glc) 72.6 18.5 56.2 20.8 
Table 23: Mean binding levels and SD registered with the biosensor assay. 
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A significant difference of binding signals between the two groups was registered on each 
immobilized molecule, observing the higher values in MS sera (Figure 49). 
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Figure 49: Column scatters for the distribution of the binding levels registered on immobilized HMW1ct-Glc, 
HMW1ct and CSF114(Glc) with MS and NBD sera; mean values and Standard Deviation are shown for each group. 
Because a difference between the two groups of sera was detected with CSF114(Glc) and with 
both immobilized proteins, a receiver operating characteristic (ROC)-based analysis was 
employed comparing different combinations of cut-off values, specificities and sensitivities. 
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Three ROC curves for anti-HMW1ct-Glc, anti-HMW1ct and anti-CSF114(Glc) activities were 
constructed based on 18 cases of MS versus 20 controls (Figure 49). 
  
 
Figure 50: ROC curves analysis of antibodies interacting with HMW1ct-Glc, HMW1ct and CSF114(Glc) in MS 
versus NBD sera. 
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A discriminative power for the anti-HMW1ct-Glc antibodies was found with an area under the 
curve of 0.79 and a p-value of 0.002; the optimal diagnostic cut-off for the method was 41.2 RU 
with a sensitivity of 38.9% and a specificity of 95.0%. According to this cut-off value, an 
increased antibody level was detected in 7/18 MS sera (38.9%) and in 1/20 NBD sera (5%). 
In the case of the non-glucosylated protein, a discriminative power was also found: the area under 
the curve was 0.76 and the p-value 0.006, the diagnostic cut-off for this method was 22.0 RU 
with a sensitivity of 27.8% of and a specificity of 95.0%. Consequently an increased antibody 
level was registered in 5/18 MS sera (27.8%) and in 1/20 NBD sera (5%).  
Analyzing the data obtained with immobilized CSF114(Glc), we obtained a discriminative power 
indicated by an area under the curve of 0.82 and a p-value of 0.0007; the diagnostic cut-off for 
the method was set at 71.1 RU with a sensitivity of 38.9% and a specificity of 90 %. We 
registered an increased antibody level in 7/18 MS sera (38.9%) and in 2/20 NBD sera (10.0%). 
The results of the present binding study confirmed the ability of SPR biosensor to specifically 
detect autoantibodies in MS patients’ sera as compared to health subjects, when CSF114(Glc) 
was covalently immobilized on the chip surface46. 
Another interesting aspect was that, from this preliminary screening assay, both adhesin proteins 
resulted to be able to detect antibodies in MS patients’ sera compared to NBD ones with a 
specificity of 95.0 % but with a higher sensitivity in the case of glucosylated HMW1ct. 
From the graph shown in Figure 51 we could see that the same trend of binding values was 
conserved among the different injected sera on the three immobilized antigens and, in particular, 
they were generally higher on the glucosylated protein than on the non glucosylated one and the 
highest binding values were registered on CSF114(Glc) both in NBD and in MS groups. The 
wide difference in binding values among MS sera was registered with MS 1 and MS 3 which 
showed the highest signal on HMW1ct-Glc and a low signal on HMW1ct indicating that the two 
sera contained a high concentration of antibodies recognizing the glucosyl moieties of HMW1ct-
Glc. Concerning the NBD group, a significant difference in binding level was obtained with NBD 
2 and NBD 3 sera displaying the highest interaction signal on CSF114(Glc), but resulting below 
the cut-off value on both immobilized adhesin proteins.  
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Figure 51: Comparison between binding signals obtained with each MS serum or each NBD serum on the different 
immobilized ligands  
IgG and IgM levels detected in SP-ELISA coating the same three antigens and applying the 18 
MS sera and the 20 NBD used in the present SPR assay, were compared with SPR binding data. 
As indicated by the correlation graphs for MS sera shown in Figure 52, the two methods 
exhibited different overall results.  
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Figure 52: Biacore-ELISA correlation of the reactivity of HMW1ct-Glc, HMW1ct and CSF114(Glc) for MS 
patients’ sera. IgM and IgG observed in ELISA are indicated by different symbols and plotted against the total 
antibody fraction detected in Biacore assay. 
Comparing data obtained with both methods when CSF114(Glc) was used as probe, 5 positive 
cases in ELISA (IgM and/or IgG) were recognized as border line samples by the biosensor, 1 
positive case in ELISA was negative by the SPR assay; 3 positive cases according to the 
biosensor were not recognized as positive in ELISA and 1 positive case by biosensor resulted 
border line in ELISA.  
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Considering data obtained with both methods when HMW1ct-Glc was used as probe, 2 positive 
cases in ELISA were also recognized as positive with the biosensor analysis, 1 positive case in 
ELISA was negative and the other positive case in ELISA resulted to be border line with the 
present SPR assay.  
When HMW1ct was used as probes in SP-ELISA very similar absorbance values were registered 
applying NBD sera or patients’ sera in the case of IgG and IgM, and when HMW1ct-Glc was 
coated no discriminative power was found for IgG antibodies, so a diagnostic cut-off was not 
established for SP-ELISA in these three cases and a precise correlation between positive or 
negative cases according to both methods could not be done.  
Nevertheless, we noticed that the best correlation between antibody levels detected with the two 
assays was registered with the IgM fraction interacting with the protein HMW1ct-Glc.  
Considering the results of the biosensor assay a general increase in antibody level was revealed in 
MS sera compared to NBD sera with the two proteins and the difference in antibody levels 
between the two groups was higher in the case of immobilized HMW1ct-Glc, confirming the 
importance of glucosyl moieties for MS antibodies detection. 
We could conclude that when the same antigens were non covalently adsorbed on ELISA plates 
or covalently immobilized on biosensor chip surface, different families of antibodies were 
detected, probably because of the different immobilization strategy that resulted in a different 
final orientation of the antigens on the solid supports. In addition low affinity antibodies were 
usually removed during the washing steps of the ELISA assay, but they could be revealed when 
continuously flowing over the antigen in the SPR assay. Furthermore the SPR study had the 
advantage of monitoring in real time the interaction, of using a few microliters of biological 
material and of limiting the variability of the assay because the same sample solution 
contemporary flows over the three immobilized ligands thanks to the complex system of valves 
that control the instrument flow. In our SP-ELISA information was provided by the use of a 
specific anti-IgM or anti-IgG secondary antibody, this was not the case of the SPR assay in which 
antibody binding was directly registered thanks to the change in mass over the surface, without 
the need of adding a secondary antibody. 
4.6.10 Immunohistochemistry assay 
In collaboration with Dr. S. Matà of the Department of Neurology, Azienda Ospedaliera 
Universitaria Careggi, Florence, we performed some immunohistochemistry assays on normal rat 
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fixed tissues to understand if antibodies present in one whole serum (patient MS 1) or antibodies 
purified with the sequential affinity chromatography process, from the same MS serum, and 
recognizing glucosyalted epitopes in our in vitro assays, could also bind in situ to some structures 
expressed in nervous tissues.  
Tissues were obtained from one healthy rat that was euthanized by an injection of an overdose of 
anesthetic and transcardially perfused with fixative solution. Brain, kidney, stomach, spinal cord 
and cerebellum were surgically removed, fixed overnight and finally stored at -80°C. Thirty 
micron coronal sections from every tissues were then cut using a cryostat and collected in the 
anti-freeze solution until use. 
4.6.10.1 Validation of tissues 
To understand if we succeeded in the fixation process and if tissues could be used for the 
following immunohistochemistry assay with MS 1 serum and purified antibodies, we decided to 
validate them by applying some positive controls. We chose four previously tested sera 
containing antibodies with different known specificity and recognizing the following antigens on 
rat tissues: the trisaccharide Human Natural Killer-1 (HNK-1), that is associated to different 
glycoproteins or glycolipids in the nervous system, the aquaporin 4 (AQ4), an integral membrane 
protein expressed on cell membrane, the Glutamic Acid Decarboxylase (GAD) which is present 
at nerve terminals and synapses, and cell nuclei. 
Immunohistochemistry was performed on free-floating tissue sections, the positive control sera 
were diluted in PBS buffer 1:200 and incubated with tissues. After washing, a Fluorescein 
Isothiocyanate (FITC) conjugated secondary antibody was added and primary antibodies bound 
to the tissues were detected with a fluorescence microscope. 
As shown in Figure 53 a specific green fluorescence signal was detected with each serum in the 
different tissues, confirming that rat fixed tissues could be used for the next experiments. 
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Figure 53: Fluorescence signal generated after the incubation of positive control samples on different rat tissues: A) 
anti HNK1antibody detected in the limbic cortex of brain section, B) anti nucleus antibody in the brain cortex, C) 
anti AQ4 antibodies around the medium vessels of the cortex, D) anti GAD antibodies in the glomerulus of the 
kidney. 
Negative controls were also performed with each tissue by omitting the primary antibody; as 
expected, no fluorescence signal was registered. 
4.6.10.2 Immunohistochemistry with MS 1 serum 
MS 1 serum was diluted in PBS 1:50 and 1:200 and incubated with free floating rat tissues. 
After washing, double immunofluorescence was performed by applying the appropriate FITC-
conjugated secondary antibody to detect bound primary antibodies and then the 4',6-diamidino-2-
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phenylindole (DAPI) reagent was added to specifically stain cells’ nuclei. Immunostaining for 
MS 1 serum at the higher dilution gave no detectable signals in nervous sections nor in the other 
tested tissues, but some fluorescence signals were registered in the brain vessels zone, when 
serum was incubated at the lower dilution. In each section the DAPI reagent enabled the 
visualization of cells’ nuclei.  
In Figure 54 we reported FITC dependent signal obtained because of the interaction between 
antibodies present in MS 1 serum and medium or small vessels in brain sections.  
  
Figure 54: FITC fluorescence signal registered on vessels incubating rat brain sections with MS 1 serum at 1:50. 
dilution. 
Antibodies could theoretically bind to structures localized on epithelial cells around the vessels or 
to some other targets inside the vessels; to deeply understand this point we overlapped the 
fluorescence signal generated by FITC with the one produced by DAPI obtaining the image 
shown in Figure 55.  
CHAPTER 4 
99 
 
Figure 55: FITC (green) and DAPI (blue) fluorescence signals overlapped. No correlation seemed to be present. 
No co-localization was found between the two signals indicating that antibodies probably bound 
to anucleate cells inside blood vessels (e.g. erythrocytes or platelets). This result is surprising, 
since these cells should have been fully removed by the initial perfusion process, so this 
hypothesis has to be confirmed with further studies and with the application of specific markers 
to stain the different kinds of blood cells.  
4.6.10.3 Immunohistochemistry with purified antibody fractions 
We performed the immunohistochemistry assay with the 4 purified antibody fractions obtained 
through the sequential affinity chromatography process: anti-HMW1ct Abs, anti-HMW1ct-Glc, 
anti-CSF114 Abs and anti-CSF114(Glc) Abs. Each sample was incubated with rat fixed sections 
at a concentration of 10 µg/mL. The FITC-conjugated secondary antibody was added and 
fluorescence was read at the appropriate wavelength.  
Analyzing the fluorescence signal registered with the four antibody samples on the different fixed 
rat tissues, we could summarize that anti-HMW1ct-Glc Abs not specifically interacted with 
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stomach sections (Figure 56 A) but they didn’t bind to nervous tissues as shown in Figure 56 B. 
Applying anti-CSF114 Abs and anti-CSF114(Glc) Abs no fluorescence signal was registered on 
any tissues. 
  
Figure 56: Results of the immunohistochemistry assay performed with anti-HMW1ct-Glc Abs purified from MS 1 
patient. A) unspecific signal on stomach section; B) lack of signal on brain section. 
From the immunohistochemistry assay performed with anti-HMW1ct Abs we observed a specific 
interaction signal on brain and spinal cord sections (Figure 57). This signal was localized along 
the pia mater, a thin highly vascular membrane composed of fibrous connective tissue that 
closely envelops the brain and spinal cord, hosting a large number of blood vessels, which pass 
through the pia mater to go inside the brain or the spinal cord. 
A 
B 
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Figure 57: FITC fluorescence signal registered incubating anti-HMW1ct Abs with spinal cord (A) and brain (B,C) 
sections. 
As expected, anti-CSF114 Abs did not recognize any structure on tested tissues, but no 
interaction signal on nervous sections (brain, cerebellum and spinal cord) was detected applying 
anti-HMW1ct-Glc and anti-CSF114(Glc) Abs that, through in vitro studies, we demonstrated to 
be highly specific for N-glucosylated epitopes. To understand if this lack of reactivity was due to 
low sample concentration, the assay was repeated by incubating samples at their initial 
concentration without dilution, but the same results were obtained. We were sure that 
A 
C 
B 
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glucosylated epitopes were preserved on fixed tissues because in the validation step a specific 
fluorescence signal was obtained with the serum containing antibodies recognizing the HNK1 
epitope, whose antigenic portion was known to be its terminal sulfated trisaccharide. The most 
consistent explanation for this lack of signal could be that N-glucosyalted proteins, or un-
glucosylated structures mimicked by the N-glucosylated molecules used to characterize the 
antibodies, were not present in the nervous tissues from the selected normal healthy rat. To 
clarify this point we decided to repeat the study on tissues from Experimental Autoimmune 
Encephalomyelitis (EAE) mice, animal model of the disease. This part of the work is going to be 
performed by the Immunology Department of the Weizmann Institute of Science in Israel. 
The interaction registered between anti-HMW1ct Abs and the pia mater membrane of the brain 
and of the spinal cord, could indicate that structures mimetic of the bacterial protein were present 
on the pia mater membrane. A certain level of antibodies recognizing the non glucosylated 
bacterial protein were detected in MS sera with the SP-ELISA assay and with the SPR binding 
study and, in line with results obtained from competitive ELISA, this immunohistochemistry 
assay confirmed that they did not recognize the same epitope as anti-HMW1ct-Glc Abs. We 
believed that anti-HMW1ct Abs are not related to MS disease and to confirm this point, the same 
immunohistochemistry assay is going to be repeat by the Immunology Department of the 
Weizmann Institute of Science, incubating tissues with the total antibody fraction purified from 
one normal blood donor by protein G chromatography. If the same interaction with the pia 
membrane is detected, it will be definitively proved that anti-HMW1ct antibodies are 
physiologically present in serum of each person having been in contact with H. inlfuenzae, and 
that they are not involved in the autoimmune response typical of the disease. On the other hand 
we can speculate that only if adhesin mimetic structures, which could be present somewhere on 
nervous tissue (e.g. on the pia membrane), are aberrantly N-glucosylated, they can be recognized 
by specific anti-HMW1ct-Glc antibodies (that we demonstrated to be exclusively of MS 
patients); those anti-HMW1ct-Glc antibodies could trigger the harmful autoimmune response 
typical of Multiple Sclerosis disease that lead to the destruction of myelin. It has already been 
shown that B cell activation in MS may be dependent on bacterial or viral antigens56 and a 
pathogenic link between the antibody responses to bacterial carbohydrate products and those to 
myelin antigens has been documented57. This considerations could support the idea that, together 
with the molecular mimicry between pathogen structures and self-molecules, one or more 
aberrant N-glucosylations of endogenous proteins caused by a bacterial enzyme (such as 
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HMW1C glycosyltransferase of H.influenzae), could be the possible mechanisms responsible for 
the activation of the immune response involved in the development of MS disease. 
4.7 Conclusions 
This study demonstrated, with different in vitro assays, the cross-reactivity between the 
autoantibodies detected in MS patients’ sera with the use of the synthetic N-glucosylated peptide 
probe CSF114(Glc) and the N-glucosylated protein HMW1ct corresponding to the C-terminal 
portion of the adhesion protein HMW1 that is expressed on the outer membrane of the human 
pathogen Haemophilus inlfuenzae.  
More in detail the following considerations emerged from the experiments performed during the 
study: 
• SP-ELISA assay’s results indicated that unglucosylated HMW1ct was not able to detect 
specific antibodies in MS sera as compared to NBD ones, while glucosylated HMW1ct-
Glc could discriminate between MS and NBD group only in the case of serum IgM. 
Another important aspect was that in the case of NBD a similar level of antibodies 
interacting with HMW1ct-Glc and with HMW1ct was registered, suggesting that those 
antibodies did not recognize glucosylated epitopes; 
• Competitive ELISA assays showed that HMW1ct-Glc bearing eight N-linked glucose 
moieties were able to inhibit the binding of anti CSF114(Glc) antibodies in 5 
representative MS sera. Similar results were obtained with all the HMW1ct mutants 
containing a lower number of glucose units and the minimal number of glucosylations 
required to inhibit MS antibodies binding with the same high affinity of the fully 
glucosylated HMW1ct (average IC50=10-9 M) was four. On the other hand non-
glucosylated proteins did not inhibit MS sera binding, confirming the importance of the 
presence of the glucosyl moiety on the proteins and on the peptide for the interaction with 
MS antibodies. In the case of NBD sera, antibody binding to HMW1ct-Glc was inhibited 
with similar affinity by both proteins, glucosylated and unglucosylated, thus confirming 
that these antibodies were physiologically present in the blood of people who probably 
were infected by the very common pathogen H. influenzae during their life and 
consequently developed antibodies able to recognized an epitope shared by the two 
proteins and not related to the presence of N-glucosylation moieties; 
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• The adhesin derived peptide pept(5,6)glc was selected to perform SPR-binding study, but 
because of its poor solubility in the immobilization buffer and of the too low electrostatic 
interaction with chip surface, peptide covalent immobilization failed. A longer version of 
that peptide with and without three glucosylation units were synthesized and the non 
glucosylated sequence was successfully immobilized on chip surface. The same 
immobilization strategy is going to be applied for the immobilization of the glucosylated 
peptide; 
• Antibody purification from one MS serum by two sequential affinity chromatographies 
was successfully set up, enabling us to obtain an antibody fraction recognizing 
exclusively the glucosyl units of HMW1ct-Glc and of CSF114(Glc); 
• SP-ELISA titration assay with purified antibody fractions confirmed the ability of the 
sequential affinity chromatography process to deplete serum from antibodies recognizing 
the non glucosylated epitopes and consequently to obtain two fractions containing 
antibodies highly specific for the glucosylated moieties of HMW1ct-Glc and 
CSF114(Glc), respectively; 
• SPR kinetic and affinity studies demonstrated the cross-reactivity between anti-
CSF114(Glc) and anti-HMW1ct-Glc antibody fractions: in particular anti-CSF114(Glc) 
antibodies interacted with both glucosylated molecules with one fold higher affinity (KD= 
10-9 M) than anti-HMW1ct-Glc antibodies, which bound the same two molecules with 
lower affinity (KD= 10-8 M); 
• SPR binding study on immobilized HMW1ct and HMW1ct-Glc indicated that both 
adhesin proteins were able to detect antibodies in MS patients’ sera as compared to NBD 
ones with the same specificity but with a higher sensitivity in the case of HMW1ct-Glc. 
Binding values registered with the different sera did not correlate with absorbance levels 
obtained with the SP-ELISA assay, indicating that when the same antigens were non 
covalently adsorbed on ELISA plates or covalently immobilized on the biosensor chip, 
different families of antibodies were detected; 
• The immunohistochemistry assay performed with the whole MS serum showed an 
interaction signal with anucleate cells inside the blood vessels of brain sections, but this 
result has to be confirmed by further experiments. In the case of purified antibodies, a 
fluorescence signal was obtained only with anti-HMW1ct antibodies, which appear to 
stain putative mimetic structures of the HMW1ct protein, present on the pia mater 
CHAPTER 4 
105 
membrane; a control experiment with antibodies purified from one normal blood donor 
serum will be performed to confirm the hypothesis that the registered interaction is not 
specific of MS disease. No interaction was revealed applying anti-HMW1ct-Glc 
antibodies probably because N-glucosylated proteins or non glucosylated structures 
mimicked by HMW1ct-Glc were absent in the nervous tissues of the selected normal rat. 
Further assays will be performed to deeply investigate this aspect. 
The overall results suggested that the induction of the specific autoantibodies observed in MS 
patients’ sera within this study could be ascribed either to a molecular mimicry process between 
bacterial N-glucosylated proteins and endogenous structures on nervous tissues or to an aberrant 
N-glucosylation of endogenous human proteins caused by a bacterial enzyme. The 
immunohistochemistry assays that are planned to be performed with purified anti-HMW1ct-Glc 
antibodies on nervous tissues from experimental autoimmune encephalomyelitis mice, will be 
fundamental to choose between these two hypothesis.  
Taken together, these results contribute to understand if pathogen delivered innate immune 
signals could have important implications in triggering the pathogenic self-reactive response of 
Multiple Sclerosis. In this context it is important to consider that proteins from neurotropic 
pathogens could be possible candidate target antigens only if they derive from an intracellular 
pathogen that must enter the CNS and persist there without being associated with any life-
threatening diseases and indeed the bacterium Haemophilus influenzae fulfills these 
requirements. 
4.8 Matherials and methods  
4.8.1 SP-ELISA 
Peptides were diluted in Coating Buffer (12 mM Na2CO3, 35 mM NaHCO3, 3 mM NaN3, pH 9.6) 
and proteins in PBS buffer pH 7.2 up to a final concentration of 10 µg/mL and 100 µL 
solution/well were dispensed on Nunc MaxiSorp 96 wells immunoplates. Incubation was at +4C 
overnight. Plates were washed 5 times with the automatic washer Hydroflex (Tecan) using the 
washing buffer (NaCl 0.9%, Tween 20 0,05%). Immediately after drying, the potential aspecific 
binding sites were blocked using 120 µL/well of FBS Buffer (10% Fetal Bovine Serum in 
Washing Buffer) for 1 hour at room temperature. FBS solution were manually removed and 
100µL/well sera were dispensed in duplicate at 2 dilutions (1:100 and 1:1000 in FBS Buffer) and 
incubated overnight at +4C. Plates were automatically washed 5 times.100µL/well of secondary 
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antibody diluted in FBS Buffer were added: anti human IgG-Alkaline Phosphatase(Sigma) 
1:8000 and anti-human IgM-Alkaline Phosphatase (Invitrogen) 1:1200; incubation was 3 hours at 
room temperature. Plates were automatically washed 5 times. 100µL/well of p-
nitrophenilhosphate [1mg/mL] in Substrate Buffer (1 M diethanolamine, 1 mM MgCl2, 3 mM 
NaN3, pH 9.8) were added. After about 30 minutes the colorimetric reaction was quenched by 
adding 50 µL/well of 1 M NaOH and the absorbance was read at 405 nm with a multichannel 
ELISA reader (Tecan Sunrise). 
4.8.2 SP-ELISA denaturant conditions  
100 µL/well of HMW1ct and HMW1ct-Glc proteins were diluted in PBS buffer up to a final 
concentration of 10 µg/mL and incubated overnight at +4C. Plates were automatically washed 5 
times with PBS buffer. 100 µL/well of denaturing solution (8 M urea, 10 mM β-mercaptoethanol) 
was added and incubated 4 hours at room temperature. Plates were washed 5 times with Washing 
Buffer. 100 uL/well of 25 mM iodoacetamide solution were added and plates were incubated 
overnight at room temperature. Plates were washed 5 times and remaining free sites on plate were 
blocked with 120 µL/well of FBS buffer. Following the standard SP-ELISA protocol absorbance 
was read at 405 nm 
4.8.3 Titration ELISA 
Peptides and proteins were coated on plate surface and free sites on plate were blocked according 
to the same protocol used for a classical SP-ELISA assay. 100 µL/well of sera were applied in 
triplicate at 6 different dilutions (1:100, 1:200, 1:300, 1:400, 1:600 and 1:800), flow through 
fraction was applied at 7 dilutions (without dilution, 1:2, 1:10, 1:50, 1:100, 1:200 and 1:400) and 
purified antibodies were applied at 6 final dilutions (1:2, 1:10, 1:50, 1:100, 1:200 and 1:400); 
samples were incubated on the plate for 1 hour at room temperature. The assay kept on following 
the standard SP-ELISA protocol and using only the human anti IgG-alkaline phosphatase 
antibody as secondary antibody. 
4.8.4 Competitive ELISA 
The protocol used for this assay is the same followed for the titration ELISA; the only difference 
is about sample application. For the competitive ELISA the selected sera were used at the semi-
saturating dilution (corresponding to the dilution giving an absorbance of around 0.5 in the 
titration test). Serum and inhibitor in FBS buffer were mixed (50:50) and 100 µL/well  were 
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immediately dispensed. Each inhibitor were tested at 6 final concentrations: 10-6, 10-7, 10-8, 10-9 
,10-10 and 10-11 M, prepared by serial dilution. IC50 was calculated for each inhibitor as the molar 
concentration need to obtain half of the maximum absorbance signal. 
4.8.5 Proteins conjugation to sepharose: thiol coupling 
100 mg of CNBr-sepharose resin (Sigma) were washed twice with 1 mM HCl 1.5 mL and 
cetrifugated at 4000 rpm for 3 minutes; the washing step was repeated with 1.5 mL of Milliq 
water and with 1.5 mL of coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.3). 
5 mg of N-(2-Aminoethyl)maleimide (Sigma) were dissolved in 1.5 mL of coupling buffer and 
applied to the resin overnight at room temperature. The resin was twice washed with 1.5 mL of 
coupling buffer and free sites on resin were blocked adding 1,5 mL of 0.2 M glycine pH 8.0 for 2 
hours at room temperature. The resin was twice washed with 1.5 mL of coupling buffer and 1.5 
mL of acetate buffer (0.1 M CH3COO-Na+, 0.5 M NaCl, pH 4.3). 1.5 mg of proteins were 
reduced by the addiction of DTT (1:2) in 1.5 mL of 10 mM HEPES pH 7.2 for 2.5 hours at room 
temperature; this solution was then added to 100 mg of previously washed sepharose resin. Free 
sites on sepharose were blocked with 1.5 mL of 0.2 M cysteine 10 mM HEPES pH 7.2 for 2 
hours at room temperature. The resin was twice washed with 1.5 mL of coupling buffer and 
1.5mL of acetate buffer. 
4.8.6 Proteins and peptides conjugation to sepharose: amine coupling 
200 mg of CNBr-sepharose resin (Sigma) were washed twice with 1.5 mL of 1 mM HCl and 
centrifuged at 4000 rpm for 3 minutes; the washing step was repeated with 1.5 mL of Milliq 
water and with 1.5 mL of coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.3). 
2 mg of proteins or peptides were dissolved in 2 mL of coupling buffer and applied to the resin 
overnight at room temperature. The resin was twice washed with 2 mL of coupling buffer and 
free sites on resin were blocked adding 2 mL of 0.2 M glycine pH 8.0 for 2 hours at room 
temperature. Finally the resin was twice washed with 2 mL of coupling buffer and 2 mL of 
acetate buffer (0.1M CH3COO-Na+, 0.5M NaCl, pH 4.3). 
4.8.7 Sequential affinity chromatography 
The resins functionalized with the different antigens were transferred to chromatography columns 
of approximately 4 mL volume. 2 mL of serum were filtered with a 0.22 µm filter and diluted 
1:10 in PBS buffer pH 7.2. Diluted serum was applied three times to the first resin containing the 
CHAPTER 4 
108 
non glucosylated antigen; the not retained fraction was directly applied to the second column 
containing the glucosylated antigen for three times at room temperature. Both columns were 
washed with 12 mL of PBS buffer and specific antibodies were eluted with 12 mL of 0.2 M 
glycine at pH 2.6 and immediately neutralized adding 1.2 mL of 0.5M NaHCO3. Eluted fractions 
were concentrated with 50K amicon centrifugal filter and recovered in PBS buffer. IgG 
concentration was calculated by A280nm, considering 1.4 as mg/mL extinction coefficient. 
4.8.8 Surface Plasmon Resonance studies 
All experiments were conducted using a Biacore T100 instrument from GE Healthcare. All 
solutions and buffers were prepared with milliQ water obtained by the Sartorius system (arium 
611 VF). Sensor chips CM5, amine coupling kit and Running Buffer HBS-EP+ 10x (0.1 mol/L 
HEPES, 1.5 mol/L NaCl, 30 mmol/L EDTA, 0.5% v/v p20) were purchased by GE Healthcare. 
Running Buffer was diluted ten times with MilliQ water at pH 7.4 and filtered daily with a 
Millipore Express™ PLUS 0.22µm system.  
4.8.8.1 Antigen immobilization on CM5 sensor chip 
Immobilization buffers were selected separately for each peptide and protein through the pH 
scouting procedure, using the following buffers: PBS pH 7.2, Running Buffer pH 7.4, 0.1 mM 
CH3COO-Na+ pH 4.5 and pH 5.0, 1 mM CH3COO-Na+ pH 4.5 and pH 5.0, 5 mM CH3COO-Na+  
pH 4.5 and pH 5.0, 10 mM CH3COO-Na+ pH 4.5 and 20 mM CH3COO-Na+ pH 4.5. Molecules 
were solubilized in each buffer at a final concentration of 10 µg/mL and injected over the non-
activated sensor chip surface for 120 s at a flow rate of 10 µL/min; after each injection chip 
surface was regenerated with a pulse of 0,1 M NaOH for 30 s at a flow rate of 10 µL/min. The 
selected buffer and the immobilized peptide quantities are reported in Table 19. 
Each molecule were covalently linked on the surface of a chip CM5-type according to the amine 
coupling strategy that includes: sensor chip surface activation with two injections of 0.1 M N-
hydroxysuccinimide and 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (50:50) for 420 
and 240 s at a flow rate of 10 µL/min; ligand injection at a concentration of 10 µg/mL in the 
previously selected immobilization buffer for 420 s and 60 s at a flow rate of 10 µl/min; free 
reactive sites block with two pulses of ethanolamine-HCl 1 M pH 8.5 for 420 s and 60 s at a flow 
rate of 10 µl/min.  
Reference channel was activated and directly blocked with ethanolamine-HCl 1 M pH 8.5 
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4.8.8.2 Binding studies with sera 
Binding studies were conducted on the immobilized ligands diluting each serum 1:50 and 1:100 
in Running Buffer. Each serum was tested in a different cycle of analysis formed by the 
following steps: sample injection for 120 s, running buffer flow for 200 s, surface regeneration 
with one injection of 10 mM glycine at pH 2.5 for 30 s and one injection of 0.1 M NaOH for 60 
s; for every step a flow rate of 30 µL/min was used. Binding values were registered at the end of 
every sample injection. 
4.8.8.3 Kinetic and affinity studies with purified antibodies 
The 4 purified antibody fractions were diluted in running buffer to obtain the final concentrations 
of 20.0, 10.0, 5.0 and 2.5 µg/mL. Each concentration was injected over the immobilized ligands 
in a different cycle of analysis based on: sample injection for 120 sec, Running Buffer flow for 
200 s and sensor surface regeneration with 10 mM Gly pH 2.5 for 30 s and 0.1 M NaOH for 60 s; 
for every step a flow rate of 30 µL/min was used. 
4.8.9 Tissues fixation 
One normal health rat was anesthetized with 1 mL/g of a 4% chloriol solution and then perfused 
using a peristaltic pump with fixative solution (4% paraformaldeyide in PBS buffer). Brain, 
cerebellum, spinal cord, kidney and stomach were surgically removed and kept in fixative for 24 
hours at +4°C. Tissues were washed with 9% NaCl and put in 30% sucrose in PBS buffer for 3 
days at +4°C. 3 days later, tissues were washed again with 9% NaCl , frozen in isopentane and 
stored at -80°C .  
Frozen tissues were then cut with a cryostat in order to obtain some slices of 30 µm thickness; 
slices were stored at -20°C in the anti-freeze solution (40% PBS, 30% glycerol and 30% ethylene 
glycol). 
4.8.10 Immunofluorescence test with paraformaldehyde-fixed tissues 
Paraformaldheyde-fixed tissue's slices were transferred from the anti-freeze solution (40% PBS, 
30% glycerol and 30% ethylene glycol) to a 24 wells plate (Greiner). 2 slices were applied in 
each well and 1,5 mL of TBS Buffer (20 mM TRIS, 135 mM NaCl) were add. The plate was left 
in slight oscillation for 15 minutes; the washing step was repeated 3 times. 
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Free sites on tissues were blocked with 400 µL/well of FBS buffer (10% FBS, TBS buffer, 0.15% 
Triton) and incubate at room temperature in slight oscillation for 30 minutes. Serum were diluted 
in FBS buffer 1:200 and 1:50, purified antibodies were tested at 10 µg/mL or at their starting 
concentration and incubated with the tissues overnight at +4°C. 
After 3 washing with 1.5 mL/well of TBS buffer, 400 µL/well of secondary antibody (polyclonal 
rabbit anti human IgG-FITC (Dako) or polyclonal rabbit anti human IgM-FITC (Sigma) 1:275 in 
FBS buffer, were applied for 2 hours at room temperature in slight oscillation in the dark. 
Tissues were washed 3 times with 1,5 mL/well of TBS buffer.  
To stain nuclei 4',6-diamidino-2-phenylindole (DAPI) stock solution (1 mg/mL DAPI in 
dimethylformamide (DMF) stored at -20C) was diluted 1:1000 in TBS buffer and 400 µL/well 
were incubated with tissues for 30 minutes at room temperature in slight oscillation.  
After 3 washing with 1.5 mL/well of TBS buffer, each slice was transferred to a gelatin-coated 
glass slide and put at 4°C overnight in the dark. 200 µL of anti-fade mounting medium 
(DiaMedix) were then applied on each slide and an appropriate glass cap was put on them. 
Slides were observed at a fluorescence microscope using an incident wave of light at 494nm to 
obtain a green fluorescent light at 518nm because of the FITC presence and using an incident 
wave of light at 358nm to obtain a blue fluorescent light at 461nm because of DAPI optical 
properties. 
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5: Affinity determination of human recombinant domain antibodies specific 
for CSF114(Glc) 
 
5.1 Human single domain antibodies: origins and applications 
Most of the antibodies present in vertebrates are composed of two heavy and two light chains and 
both chains contribute to two identical antigen binding sites. In addition to these conventional 
antibodies, camelids produce a significant proportion of functional antibodies composed of heavy 
chains only 1, consequently their antigen binding sites are formed by a single domain defined 
VHH2 that is directly linked to the Fc-domain. Camelid heavy chain antibodies come in two 
variants, distinguished on the basis of the lengths of their hinge region and designated as long- 
and short-hinge isotypes (Figure 58). 
 
Figure 58: Structural feature of a conventional antibody formed by heavy (H) and light (L) chains and of a heavy 
chain antibody formed by heavy chains only. 
This discovery raised interest in isolating soluble and functional human antibody domains. The 
human formats (hVH) have many advantages from a genetic engineering point of view, since they 
can be easily cloned and amplified, because they are encoded by a single coding sequence. Other 
advantageous features of hVH include high solubility, thermal stability, refolding capacity, and, 
because of their small size (molecular weight is approximately 15 kDa), they have a better tissue 
penetration in vivo and they can recognize epitopes that are inaccessible to conventional 
antibodies3. Lastly, being derived from human scaffolds, hVH are promising for a potential use in 
immunotherapy because of their reduce immunogeneticity4. 
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It has already been demonstrated that in vitro panning procedures allow to obtain structure 
sensitive antibody fragments5, and it is widely accepted that a single variable heavy domain 
isolated from natural antibodies may contribute to antigen binding with comparable affinities and 
specificities to the whole antibody6.  
5.2 Objective 
The immunoenzymatic assay based on the synthetic probe CSF114(Glc) was shown to identify 
Multiple Sclerosis specific autoantibodies, and it is actively used in diagnostics and research to 
monitor and quantify MS associated Ig levels. We reasoned that high affinity engineering hVH 
raised against the same probe, could be relevant for the development of antigen detection 
strategies to be used in MS diagnosis. The aim of the present research was to detect and to 
quantify the interaction between some phage clones and the glucosylated peptide CSF114(Glc) 
and subsequently to determine the affinity and the kinetic of binding of one selected hVH 
fragment for CSF114(Glc) and for its unglucosylated version, using the Surface Plasmon 
Resonance biosensor Biacore T100. 
5.3 Results and discussion 
In collaboration with the Department of Experimental and Clinical Biomedical Sciences of the 
University of Florence (Prof. Donatella Degl’Innocenti), we received eight different phage clones 
expressing on their surface a different hVH antibody specific for the CSF114(Glc) peptide. 
The ability of every phage to specifically bind to CSF114(Glc) was previously tested in SP-
ELISA assay and we tried to understand if these phages, when injected in a continuous flow, 
could recognize the glucosylated peptide immobilized on the surface of the chip of the biosensor. 
Then, soluble hVH fragments, produced from the phages selected thanks to SPR binding studies, 
were deeply characterized through affinity and kinetic studies on immobilized CSF114(Glc) and 
CSF114.  
5.3.1 Peptides immobilization on Biacore chip 
The CSF114(Glc) peptide and its unglucosylated counterpart CSF114, whose sequences are 
reported in Table 24, were immobilized on two different channels of a CM5-type sensor chip.  
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Peptide Sequence 
CSF114(Glc) TPRVERN(Glc)GHSVFLAPYGWMVK-NH2 
CSF114 TPRVERNGHSVFLAPYGWMVK-NH2 
Table 24: Sequence of peptides covalently immobilized on sensor chip surface. 
Peptides were covalently linked according to the amine coupling strategy. An amine bond was 
formed between one primary amine group of each peptide and the previously activated carboxylic 
group on chip surface. Immobilization buffers were selected separately for each peptide using the 
pH scouting procedure in order to maximize electrostatic interactions between chip and peptides. 
At the end of the coupling protocol an immobilization level of 1126 RU was obtained for 
CSF114 in 0.5 mM in sodium acetate buffer pH 5.0 and 1327 RU for CSF114(Glc) in 0.1 mM 
sodium acetate buffer pH 5.5. The instrumental signal registered with the pH scouting procedure 
and the amine coupling immobilization of CSF114(Glc) is reported in Figure 59. 
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Figure 59: Sensorgrams showing the electrostatic pre-concentration on chip surface and the covalent immobilization 
of CSF114(Glc) on channel 2 of a CM5-type chip. 
For SPR binding studies with phages and kinetic and affinity studies with soluble hVH fragments, 
the channel containing the unglucosylated peptide CSF114 was used as reference and the channel 
with immobilized CSF114(Glc) was used as the active one. To better quantify the binding 
between soluble hVH fragments and each single peptide, SPR binding studies were performed 
considering as reference one ethanolamine containing channel. 
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5.3.2 SPR binding studies with specific hVH-CSF114(Glc) phages 
Binding studies with phages were conducted diluting each phage up to the same final 
concentration in running buffer and flowing it at a low flow rate over the immobilized peptides. 
Each phage was tested in a different cycle of analysis formed by the sample injection, the running 
buffer flow and finally the chip surface regeneration. The interactions between phages and 
peptides were quantified, considering the maximum binding values registered at the end of the 
injection (Figure 60). 
 
Figure 60: Binding values (RU) registered on immobilized CSF114(Glc) for the eight selected phages. 
Binding study results, in line with SP-ELISA ones, confirmed the positivity of all tested phages 
for CSF114(Glc), and indicated phage 16 as the most promising for the expression of hVH soluble 
antibodies.  
5.3.3 Kinetic and affinity characterization of hVH-CSF114(Glc)6xHis 
Phage 16, selected from the previous study, could not be obtained in the soluble form because of 
technical problems; so the characterization of the interaction was continued with clone 22, the 
only one from which it was possible to express in high concentration the soluble form of hVH-
CSF114(Glc)6xHis. 
Biosensor analysis started diluting the hVH-CSF114(Glc)6xHis sample in running buffer at six 
different final concentrations and considering the stability signal registered on both single 
channel 15 s after the end of the injection of each sample concentration. As shown in Figure 61, 
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for each tested antibody concentration, we obtained an instrumental signal that was directly 
proportional to hVH-CSF114(Glc)6×His bounded to glucosylated peptide. Stability signals were 
found to be significantly higher (5-fold to 10-fold) for CSF114 (Glc) than for CSF114. The direct 
dependence of signals on antibody concentration further indicated a specific interaction mainly 
linked to the presence of the N-glucosyl moiety. On the contrary, signals generated by the 
association with the unglucosylated sequence CSF114 were not proportional to hVH-
CSF114(Glc)6×His concentration, a behavior typical of a non-specific interaction. 
 
Figure 61: Stability values registered on CSF114(Glc) (black) and CSF114 (light grey) at the different tested 
concentration (µg/mL). 
Considering the results of the SPR binding study, we decided to characterize the kinetic and 
affinity of the interaction between hVHCSF114(Glc)6×His antibody and CSF114(Glc) peptide. 
According to the same method applied for binding experiments, the hVHCSF114(Glc)6×His was 
injected in different concentrations and final results were elaborated with the software associated 
to the instrument to obtain the affinity constant and the kinetic parameters. Fitting experimental 
curves to the theoretical 1:1 interaction model as shown in Figure 62, ka was found to be 1.20 ± 
0.10 × 105 M-1s-1 and kd was 1.09 ± 0.07 × 10-3 s-1, resulting in an overall equilibrium dissociation 
constant (KD = kd/ka) of 9.08 ± 0.13 × 10-9 M.  
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Figure 62: In the upper part sensorgrams showing the interaction between hVHCSF114(Glc)6×His and peptide 
CSF114(Glc); the graph represents experimental curves corresponding to six different antibody concentrations in 
different colors and the corresponding curves obtained by fitting with a theoretical 1:1 interaction kinetic model 
(black); in the lower part the residual values indicating the difference between experimental and mathematical curves 
are shown and they are closely distributed along the zero. 
Affinity measurements indicated that hVH-CSF114(Glc)6×His antibody established a very strong 
interaction with CSF114(Glc) peptide. Another experimental aspect that confirmed the strength 
of the interaction between hVH-CSF114(Glc)6×His antibody and CSF114(Glc) was the difficulty 
of regenerating the sensor chip after measurements; three consecutive regeneration steps were 
needed to completely detach the antibody from the sensor chip surface instead of the one or two 
regeneration cycles, usually used in similar experiments7. 
Previous attempts to use the SPR technology to characterize purified human anti-CSF114(Glc) 
antibodies from MS patient sera confirmed the specificity of auto-antibodies for the glucosylated 
peptide and provided a kd parameter of 2.2 × 10-4 s-1 8. Kd parameter obtained in the present study 
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was in the range of 10-3 s-1, indicating that hVHCSF114(Glc)6×His antibody dissociated from 
CSF114(Glc) about five times faster than human autoantibodies obtained from MS patients’ sera. 
This observation could be at least in part explained taking into account that the mass transport 
that influences the SPR signals is influenced by several factors, among which the molecular 
weight of the analyte and the observation that the dissociation rate inversely correlates to the 
analyte size. In this case, the molecular weight of the hVH (~15 kDa) is at least 10-fold lower than 
that of a common human immunoglobulin, leading to a faster dissociation rate. 
Considering the obtained results, we could suggest some application in humans; in fact, since the 
peptide CSF114(Glc) has been used as an immunological probe to develop a patented 
immunoenzymatic diagnostic assay to detect specific autoantibodies in MS patients’ sera (MS 
PepKit), a human anti-CSF114(Glc) hVH domain antibody could be effectively exploited as a 
positive standard/calibrator of this assay. In addition, because the current form of the assay is a 
classical ELISA sandwich, we may speculate on a possible evolution into a competitive assay 
based, for example, on a labeled recombinant antibody pre-coupled to CSF114(Glc) that is 
displaced by patients’ MS specific autoantibodies, with evident benefits in terms of speed and 
accuracy. Interesting perspectives could also be the possible use of antibody constructs for 
blocking in vivo the interaction of auto-antibodies with small antigenic structures within the 
brain, diminishing or suppressing the antibody mediated damage. In this perspective, a human 
domain antibody characterized by a high affinity for antigens in MS, lacking the effector region 
of a normal Ig molecule and with a low overall immunogenicity in the human body, could be 
ideal to block the auto-antibodies and display beneficial effects in vivo. 
5.4 Conclusions 
In this part of the work some phages coming from a previously panned human domain antibody 
library and the soluble form of one human domain antibody was characterized with an SPR 
biosensor, looking for the antibody clone that could recognize the N-glucosylated CSF114(Glc) 
peptide with high affinity, to be used for further studies in MS.  
From a technical point of view, the results obtained from binding experiments with hVH-
CSF114(Glc) phages indicate that this kind of biosensor can successfully be used to quantify the 
interaction of immobilized ligands with high molecular weight analytes such as phages; indeed in 
the present study the most promising phage, that could be used to express a soluble antibody, was 
selected considering its interaction with the glucosylated peptide. 
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In a recent publication9 we reported affinity and kinetic measurements of hVH-
CSF114(Glc)6×His showing that the soluble antibody specifically recognized the glucosylated 
peptide with high affinity as indicated by the equilibrium dissociation constant KD that is in the 
nanomolar range. 
Considering these aspects it could be interesting to use the selected hVH-CSF114(Glc)6×His as a 
positive control in diagnostic tests, or as a molecular probe in immunohistochemistry assays and 
more importantly it could be test in vivo as a competitive probe for MS autoantibodies. 
5.5 Materials and methods 
5.5.1 Production of hVH soluble antibodies 
Soluble hVH antibodies were produced by the Department of Experimental and Clinical 
Biomedical Sciences of the University of Florence (Prof. Donatella Degl’Innocenti) starting from 
a commercial human domain antibody library according to manufacturer instructions10. Briefly, 
after phage manipulation, selection was performed thanks to a magnetic beads-based biopanning 
using 50 pmol of the biotinylated CSF114(Glc); then individual phage clones were grown and 
tested in ELISA against CSF114(Glc). Phagemides from positive clones were sequenced, 
amplified and ligated into an expression vector used to transform competent E.Coli in order to 
express hVH specific for CSF114(Glc) as a 6xHis tagged antibody (hVH-CSF114(Glc)6xHis). 
Purified hVH-CSF114(Glc)6xHis specificity for the glucosylated peptide was confirmed in SP-
ELISA assays. 
5.5.2 Peptides immobilization on Biacore CM5 chip 
The pH scouting procedure was employed to select the optimal immobilization buffer for each 
peptide using PBS buffer pH 6.5 and 7.2 and sodium acetate buffers 0.1, 0.5, 5.0 and 10 mM pH 
5.0, 5.5 and 6.0. The CSF114 peptides (with or without glucosyl moiety) were dissolved in each 
buffer to a final concentration of 10 µg/mL and injected for 120 s at a flow rate of 10 µL/min. 
After this step, chip surface was regenerated with 0.1 M NaOH for 30 s at a flow rate of 10 
µL/min. Buffer selection was based on the maximal RU signal observed at the end of the 
injection. Peptide were immobilized on the surface of a chip CM5-type according to the amine 
coupling strategy that includes: sensor chip surface activation with two injections of a solution of 
(1:1) N-hydroxysuccinimide 0.1 M and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 0.4 M 
for 420 s and 240 s at a flow rate of 10 µL/min; peptide injection at a concentration of 10 µg/ml 
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in the previously selected immobilization buffer for 420 s at a flow rate of 10 µL/min; free 
reactive sites block with two pulses of ethanolamine-HCl 1 M pH 8.5 for 420 s and 60 s at a flow 
rate of 30 µL/min. This procedure was used on both active and reference channels, containing 
glucosylated and non-glucosylated CSF114 peptides, respectively. 
5.5.3 SPR binding studies with specific hVH-CSF114(Glc) phages 
Binding studies were conducted on the immobilized CSF114(Glc) peptide with 8 phages, 
previously selected with the phage display technique for their positivity versus the same peptide 
and with 1 negative control. Each phage was diluted up to the final concentration of 5 × 1010 
Colony Forming Unit in running buffer (0.1M HEPES, 1.5 M NaCl, 30mM EDTA, 0.5% v/v 
Surfactant p20) and tested in a different cycle of analysis. One cycle was formed by the following 
steps: phage injection for 420 s at a flow rate of 5 µL/min, running buffer flow for 200 s, surface 
regeneration with one injection of 10mM glycine solution pH 2.5 for 30 s and one injection of 0.1 
M NaOH for 60 s. Binding values were registered at the end of every sample injection. 
5.5.4 SPR characterization of hVH-CSF114(Glc)6xHis 
hVH-CSF114(Glc)6×His antibody was diluted in running buffer to final concentrations of 3.0, 
2.5, 2.0, 1.5, 1.0 and 0.5 µg/mL. Each concentration was injected over immobilized peptides in 
both active and control channels for 120 s at a flow rate of 30 µL/min. Running buffer was then 
flushed for 200 s at a flow rate of 30 µL/min to allow dissociation, and finally, chip surface was 
regenerated by injecting a 0.1 M NaOH solution for 60 s followed by a 10 mM glycine solution 
pH 2.5 for 30 s and then again a 100 mM NaOH solution for 60 s at a flow rate of 30 µL/min. 
Obtained results were elaborated using the Biacore T100 Evaluation software 2.0 fitting 
experimental data to a theoretical 1:1 interaction kinetic model in order to calculate the 
association rate (ka), the dissociation rate (kd) and the equilibrium dissociation constant (KD = 
kd/ka). 
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6: SP-ELISA detection of anti N-glucosylation antibodies in Rett Syndrome 
patients’sera 
 
6.1 Proposed correlation between Multiple Sclerosis and Rett syndrome 
Rett syndrome is an X-linked dominant postnatal severe and disabling neurodevelopmental 
disorder, which is the second most common cause for genetic mental retardation in girls and the 
first pervasive disorder with a known genetic basis. The classical variant is characterized by 
apparently normal development for the first 6-18 months, accompanied then by early deceleration 
of head growth, followed by loss of acquired cognitive, social and motor skills and other 
neurological and related symptoms, together with development of autistic behavior1. Rett 
syndrome is formely placed in the heterogeneous group of Autism Spectrum Disorders (ASD), 
but is now regarded as a distinct pathological entity. To date, no effective therapy for preventing 
or arresting the neurologic regression in the disease in its various clinical presentations is 
available. The syndrome is primarily associated to a single monogenic mutation in the Methyl 
CpG binding protein 2 (MeCP2) gene in up to 95% of cases2, more rarely by mutation in Cyclin-
Dependent Kinase-Like 5(CDKL5)3 or in Forkhead box protein G1 (FOXG1)4. Rett patients with 
atypical clinical presentation, usually harbor CDKL5 or FOXG1 mutations, while the preserved 
speech variant is usually linked to MeCP2 mutations5. Despite almost two decades of research 
into the functions and role of MeCP2, little is known about the mechanisms leading from MeCP2 
deficiency to disease development.  
MeCP2 protein product acts as a transcriptional repressor or activator depending on the target 
gene associated. Overall, the evidence in both MeCP2 deficient patients and knock-out mice 
implies that loss of MeCP2 causes malfunction of numerous synapses throughout the brain, 
which creates less efficient neuronal networks and gives rise to Rett-like phenotypes6.  
Recent studies on MeCP2 null mice identified the Brain Derived Neurotrophic Factor (BDNF), 
playing a major role in neuronal survival, neurogenesis and plasticity, as a major MeCP2 target, 
consequently abnormalities in BDNF homeostasis are believed to contribute to the neurologic 
phenotype and to the patophysiology of part of the symptoms of Rett syndrome. In the last year a 
clinical correlation between Rett and Multiple Sclerosis has been suggested on the basis of 
preliminary results obtained with Glatiramer acetate, an immunomodulator with proven safety 
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and efficacy in Multiple Sclerosis treatment, that has been reported to cause elevated secretion of 
BDNF in Rett animal model too7. 
6.2 Objective 
Taking care of the above mentioned clinical correlation and considering that both Rett and 
Multiple Sclerosis are central nervous system pathologies and that the synthetic N-glucosylated 
peptide CSF114(Glc) has successfully been used to detect specific autoantibodies in a subgroup 
of MS patients8, the ability of the same probe to reveal antibodies in Rett patients’ sera, by 
comparison to healthy controls and pathological controls, was investigated. Subsequently, taking 
into account the results obtained during the present PhD research, indicating that specific 
antibodies that recognize the N-glucosylated HMW1ct protein from H.influenzae were present in 
MS sera and that they cross-reacted with CSF114(Glc), we investigated if this bacterial protein 
could also be used to reveal antibodies in Rett patients’ sera. 
This study could be useful to understand if a putative perturbation of the humoral response is 
present in Rett patients and if specific antibodies could be revealed for diagnostic or prognostic 
purpose. 
6.3 Results and discussion 
6.3.1 Determination of specific anti N-glucosylated peptide antibodies by SP-ELISA 
The presence of serum antibody in patients’ sera was evaluated by a SP-ELISA assay according 
to a standard optimized procedure, the N-glucosylated peptide probe CSF114(Glc) was coated to 
the plates and a total of 164 human sera consisting of Rett patients, normal health children and 
pathological controls were applied. The IgG and IgM titer of anti-CSF114(Glc) antibodies was 
determined thanks to the application of a specific enzyme labeled secondary antibody; after the 
addition of its substrate the colorimetric reaction was measured at 405nm; absorbance values 
were directly dependent on the quantity of the antibodies that bound the adsorbed peptide. In 
Figure 63 the absorbance values for IgG and IgM are reported for each group of sera.  
CHAPTER 6 
127 
IgM
Rett non-Rett PDD Normal subjects
0.0
0.5
1.0
1.5
2.0
2.5
B
A4
05
nm
 
Figure 63: Distribution graphs of the anti-CSF114(Glc) IgG (A) and IgM (B) revealed by the immunoenzymatic 
assay in each group of sera; horizontal line indicate the median absorbance value for each group. 
The IgM antibody titer found in Rett patients was significantly higher than those observed in the 
control groups, both healthy subjects and non-Rett PDD patients. Calculated Receiver-Operating 
Characteristic (ROC) curves indicated that anti-CSF114(Glc) IgM were able to discriminate Rett 
syndrome from either non-Rett PDD patients and control subjects (Figure 64). Considering a cut-
off value of 0.61 this test can distingue between Rett and non-Rett pervasive developmental 
disorder (non-Rett PDD) groups with a sensitivity of 60.4% and a specificity of 71.9%, the area 
under the curve was 0.669 and the p-value 0.0006. When comparing Rett and normal health 
subjects group, setting a cut-off of 0.62 a specificity of 82.9% and a sensitivity of 60.4% were 
obtained, with an area under the curve of 0.697 and a p-value of 0.0016. 
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Figure 64: Receiver-Operating Characteristic analysis for anti CSF114(Glc) IgM in Rett vs non-Rett PDD groups(A) 
and in Rett vs normal subjects groups (B). 
At variance, the CSF114(Glc) antigen failed to detect a significant IgG serum antibody 
population in both patient groups and healthy controls; a higher but not significant IgG titer was 
only found in 3 Rett patients and interestingly they were the oldest inside their group.  
Although, a number of studies have addressed the relationship between Rett syndrome and 
immune system dysfunction, these have mainly focused on their influence on peripheral immune 
cells9, although some recent reports investigated humoral immunity in RTT patients, observing 
evidences of immune system activation10. Results obtained by this SP-ELISA screening indicated 
that Rett patients showed a consistent and highly significant increase of the serum IgM relative to 
both healthy controls and non-Rett PDD patients group. 
The specificity of interaction between CSF114(Glc) and IgM antibodies was demonstrated by the 
ROC curve, widely considered a test of accuracy for discriminating between patients and normal 
subjects. Thus, it appears that the Rett patients group can be distinguished with confidence on the 
basis of serum IgM titer detected by the CSF114(Glc)-based assay. It is of interest that the large 
serum IgM increases, noted here, were also observed with the same assay, in a subset of multiple 
sclerosis patients. It is plausible that the IgM changes, noted in these CNS pathologies, could be 
linked to a common mechanism based on a pervasive neuroinflammation. Maybe the association 
between neuroinflammation and the observed serum IgM rise could be causal to the Rett disease 
initiation and/or progression together with the combination of epigenetic modification and 
environmental factors. 
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6.3.2 Determination of specific anti N-glucosylated adhesin antibodies by SP-ELISA 
A significant cross-reactivity was found, during this PhD research, between anti-CSF114(Glc) 
antibodies in MS patients’ sera and the 8 times N-glucosylated protein HMW1ct corresponding to 
the C-terminal fragment (aa 1205 – 1536) of the HMW1 adhesion protein of H. influenzae. 
Considering also the above described pathophysiological relevance of antibodies recognizing 
CSF114(Glc) in Rett patients’ sera, we investigated if those antibodies could cross-react with the 
protein HMW1ct-Glc.  
With this aim, the presence of serum antibodies in Rett patients’ sera was estimated by SP-
ELISA coating HMW1ct-Glc and the corresponding non glucosylated sequence HMW1ct. 31 
Rett patients’ sera and 25 non-Rett PDD control sera were applied in this preliminary screening 
phase. Antibodies recognizing the adsorbed proteins were revealed thanks to the application of 
appropriate enzyme labeled secondary antibodies and quantified according to the absorbance 
values registered at 405nm as illustrated in Figure 65 for each group of sera.  
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Figure 65: Distribution graphs of the anti-HMW1ct-Glc IgM or IgG and of the anti-HMW1ct IgM or IgG revealed 
by the immunoenzymatic assay in Rett and non-Rett PDD sera; horizontal line indicate the mean absorbance value 
for each group. 
The IgM antibody titer against both HMW1ct proteins found in Rett patients was higher than 
those in the control non-Rett PDD patients; on the other hand, high levels of serum IgG were 
found in both groups coating both proteins, indicating that anti-adhesin antibodies of IgG isotype 
were present in the most part of tested sera independently of patient disease.  
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Calculated Receiver-Operating Characteristic (ROC) curve indicated that anti-HMW1ct-Glc IgM 
antibodies were able to discriminate Rett syndrome from non-Rett PDD with an area under the 
curve of 0.79 and a p-value of 0.0002; the diagnostic cut-off for the method was set at 1.0 with a 
sensitivity of 35.5% (11/31) and a specificity of 96.0% (1/25). 
From the ROC analysis of anti-HMW1ct IgM antibodies, we obtained a discriminative power 
indicated by an area under the curve of 0.76 and a p-value of 0.0007; the cut-off of 0.93 was 
selected with a sensitivity of 19.4% (6/31) and a specificity of 96.0% (1/25). ROC curves are 
shown in Figure 66. 
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Figure 66: ROC analysis for anti HMW1ct-Glc and anti-HMW1ct IgM in Rett vs non-Rett PDD groups. 
The same specificity in detecting serum IgM in Rett patients was found for both HMW1ct and 
HMW1ct-Glc proteins adsorbed on the ELISA support, but a higher sensitivity and a higher 
statistical significance for the test was calculated for the N-glucosylated protein.  
From the screening of this small cohort of sera an overall higher IgG and IgM antibodies level 
was detected with the two proteins as compared to the coated peptide CSF114(Glc); probably 
because when a high molecular weight antigen is used as probe on the solid support, 
heterogeneous families of antibodies, recognizing a variety of epitopes, are revealed and it is not 
possible to know if the absorption on the plastic support alters the natural conformation of the 
proteins, masking real epitopes or creating new ones. For this reason, we decided to continue the 
project by coating on the solid support peptide CSF114(Glc) that was the best performing probe 
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in detecting specific antibodies in Rett sera, and by testing the two proteins as inhibitors in 
solution.  
6.3.3 Competitive ELISA assay with Rett sera 
Two Rett sera, showing a high IgG level against CSF114(Glc), were selected to be used in 
competitive ELISA assays according to the method of Wrath, Stanley and Steward11.  
At first, sera were titrated by testing them at four different dilutions in order to find the semi-
saturating dilution giving an absorbance of around 0.5, to be used in competitive ELISA. The 
competitive ELISA was then performed on coated CSF114(Glc) with the only one serum (SR 1) 
showing a sufficient IgG titer in the experimental conditions required to perform the assay. SR 1 
was incubated with six different concentrations (from 10-5 to 10-10 M) of HMW1ct, HMW1ct-
Glc, CS114 and CSF11(Glc). From the inhibition curves reported in Figure 67, the IC50 for each 
inhibitor was calculated. 
 
Figure 67: Inhibition curves describing the relative mean affinity of anti-CSF114(Glc) antibodies from SR1 serum 
for the four inhibitors applied in solution. 
This experiment confirmed the proposed cross-reactivity of anti-CSF114(Glc) antibodies with the 
protein HMW1ct-Glc, and indicated that N-glucosylation moieties were fundamental for the 
interaction with antibodies; indeed non glucosyalted CSF114 and HMW1ct were not able to 
inhibit antibody binding. From the calculated IC50 values, as in the case of Multiple Sclerosis 
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sera, we observed a significant higher affinity of anti-CSF114(Glc) antibodies for the 
glucosylated protein (10-8.5 M) than for the glucosylated peptide (10-6 M). 
6.4 Conclusions 
The SP-ELISA assay based on the N-glucosylated CSF114(Glc) that was recently reported in a 
scientific paper by our research group12, provided evidence for an increase in IgM titer, but not in 
IgG, in Rett patients relative to both healthy controls and non-RTT PDD ones, suggesting that 
this synthetic probe was able to specifically detect IgM antibodies that are relevant for the Rett 
syndrome.  
The other interesting aspect was that this study contributed to elucidate that two disease 
conditions such as Rett and the diffuse autism (non-Rett PDD patients), seemingly contiguous as 
they share some behavioral traits, are in fact different for their severity, life-span expectancy and, 
as we demonstrated, immune system derangement. 
Preliminary results obtained when the bacterial proteins HMW1ct-Glc and HMW1ct were used in 
SP-ELISA, indicate the presence of high IgG levels in the majority of Rett and non-Rett PDD 
sera, suggesting that IgG antibodies targeting some non glucosylated epitopes on adhesion 
proteins of a common human pathogen as H.influenzae, were present in human sera and that they 
were not related to Rett nor to non-Rett PDD diseases. On the other hand higher level of serum 
IgM recognizing the glucosylated protein HMW1ct were found in Rett patients as compared to 
the non-Rett PDD group and a certain cross-reactivity of anti-CSF114(Glc) with HMW1ct-Glc 
emerged from the competitive assay. Considering the overall results of this study we could 
assume that N-glucosylated moieties are very relevant epitopes targeted by specific antibodies 
present in Rett patient’sera.  
6.5 Materials and methods 
6.5.1 Patients  
A total of 164 human sera coming from the Child Neuropsychiatric Unit, University Hospital of 
Siena (Dr. Hayek) was employed in this study. This population consisted of 3 different groups: 
53 Rett patients sub-divided into 41 patients with classical clinical presentation and MeCP2 gene 
mutation, and 12 with atypical presentation and other gene mutations; 82 pathological controls 
affected by non-Rett pervasive developmental disorders (non-Rett PDD); 35 age matched healthy 
controls. 
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6.5.2 SP-ELISA assay 
96 well activated polystyrene ELISA plates (NUNC Maxisorp SIGMA) were coated with 1 
µg/100 µL of glycopeptide in Coating buffer (12 mM Na2CO3, 35 mM NaHCO3, 3 mM NaN3, 
pH 9.6) or with 1µg/100 µL of proteins in PBS buffer pH 7.2 and incubated at +4°C overnight. 
After five washes with Washing Buffer  (NaCl 0.9%), nonspecific binding sites were blocked by 
Fetal Bovine Serum (FBS) 10% in Washing Buffer (120 µL/well) at room temperature for 60 
min. FBS buffer were manually removed and sera samples were dispensed in duplicate at 3 
dilutions (1:100, 1:1000 and 1:10000 in FBS buffer containing Tween 20 0.05%) 100 µL/well; 
incubation was performed at 4°C overnight. Plates were washed 5 times with Washing Buffer  
containing Tween 20 and 100 µL of alkaline phosphatase conjugated anti-human IgM (Sigma) 
diluted 1:200 in FBS buffer/Tween 20 or IgG (Sigma) diluted 1:8000 in in FBS buffer/Tween 20 
was added to each well. After 3 h at room temperature incubation and five washes, 100µL of 
substrate solution consisting of 1mg/mL p-nitrophenyl phosphate (Sigma) in Substrate buffer (1 
M diethanolamine,  1 mM MgCl2, 3 mM NaN3, pH 9.8) was applied. After 30min, the reaction 
was stopped with 1M NaOH (50 µL/ well), and the absorbance was read in a multichannel 
ELISA reader (Tecan Sunrise) at 405 nm. Antibody levels were expressed as absorbance in 
arbitrary units at 405nm (sample dilution 1:100). Differences between groups were evaluated and 
the efficiency of anti-CSF114(Glc) IgM and anti-HMW1ct-Glc IgM in discriminating Rett from 
non-RTT PDD patients or healthy control subjects were evaluated using a Receiver Operating 
Characteristic (ROC) curve analysis. 
6.5.3 Competitive ELISA 
The protocol used for this assay was the same followed for the SP-ELISA; the only difference is 
about sample application. The selected serum was used at the semi-saturating dilution 
(corresponding to the dilution giving an absorbance of around 0.5). Serum and inhibitors in FBS 
buffer were mixed (50:50) and 100 µL/well were immediately dispensed. Each inhibitor was 
tested at 6 final concentrations: 10-5, 10-6, 10-7, 10-8, 10-9 and 10-10 M, prepared by serial dilution. 
IC50 was calculated for each inhibitor as the molar concentration need to obtain half of the 
maximum absorbance signal. 
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7 LIST OF ABBREVIATIONS 
Anti-Citrullinated Peptide/Protein Antibodies  ACPA 
Aquaporin 4 AQ 4 
Autism Spectrum Disorders  ASD 
Brain Derived Neurotrophic Factor  BDNF 
Ciclic Citrullinated Peptides  CCP 
Cyclin-Dependent Kinase-Like 5 CDKL5 
Central Nervous System  CNS 
4',6-diamidino-2-phenylindole DAPI 
Dimethylformamide DMF 
Dimethyl Sulfoxide DMSO 
Dithiothreitol  DTT 
Experimental Autoimmune Encephalomyelitis  EAE 
Epstein-Barr Virus  EBV 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide EDC 
Enzyme-Linked Immunosorbent Assay  ELISA 
Fetal Bovine Serum  FBS 
Fluorescein Isothiocyanate  FITC 
Forkhead box protein G1  FOXG1 
Flow Through  FT 
Glutamic Acid Decarboxylase  GAD 
Histone Citrullinated Peptide  HCP 
Human Natural Killer-1  HNK-1 
Integrated Microfluidic Cartridge  IFC 
Multiple Antigen Peptide MAP 
Methyl CpG binding protein 2  MeCP2 
Magnetic Resonance Imaging  MRI 
Multiple Sclerosis MS 
Normal Blood Donor  NBD 
Neutrophil Extracellular Traps NET 
Normal Health Sera NHS 
N-hydroxysuccinimide  NHS 
Oligosaccharyl Transferase OT 
Peptidyl-Arginine Deiminase PAD 
Pervasive Developmental Disorder PDD 
2-(2-pyridinyldithio)ethaneamine PDEA 
Post-Translational Modification PTM 
Rheumatoid Arthritis  RA 
Rheumatoid Factor  RF 
Refractive Index  RI 
Receiver Operating Characteristic  ROC 
Reactive Oxygen Species  ROS 
Resonance Unit RU 
Standard Deviation  SD 
Surface Plasmon Resonance  SPR 
Tumor Necrosis Factor-α  TNF-α 
Two Partner Secretion  TPS 
Viral Citrullinated Peptide VCP 
 
